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ABSTRACT 
Chitosan (CS), a natural cationic polymer obtained by the partial N-deacetylation of 
chitin, has been investigated widely for its potential in the development of food and 
drug delivery systems and pharmaceutical applications, however it has not generally 
been considered in forensic applications for example fingerprints (fingermarks). The 
purpose of this study was to prepare chitosan micro/nanoparticles through cross-
linking with tripolyphosphate (TPP) utilising the ionotropic interaction between 
positively charged amino groups (CS) and negatively charged counter ions (TPP). The 
investigation into the potential of these particles was divided into two parts: forensic 
and pharmaceutical applications. Firstly, these formulations were characterized 
(relative viscosity, zeta potential, particle size, FT-IR, XRD, SEM) and evaluated for 
forensic applications (fingermark visualisation). This can be controlled by the charge 
density of CS and TPP, which depends on the pH and ionic strength of the solution. 
Secondly, the combined effects of three independent variables (pH, ionic strength and 
CS: TPP ratio) on three important physico-chemical properties (viscosity, zeta 
potential and particle size) during the preparation of microparticles were investigated. 
CS: TPP microparticles (CSMPs) were prepared using experimental design and 
equations were generated and used to predict relative viscosity, zeta potential and 
particle size under different conditions. This gives us the ability to design tuneable 
CS: TPP microparticles with desired size for specific pharmaceutical or forensic 
applications e.g. latent fingerprint visualisation. Fingerprints are a very common form 
of physical evidence. The most commonly used procedure for revealing the ridge 
pattern is powder dusting, which relies on the mechanical adherence of fingerprint 
formulation to the fatty components of the skin deposit that are secreted by sweat 
pores that exist on friction ridges. The development of latent fingermarks using 
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CSMPs was analysed by using a 23 factorial design, which considered simultaneously 
three main factors: pH, ionic strength and CS: TPP (v/v) ratio. CS: TPP ratio has the 
strongest effect on fingerprint quality. The best conditions for fingerprint visualisation 
were microparticles prepared using a buffer of pH 4.8, 0.2 M ionic strength at a CS: 
TPP of 2:1. Although we have demonstrated that CSMPs can be used to develop 
latent fingermarks there are limitations in that they are only applicable as a powder 
and are only sensitive up to the third depletion level for a fingermark aged for one 
day. 
 
In the final sections of this thesis, chitosan nanoparticles were prepared and 
characterized for potential applications in drug delivery (using ibuprofen as a model 
drug) and in terms of their interactions with mucin (mucoadhesion). It has been 
demonstrated that chitosan nanoparticles can incorporate appreciable quantities of 
ibuprofen into nanoparticles (CS-IBU-TPP), although the order addition of the 
individual components is important. The carboxylate ions of the ibuprofen (negative 
charge) and could bind strongly to the ammonium group (positive charge) of chitosan, 
thereby allowing greater drug-loading capacity in the chitosan nanoparticles. In 
addition, the interaction between different ratios chitosan nanoparticles (CS: TPP) and 
mucin were evaluated based on relative viscosity, zeta potential and particle size. It 
has been suggested that chitosan nanoparticle-mucin interactions are driven by 
electrostatic forces. The results conclude that interactions between CS: TPP 
nanoparticles and mucin occur, with a CS: TPP ratio of 4:1 displaying the strongest 
interaction with mucin. This is observed through differences in relative viscosity, zeta 
potential and particle size. 
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1 General Introduction 
1.1 Carbohydrates    
 
Carbohydrates are also known as saccharides (Greek: sakcharon – sugar) and they are 
the most broadly distributed molecules in both plant and animal tissues. In addition, 
carbohydrates are necessary for all living organisms, as skeletal structures in plants 
(cellulose), exoskeleton of some insects and crustaceans (chitin). In fact, plant and 
animal tissues differ widely in the relative abundance of the many major classes of 
organic compounds such as carbohydrates, proteins and lipids. Animals have 1 % of 
carbohydrates, whereas plants have 30 %. Some carbohydrates such as glycoproteins 
and glycolipids are present in the cell membrane and are important in cellular 
functions such as cell growth. Carbohydrates may be defined as polyhydroxy 
aldehydes or ketones or compounds which produce them on hydrolysis (Pigman and 
Goepp, 1945). 
 
Carbohydrates can be classified into three major types: monosaccharides, 
oligosaccharides and polysaccharides. This classification is based on the number of 
sugar units. Monosaccharides are the simplest type of carbohydrates which cannot be 
hydrolysed to smaller units. In addition, they contain three to seven carbons with a 
functional a free aldehyde (R—CHO) or ketone (R2=CO) group and two or more 
hydroxyl (R—OH) groups (Hedley, 2001). 
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The most abundant monosaccharides in nature are the 6-carbon sugars such as glucose 
(aldohexoses) and fructose (ketohexose). Monosaccharides are crystalline, colourless 
and readily soluble in water. Due to the presence of an asymmetric carbon atom, 
monosaccharides are optically active. The structures of D-glucose and L-glucose 
(Figure 1.1), are examples for optical isomers, based on the reference 
monosaccharide, D- and L-glyceraldehyde  (David and Michael, 2013). 
 
 
Figure 1.1: D- and L- form of glucose compared with D- and L- glyceraldehyde 
 (David and Michael, 2013) 
. 
 
There are two different forms of D-glucose known as α-form and β-form. The 6-
membered rings from sugars are derived from pyran. So, this results in the formation 
of a stable 6-membered ring oxygen heterocycle (pyranose form) (Figure 1.2). 
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Figure 1.2: Mode of conversion of α and β glucose from Haworth projections. 
 
 
There are several derivatives of monosaccharides, some of which are physiologically 
important such as amino sugars which are widely distributed naturally. Amino sugars 
have an amine group (NH2) has been replaced the hydroxyl group (OH) group usually 
at carbon 2 (C2) in the parent hexose e.g. D-glucosamine, D-galactosamine and N-
Acetylneuraminic acid (sialic acid) (Figure 1.3) (Pigman and Goepp, 1945, 
Satyanarayana and Chakrapani, 2013). 
 
H
2
2
 
Figure 1.3: Structure of D-Glucosamine. 
 
Oligosaccharides (disaccharides) are crystalline, water-soluble and sweet to taste. 
They consist of two (or more) monosaccharide units joined together by glycosidic 
bonds. Oligosaccharides consist of 2 to 10 monosaccharide molecules on hydrolysis. 
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Maltose, sucrose and lactose for example are all disaccharides (Jain et al., 2005). 
Oligosaccharides are most commonly found in plants.   
 
1.1.1  Polysaccharides 
Polysaccharides are formed of repeating units of monosaccharides or their derivatives. 
These units are joined together by glycosidic bonds, therefore polysaccharides can 
have high molecular weight. Moreover, they can be either linear or branched 
polymers, depending upon the arrangement of the monosaccharide units in the chain. 
Polysaccharides have a large number of reactive functional groups such as amino, 
hydroxyl and carboxyl groups which could form bonds with other compounds. In 
addition, polysaccharides can be changed chemically and biochemically resulting in 
many types of polysaccharide derivatives, due to the presence of reactive functional 
groups on molecular chains (Liu et al., 2008b). There are abundant source of 
polysaccharides in nature such as, plant based (e.g. pectin), animal based (e.g. 
chitosan) and microbial origin (e.g. xanthan gum). Chemically, polysaccharides may 
be classified into two types: homopolysaccharides and heteropolysaccharides (Pigman 
and Goepp, 1945). 
 
1.1.1.1 Homopolysaccharides 
When all the monosaccharides in a polysaccharide are of the same type, the 
polysaccharide is called a homopolysaccharide. Cellulose (Figures 1.4) and amylose 
for example are both linear homopolysaccharides which consist of glucose repeating 
units (Pigman and Goepp, 1945). In addition, homopolysaccharides may also be 
branched, such as amylopectin and glycogen. 
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As glycosidic linkage can be formed at any one of the hydroxyl groups of a 
monosaccharide therefore lead to the occurrence of branches in polysaccharides. 
 
β -D- glucose β -D- glucose 
n
H
2 H2
 
 
Figure 1.4: Structure of cellulose (The repeating unit ‘n’ may be several thousands). 
 
 
1.1.1.2 Heteropolysaccharides 
When the polysaccharide contains different monosaccharides or their derivatives, they 
are referred to as heteropolysaccharides, which can also be linear or branched 
polysaccharides. Mucopolysaccharides are heteropolysaccharides composed of 
repeating units of sugar derivatives, namely amino sugars and uronic acids. These are 
more commonly known as glycosaminoglycans (GAGs). Hyaluronic acid, chondroitin 
sulfate, and heparin are important examples for mucopolysaccharides. 
Polysaccharides have come under increasing attention due to their industrially useful 
physical, chemical and biological properties amongst these polysaccharides it is 
chitosan (Figure 1.5) and its derivatives, which have generated particular interest 
(Rampino et al., 2013).  
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Figure 1.5: Structure of chitosan (The repeating unit ‘n’ may be several thousands)  
(Nyström et al., 1999). 
 
 
1.2 Chitosan 
The term chitosan (CS) is generally understood to be the generic name for a family of 
strongly polycationic polysaccharide derivatives, and chitosan is classified as 
heteropolymer that consists of glucosamine and N-acetyl glucosamine residues linked 
together by β(14) glycosidic bonds. Chitosan is a biomaterial derived from 
deacetylation of chitin (poly-N-acetyl-D-glucosamine), which is second most 
abundant naturally occurring polysaccharide on earth after cellulose (Roberts, 1992). 
Moreover, chitosan is potentially more useful than chitin, due to its solubility in some 
solvents. 
In addition, chitosan refers to a family of copolymers with different fractions of 
acetylated units, and consists of two types of monomers which are chitin-monomers 
and chitosan-monomers (Roberts, 1992). Chitosan is a semi-crystalline polymer 
which appears in the form of colourless and odourless flakes. The advantage of 
chitosan over other polysaccharides is that its chemical structure allows specific 
modifications at the C-2 position without too many difficulties (Nyström et al., 1999). 
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1.2.1 Production of chitin and chitosan 
Many polysaccharides such as pectin, alginate and carrageenan are acidic/ negatively 
charged in nature (polyanions), on the other hand chitin and chitosan are the only 
examples of naturally occurring positively polysaccharides which are polycations, as 
mucin for example is negatively charged this may prove useful in mucoadhesive 
applications.  
Chitin is a linear polysaccharide consisting of (14)-linked 2-acetamido-2-deoxy-β-
D-glucose (N-acetyl-D-glucosamine), while chitosan is a linear polysaccharide 
consisting of β (14)-linked 2-amino-2-deoxy-D-glucopyranose (D-glucosamine) 
and 2-acetamido-2-deoxy-D-glucose (N-acetyl-D-glucosamine) units. Commercial 
chitin and chitosan both consist of types of monomers. Chitin is found in the cell 
walls of microorganisms such as fungi and yeasts, in the exoskeletons of crustaceans 
such as crab and shrimp, and insects, as well as in various other specialized organs, 
such as the beaks of cephalopods (Roberts, 1992).  Moreover, commercial chitosan 
can be obtained by hydrolysis of the amino acetyl group of chitin (Giri et al., 2012). 
There are three different types of structures in which chitin occurs in nature: alpha, 
beta and gamma chitin. The exoskeletons of crustaceans contain approximately 30 – 
40 % protein, 30 – 50 % calcium carbonate, and 20 – 30 % chitin on a dry basis, 
chitosan can be extracted from crustacean shells (Aranaz et al., 2009) and the 
isolation of chitosan involves four stages including: demineralization (DM), 
deproteinization (DP), decolorization, and deacetylation (DA) (Figure 1.6). 
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Figure 1.6: Production of chitin and chitosan from raw material (Aranaz et al., 2009). 
 
 
Nevertheless, the isolation of chitin (Figure 1.7) specifically consists of only two 
stages: demineralization (DM) and deproteinization (DP). The structure of α-chitin 
has been studied more widely than that of either the β- or -forms, because it is the 
most common polymorphic form (Saito et al., 1997). In addition, β-chitin is degraded 
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more easily than α-chitin (Kurita, 1998) due their crystalline and amorphous 
structures. In α-chitin, β-chitin and -chitin, the chitosan chains are ordered into 
sheets. In the α-form, adjacent sheets are oriented in opposite directions, with strong 
inter- and intra-sheet hydrogen bonds, leading to a strong crystal form which solvents 
have difficulty to penetrate. In the β-form, sheets are oriented in the same direction 
allowing only weak intra-sheet hydrogen bonds which result in higher reactivity to 
reactions such as acetylation, acetolysis, tritylation, tosylation, etc. and affinity for 
solvents than α-chitin (Buschmann et al., 2013, Kurita, 1998). In -chitin every third 
sheet has the opposite direction to the two previous sheets (Figure 1.7) (Aranaz et al., 
2009).  
 
3
3
3
 
 
Figure 1.7: Chemical structure of chitin. 
 
 
1.2.1.1 Deproteinization 
Crustacean shells are commonly ground then treated with dilute sodium hydroxide 
solution NaOH (1-10 %) at high temperature (65 - 100 °C) for 0.5 to 12 hours to 
dissolve the proteins and other sugars present. Then samples are filtered under 
vacuum, after which the filtrate is washed with water and oven dried. Reports suggest 
that the optimum conditions for deproteinization step is treatment of the crawfish 
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shells with 3.5 % (w/w) NaOH solution for 2 hours at 65 °C with constant stirring and 
the optimum ratio of a solid to solvent is 1:10 (w/v)  (No and Meyers, 1989).  
 
1.2.1.2 Demineralization  
Demineralization process is carried out on the deproteinised shells with dilute 
hydrochloric acid (HCl) at room temperature overnight with constant stirring to 
dissolve calcium carbonate as calcium chloride. This requires a solid to liquid ratio of 
approximately 1:15 - 1:20 (w/v) prior to filtration under vacuum. The filtrate is 
washed with water and oven dried (Oduor-Odeto et al., 2005, Mathur and Narang, 
1990). 
 
CaCO3 + 2HCl  CaCl2 + H2O + CO2                                                         Eq. (1.1) 
 
Previous research has shown that optimum demineralization is accomplished by 
constant stirring of the dried ground crawfish shell with 1M HCl for 30 - 60 min at 
room temperature and the solid to solvent ratio is 1:15 – 1:20 (w/v). During the 
demineralization process undesirable foams are produced due to the CO2 formed. To 
reduce these foams, it is often necessary to use a commercial antifoam which consists 
of a 10 % solution of active silicone polymer without an emulsifier (No and Meyers, 
1989, Puvvada et al., 2012). 
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1.2.1.3 Decolouration 
The pigments in the crustacean shells produce complexes compounds with chitin. 
Moreover, the deproteinization and demineralization processes produces a coloured 
chitin product from crustacean sources, therefore a decolouration step is added to 
remove pigments and obtain a white chitin powder (Rinaudo, 2006). A number of 
studies have used reagents to remove pigments from crustacean exoskeleton usually 
crab. One study has reported decolourised of chitin for overnight with a 1:1 mixture 
of acetone/ethanol at a solid: liquid ratio of 1:10 (Oduor-Odeto et al., 2005). In 
another study, it has been suggested that to produce a near white coloured product 
requires extraction with acetone and to be dried for 2 hours at room temperature after 
that bleaching with sodium hypochlorite solution NaOCl 0.315% (v/v) for 5 min. 
Also, a solid to solvent ratio is 1:10 (w/v), based on dry shell after that samples are 
washed with water and dried using vacuum for 2-3 hours until the powder is crispy 
(No and Meyers, 1989). 
 
1.2.1.4 Deacetylation 
Deacetylation can be defined as a process which to convert acetamide groups             
(NHCOCH3) of chitin to amino groups (NH2) of chitosan (Huang et al., 2004) 
(Figure 1.8). It is usually achieved by treatment of decolourised chitin with 
concentrated sodium or potassium hydroxide solution (40 - 50 % w/v) usually at 100 
°C  for 30 – 60 min or longer to remove some or all of the acetyl groups from the 
chitin (Oduor-Odeto et al., 2005). Afterwards the samples are cooled for 30 min at 
room temperature then are washed continuously with the 50 % NaOH and filtered in 
order to retain the solid substance, which is the chitosan polymer. Finally, in order to 
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dry chitosan, the samples were left in oven at 110 °C for 6 hours (Mathur and Narang, 
1990). 
 
 
 
Figure 1.8: Preparation of chitosan (B) by the deacetylation of chitin (A)  
(Pillai et al., 2009). 
 
 
The term used to describe the percentage of primary amino group in the polymer 
backbone is degree of deacetylation (DD). The majority of commercial grades of 
chitosan are obtained by alkaline deacetylation of chitin, which leads to material 
containing 70-100 % glucosamine and 0-30 % N-acetyl glucosamine units. Therefore, 
grades of chitosan vary in their degree of deacetylation (DD), as well as molecular 
weight (MW) (Hamdine et al., 2005, Sinha et al., 2004). Moreover, the DD of 
commercial chitosan is approximately 66 - 95 %, and the molecular weight (MW) 
approximately 10,000 – 1,000,000 g/mol (Kas, 1997, Mathur and Narang, 1990). 
According to chitin and chitosan chemical structures, the difference between chitin 
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and chitosan is the acetyl group content of the polymers, therefore as the chitosan 
chain has a free amino group it is the most useful derivative of chitin (Figure 1.8). 
 
The extracted chitosan has to be purified to make it suitable for the pharmaceutical 
usage. Therefore a further three processes are carried out including: filtration to 
remove of insoluble particles, precipitation of chitosan with 1N NaOH to neutralise 
the NH3
+ groups to NH2 and finally, demetallisation of retrieved chitosan (Puvvada et 
al., 2012). 
 
1.2.2 Applications for Chitosan 
Chitosan has some industrially useful characteristics such as gel-forming ability at 
low pH, and has therefore been widely studied for a number of pharmaceutical and 
biomedical applications (Kumar et al., 2004). Some applications of chitosan in both 
the polymeric and particle form over the last ten years in the pharmaceutical and 
medical fields are summarized in Table 1.1. 
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         Table 1.1: Examples of chitosan-based biomedical devices and drug delivery systems 
Type of system Active Substance (drug) Application Reference 
Chitosan:TiO2 Ibuprofen Drug-delivery system (Kamari and Ghiaci, 2016) 
Chitosan 
nanoparticles 
Docetaxel Drug delivery system for cancer 
Chemotherapy 
(Jain et al., 2016) 
Chitosan 
nanoparticles 
Timolol (Eye) drug-delivery system (Siafaka et al., 2015) 
Chitosan 
nanoparticles 
Alendronate sodium Drug-delivery system (Miladi et al., 2015) 
Chitosan polymer Catechol Mucoadhesion (Kim et al., 2015) 
Chitosan: TPP 
nanospheres  
Capecitabine Anticancer therapy (Katakam et al., 2015) 
Chitosan: TPP  
nanospheres 
Albendazole Drug-delivery system (Kang et al., 2015) 
Chitosan-
glutaraldehyde 
microspheres 
Puerarin Mucoadhesive drug-delivery carriers (Hu et al., 2015) 
CS-MMT/TPP Betaxolol hydrochloride Ocular drug delivery (Hou et al., 2015) 
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Chitosan 
Film 
Ibuprofen Oral mucosal drug 
Delivery 
(Tang et al., 2014) 
Chitosan– (PEG) 
nanoparticles 
Ibuprofen Drug delivery systems (Najafabadi et al., 2014) 
Chitosan Porcine gastric mucin Mucoadhesive buccal drug delivery 
systems 
(Meng-Lund et al., 2014) 
Chitosan Mucin from porcine 
stomach 
Mucoadhesion (Menchicchi et al., 2014) 
CS-TPP nanoparticles Thiocolchicoside Potential oral drug delivery system (Nanda et al., 2012) 
CS-TPP nanoparticles Mesobuthus eupeus venom An antigen delivery system (Mohammadpour Dounighi et al., 
2012) 
Chitosan: TPP 
microparticles 
Heparin Controlled release of drug (Martins et al., 2012) 
Chitosan: TPP 
nanoparticles 
BSA Protein drug delivery (Kafshgari et al., 2011) 
Chitosan: TPP 
nanoparticles 
Methotrexate and calcium 
folinate 
Drug delivery (Jingou et al., 2011) 
Chitosan: TPP 
nanoparticles 
(BSA), Ribonuclease A, 
Fibrinogen, α-Lactalbumin 
and Transferrin 
Drug delivery (Jarudilokkul et al., 2011) 
Chitosan: TPP 
nanoparticles 
p-DNA Gene delivery application (Gaspar et al., 2011) 
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TCS: TPP 
nanoparticles 
Cytocompatibility Biomedical applications (Anitha et al., 2011) 
CS: TPP 
nanoparticles 
Silver Biomedical applications (Ali et al., 2011) 
CS: TPP 
nanoparticles 
Ascorbyl palmitate Drug delivery (Yoksan et al., 2010) 
CS: TPP 
nanoparticles 
Snake venom Protein delivery system (Mohammadpourdounighi et al., 
2010) 
CS: TPP 
nanoparticles 
Hyaluronic acid Drug 
delivery applications 
(Nasti et al., 2009) 
CS: TPP 
nanoparticles 
Ciprofloxacin Drug delivery systems (Liu and Gao, 2009) 
CS: TPP 
microparticles 
Cyclosporin A Drug delivery systems (Cheon and Chung, 2009) 
CS: TPP 
nanoparticles 
Estradiol Drug delivery systems (Wang et al., 2008a) 
CS: TPP 
nanoparticles 
Dorzolamide and 
pramipexole 
Drug delivery systems (Papadimitriou et al., 2008) 
CS: ALG Gatifloxacin Drug carriers for ocular delivery (Motwani et al., 2008) 
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nanoparticles 
CS: TPP 
nanoparticles 
Albumin and gelatin Drug delivery Systems (Jain and Banerjee, 2008) 
CS: TPP 
nanoparticles 
Tea catechins Drug delivery 
Systems 
(Hu et al., 2008) 
CS: GA microspheres 
glutaraldehyde 
Ibuprofen Drug delivery (Kulkarni et al., 2007) 
CS: TPP 
nanoparticles 
BSA Protein delivery (Gan and Wang, 2007) 
CS: TPP 
nanoparticles 
FITC Applications in biological staining (Zhao and Wu, 2006) 
CS: TPP 
nanoparticles 
siRNA Delivery system for siRNA (Katas and Alpar, 2006) 
CS: GA microspheres 
glutaraldehyde 
Centchroman Drug delivery (Gupta and Jabrail, 2006) 
Chitosan 
Microspheres 
Carbamazepine Drug delivery (Gavini et al., 2006) 
CS: TPP 
microspheres 
Ampicillin Drug delivery (Anal et al., 2006) 
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1.2.3 Structural and physicochemical characteristics of chitosan 
The structural units of chitosan have one reactive primary amino group (NH2) on the 
C-2 position of each D-glucosamine unit, and two reactive free hydroxyl groups (OH) 
for each C-6 and C-3 position building unit (glucosamine and N-acetyl-D-
glucosamine). These groups (both amino and hydroxyl) can be modified to obtain 
different chitosan derivatives, and provide opportunities for chemical modification to 
impart useful physicochemical properties and distinctive biological functions (Giri et 
al., 2012, Chen et al., 2011, Nyström et al., 1999). 
 
In addition, the amino and hydroxyl groups are responsible for the formation of 
hydrogen bonds (H-bonds) between molecules of the polymer. The chitosan 
molecules form a large inter-chain structural network due to these hydrogen bonds, 
which affect several properties such as viscosity, solubility and absorbability. 
 
The pKa, which means the logarithmic scale of  the acid dissociation constant, of the 
glucosamine unit in chitosan is approximately 6.3, therefore it is ionised in acidic 
medium (Yalpani and Hall, 1984). Moreover, some properties of chitosan can be 
modified, such as the pKa and solubility, by changing the degree of deacetylation and 
formulating conditions such as the ionic strength and pH (Dyer et al., 2002). The free 
amine groups NH2 on chitosan molecules can be easily protonated to NH3
+ in acidic 
aqueous solutions, therefore the net charge/ zeta potential on the chitosan is 
influenced by pH. 
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-NH2 + H
+   -NH3
+                                                                              Eq. (1.2) 
 
Therefore, chitosan is present in solutions in a cationic polyelectrolyte form, which 
opens the possibility for interactions with negatively charged substances (anions and 
polyanions) including for example mucin (Qaqish and Amiji, 1999). 
 
1.2.3.1 Solubility 
Chitosan is a weak base and it is insoluble at neutral and alkaline pH, as well as in 
water and some organic solvents such as ethanol (Hu et al., 2008, Kotze et al., 1999, 
Sudha, 2017), due to the formation of intermolecular hydrogen bonds (He et al., 
1998). However, chitosan is soluble in a dilute aqueous acidic environment (pH < 
6.0). The solubility of chitosan depends on the distribution of free amino and N-acetyl 
groups. In dilute acids (pH < 6.0), the free amino groups on glucosamine units take up 
hydrogen ions (H+) which lead to protonated R-NH3
+, and consequently the chitosan 
molecule becomes a polycationic electrolyte and is then soluble (Figure 1.9) (Kwang-
hee, 1983). 
 
2
3
+
+
Insoluble form
   pH > 6.0
Soluble form
   pH < 6.0  
 
Figure 1.9: Protonated chitosan in acid solution (Kumirska et al., 2011). 
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Therefore, chitosan is capable of reacting with organic and inorganic acids, such as 
hydrochloric acid and acetic acid, under acidic conditions (Rinaudc et al., 1999, Kim 
et al., 2006). On the other hand, in alkaline solutions or with polyanions, chitosan 
tends to lose its charge on the NH3
+ group, and therefore may precipitate from 
solution due to deprotonation of the amino groups (Nyström et al., 1999). There are 
factors which affect the solubility of chitosan. The solubility increases with increases 
in the degree of deacetylation, temperature and stirring rate, whereas it decreases with 
increasing molecular weight (Wu et al., 2005). 
 
1.2.3.2 Biodegradability, biocompatibility and toxicity 
In the recent decades, chitosan has been one of the major interesting research subjects 
due to its significant biological, physical and chemical properties, such as 
biocompatibility, biodegradability, hydrophilicity, nontoxicity, adsorptive properties, 
film-forming ability and antimicrobial activity (Lee et al., 1995, He et al., 1998). 
Chitosan is a biodegradable polysaccharide. Biodegradation is the breakdown of 
polymer chains into oligomers and monomers assisted via a biological compounds 
after responding to the physio-chemical conditions (Chellat et al., 2000). The most 
significant advantage of biodegradable substances is the ease of disappearance of 
these substances from the body as a result of their biodegradation after implantation in 
human body (Yang et al., 2007). Using chitosan as drug delivery system depends on 
its biodegradation and metabolic fate in the body (Kean and Thanou, 2010). There are 
two biodegradation mechanisms: chemical and enzymatic. An acid catalysed 
degradation i.e. in the stomach for example is a chemical degradation. Moreover, 
lysozymes in the body example is an enzyme degradation of chitosan into 
glucosamine and N-acetyl-glucosamine (Dash et al., 2011). The biodegradation of 
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chitosan depends on its degree of deacetylation, molecular weight and strength of 
cross-linking (for example with TPP as an ionic cross-linker). Therefore, the higher 
degree of deacetylation, molecular weight and strength of cross-linking of chitosan 
results in the slower biodegradation (Yamamoto and Amaike, 1997, Zhang and Neau, 
2001, Kean and Thanou, 2010). Moreover, chitosan is degraded slowly by the 
chitanase enzyme to monomers of amino sugars, which are harmless and can be 
completely absorbed by the human body (Aiba, 1992, Chellat et al., 2000). 
 
1.3 Mucin 
Mucus is a thick complex material that lines the luminal surface of the 
gastrointestinal, urogenital, respiratory and eye tissues, also, the peritoneal surface of 
intra-abdominal organs in humans and most animals (Lai et al., 2009). The function of 
mucus is as a protective barrier against pathogens and toxins, as well as providing the 
innate defensive system in mucosal immunology. Moreover, mucus is continuously 
secreted, recycled, digested and discarded (Rose and Voynow, 2006). In addition, 
mucus is the first boundary with which nutrients and enteric drug must interact with 
then diffuse through, in order to be absorbed and obtain access to the circulatory 
system and their target end organs (Bansil and Turner, 2006, Lai et al., 2009). Mucus 
is composed mostly of water (~95 %). However, it contains inorganic salts, lipids, 
enzymes such as lysozyme, immunoglobulins, growth factors and trefoil factors. 
Nevertheless, the main components of mucus which are responsible for the viscous 
and elastic gel-like properties are mucins (Bansil and Turner, 2006).  Mucins are a 
family of complex high molecular weight (5 - 20 x 105 g/mol) glycoproteins secreted 
by the epithelia of the intestinal, respiratory and urogenital tracts, consisting of linear 
or branched oligosaccharides attached to the protein core. These glycoproteins consist 
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mostly of carbohydrates, which can account for 60-80 % of their weight. The 
carbohydrate fraction consists of five sugars are N-acety-lglucosamine, N-acetyl-
galactosamine, galactose, and fucose and sialic acid (N-acety-lneuraminic), as well as 
traces of mannose and ester sulfate (Figure 1.10) (Thornton and Sheehan, 2004, 
Abodinar et al., 2016). The rigidity of the structure of mucin is mostly due to the high 
sialic acid and sulfate ester contents which leads to a negative charge on mucin which 
is the main reason for its gelling and mucoadhesive properties (Harding et al., 1999). 
 
 
 
Figure 1.10: Representative structures of (a) Fucose, (b) Sialic acid (c) N-Acetyl-
Galactosamine, (d) Galactose, and (e) Mannose. 
 
 
Sialic acid, which is distributed throughout human tissues, is present in several fluids, 
including, cerebrospinal fluid, serum, urine, amniotic fluid saliva, and breast milk. In 
addition it is found in high levels in some organs such as the heart, adrenal glands, 
and brain (Matsuno and Suzuki, 2008). The glycosylated proteins have a defining 
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feature of a repeating sequence of amino acids, namely serine and threonine. The 
oligosaccharides chains consist of about 5–15 units indicating moderate branching 
and are attached to the protein by O-glycosidic linkages to the hydroxyl (OH) side 
chains of serine and threonines then arranged in a bottle brush shape about the protein 
core (Figure 1.11) (Bansil and Turner, 2006). 
 
 
 
 
Figure 1.11: Representative structure of mucin glycoproteins and interaction sites where 
mucoadhesion may take place (Yang et al., 2012). 
 
 
 
Mucins can be classified by their MUC protein backbone into three groups and are 
summarized in Table 1.2. 
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Table 1.2: Classification of mucins classification of mucins (Niv and Boltin, 2012). 
Classification Mucins Presence 
Secreted, gel-forming mucins MUC2, MUC5AC, MUC5B, 
MUC6, MUC19 
Eyes, middle ear epithelia, small intestines, colon, respiratory tract, 
stomach, cervix, salivary glands, gallbladder, seminal fluid, duodenum, 
pancreas and submandibular gland 
Secreted, non-gel-forming 
mucins 
MUC7, MUC8 In salivary glands, respiratory tract and middle ear epithelium (Linden et 
al., 2008) 
Membrane bound (structural) 
members 
MUC1, MUC3A, MUC3B, 
MUC4, MUC12, MUC13, 
MUC15, MUC16, MUC17, 
MUC20 and MUC21 
On the apical membrane of epithelial cells (Linden et al., 2008) 
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All mucins have one or more mucin-like domain which hold the usual mucin O-
glycosylation. In addition, the domain is made of different tandem repeats (TR) rich 
in threonine, serine and proline residues in the protein backbone (Rose and Voynow, 
2006). 
 
The glycoprotein core is arranged into different regions. Firstly, a central glycosylated 
region involved of a large number of tandem repeats which are rich in serine, 
threonine and proline (STR) repeats that may make up more than 60 % of the amino 
acids. Secondly, located on the amino and carboxyl groups, and occasionally 
interspersed between the STP-repeats, are regions with an amino acid conformation 
more representative of proteins, relatively few O-glycosylation and a few N-
glycosylation sites Figure 1.12 (Bansil and Turner, 2006). 
 
 
 
Figure 1.12: A secretory mucin glycoprotein representing a MUC protein backbone and its 
O-glycans. A MUC protein backbone usually consists of an NH2 group domain (blue), one or 
more central domain with a high number of tandem repeat (TR) domains (yellow), and            
a COOH group domain (green) (Rose and Voynow, 2006). 
 
 
Mucoadhesive drug delivery systems are advantageous in several ways. Other than 
prolonged contact time resulting in high drug flux at the intended tissue site, they are 
able to target and localise a dose form at a specific site, for example, oral cavity, eye 
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conjunctiva, vagina, nasal cavity and gastrointestinal tract (GIT). Due to preventing 
the washing away of the active agent by oral secretions, the delivery systems are 
usually coated with a drug and water impermeable film (Remuñán-López et al., 
1998). 
 
There are several possibilities for mucoadhesive drug delivery systems. 
Mucoadhesive tablets can adhere to any mucosal tissue including those found in 
stomach, as a result offering the possibilities of localised and systemic controlled 
release of drugs. The application of mucoadhesives in a semisolid dosage form, such 
as gels and ointments, provide an extended retention time in the oral cavity, suitable 
drug penetration and high efficacy and patient acceptability (Boddupalli et al., 2010). 
 
1.3.1 Mucoadhesive properties 
Mucoadhesion is often defined as the adherence of a bioadhesive polymer to 
biological surfaces (either secreted mucus or a mucosal surface) (Meng-Lund et al., 
2014, Madsen et al., 1998). Mucosal membranes in the human organism are relatively 
porous surfaces and allow fast drug absorption. Mucus is a complex biological 
substance that lubricates and protects epithelial surfaces in the human body including 
lungs, gastrointestinal (GI) tract, vagina, eyes, and other moist mucosal surfaces. 
Furthermore, the mucus contains 5 % mucin glycoproteins, lipids, inorganic salts and 
95 % water, DNA, cellular debris, secretory IgA, lactoferrin, lysozyme, uric acid, 
ascorbic acid, reduced glutathione and prostaglandins (Lai et al., 2009, Caramella et 
al., 2015, Hoang et al., 2010) (Figure 1.13). 
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Figure 1.13: Mucus membrane structure (Boddupalli et al., 2010). 
 
 
Chitosan is very highly regarded in the medicinal world because it demonstrates 
mucoadhesive behaviour, however the interactions of chitosan with mucus are 
complicated. Depending on the physiological conditions and physiochemical 
properties such as pH and the presence of other materials, it is generally understood 
that electrostatic interactions can occur between chitosan’s positively charged amino 
groups and the negatively charged sialic acid residue on mucin, as well as 
hydrophopic, hydrophilic interactions and hydrogen bonding are also very important 
(Illum et al., 1994, Deacon et al., 1999). Mucoadhesion is divided into stages based on 
the interaction between mucoadhesive materials and a mucous membrane. Firstly, the 
contact stage also known as the wetting stage, which is contact between the 
mucoadhesive material and the mucous membrane. Secondly, the consolidation stage 
it is at this stage adhesive interactions are formed (Smart, 2005) (Figure 1.14). 
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Figure 1.14: The contact and consolidation stages of mucoadhesion (Smart, 2005). 
 
 
During the consolidation stage, if mucoadhesive materials are activated by the 
presence of moisture, it leads to a strong adhearance between mucoadhesive materials 
and dry solid surfaces. The presence of moisture is very important that will effectively 
plasticize the system, allowing mucoadhesive materials to break free and interact via 
weaker van der Waal forces and hydrogen bonding or electrostatic interactions. 
Therefore, there are electrostatic interactions between cationic chitosan and negatively 
charged groups, for example, carboxylate ions or sulphate ions on cell or the mucous 
surfaces (Artursson et al., 1994, Illum et al., 1994). There are five different theories of 
mucoadhesion which are summarized in Table 1.3 (Vasir et al., 2003). 
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Table 1.3: Theories of mucoadhesion. 
Theory Mechanism of adhesion Comments 
Electronic Based on the electrostatic forces (opposing 
electrical charges) between the mucoadhesive 
material and biological materials 
When both materials combine together, the electrons transfer, as a result a double 
electronic layer is formed at the surface 
Adsorption Based on a chemical bonds due to a surfaces 
forces 
The mucoadhesive material adheres to the biological material (mucus) by 
formation of van der Waals forces, hydrogen bonds, electrostatic attraction or 
hydrophobic interactions 
Wetting (Figure 1.15) 
Carvalho et al., 2010 
Based on the ability of bioadhesive polymers 
to spread onto mucus membranes 
Applies to fluid systems which present affinity to the surface in order to spread 
over it. Contact angle between mucoadhesive polymer and cells must be near to 
zero 
Diffusion (Figure 1.16) 
Carvalho et al., 2010 
Physical entanglement of mucin strands and 
the flexible polymer chains 
 
The interpenetration of both polymer and mucin chains to a enough depth to create 
a semi-permanent adhesive bond. Therefore, the adhesion force rises with the 
degree of penetration of the polymer chains 
Fracture (Figure 1.17) 
Carvalho et al., 2010 
Analyses the maximum tensile stress 
developed during detachment of the 
bioadhesive drug delivery system from 
mucosal surfaces 
Does not require physical entanglement of bioadhesive polymer chains and mucin 
strands, therefore suitable to study the bioadhesion of hard polymers which lack 
flexible 
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Figure 1.15: Schematic diagram showing wetting theory of mucoadhesion 
(Carvalho et al., 2010). 
 
 
 
 
Figure 1.16: Diffusion theory of mucoadhesion (Carvalho et al., 2010). 
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Figure 1.17: Fracture theory of mucoadhesion (Carvalho et al., 2010). 
 
 
1.3.2 Factors Influencing Mucoadhesive Properties 
1.3.2.1 Molecular Weight of polymer 
There is positive correlation between the mucoadhesive strength of a linear polymers 
and their molecular weights above 100,000 g/mol, because linear polymers enable 
better interpenetration and entanglement which is significant for bioadhesiveness. On 
the other hand, the same relationship does not hold for non-linear polymers. 
Moreover, lower molecular weight polymers can readily dissolve then form weak 
gels, whereas, large molecular weight polymers do not hydrate readily to allow 
binding groups on polymers to interact with mucus layer. (Lee et al., 2000, 
Boddupalli et al., 2010, Smart, 2005). 
 
1.3.2.2 Concentration of polymer 
A very low concentration polymer would result a weak adhesive bond with the 
mucus, due to the number of penetrating polymer chains per unit volume of the mucus 
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being small and lead to the interaction between polymer and mucus being unstable. 
However, the a concentrated polymer system would result in a strong adhesive bond 
with the mucus, due to more polymer chains being available to penetrate into the 
mucus layer and better adhesion. On the other hand, there is a critical concentration 
for each polymer. For a highly concentrated formulation (higher than the a critical 
concentration level), the adhesive strength decreases due to the coiled molecules 
separating from the medium, therefore the chains available for interpenetration 
become limited (Lee et al., 2000). 
 
1.3.2.3 Flexibility, length of polymer chains and cross-linking 
density 
Chain flexibility is very important to combine the interpenetration between 
formulation and mucus. If a polymer is a higher flexibility, this leads to more 
diffusion into the mucus network. Cross-linked hydrophilic polymers swell in the 
presence of water allowing them to keep their structure. The swelling process allows 
more control of drug release and increases the surface area for polymer/mucus 
interpenetration (Andrews et al., 2009). Therefore, as the cross-linking of water-
soluble polymer increases, the mobility and flexibility of the polymer chains decrease, 
and consequently the effective length of the chain which can penetrate into the mucus 
membrane decreases, which reduces bioadhesive strength (Lee et al., 2000, 
Boddupalli et al., 2010). 
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1.3.2.4 Functional group contribution 
Mucoadhesive polymers commonly have a several hydrophilic polar functional 
groups such as, carboxyl (COOH), hydroxyl (OH) and amine groups (NH2). The 
bonding of bioadhesive polymers to the mucus layer occurs essentially through 
interpenetration followed by secondary bonding between mucus layers. Moreover, the 
secondary bonding mainly increases due to hydrogen bond formation (Andrews et al., 
2009). Typically, hydrogen bonds contribute to the formation of a strengthened 
network; therefore polymers that demonstration a large density of available hydrogen 
bonding groups would be able to interact more strongly with mucus membrane 
(Madsen et al., 1998). 
 
1.3.2.5 pH and polymer charge 
The pH can affect the formation of ionisable groups in bioadhesive polymers and the 
formation of charges on the mucus surface. Bioadhesive polymer charges are affected 
by the pH of the physiological environment due to the dissociation of functional 
groups. In addition, mucus possesses a different charge density depending on pH due 
to differences in dissociation of functional groups on substances such as the 
carbohydrate and the amino acids of the polypeptide backbone (Lee et al., 2000). 
Mucoadhesive polymers can be divided into three main types in terms of overall 
charge, i.e., anionic, cationic and non-ionic systems. Non-ionic polymers exhibit a 
smaller degree of adhesion compared to anionic polymers. Strong anionic and cationic 
polymers are one of the required characteristics for mucoadhesion (Andrews et al., 
2009, Boddupalli et al., 2010). In general, carboxylated polymers, at pH values below 
its pKa value would be favourable (Riley et al., 2001). For example, mucoadhesion of 
polyacrylic acid is favoured when the most of the carboxylate groups (COOH) are in 
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the non-ionised form, which occurs at pH below the pKa. However, at higher pH 
values, there is electrostatic repulsion of the carboxylate anions (COO-) between 
mucin and polyacrylic acid (Smart, 2005, Lee et al., 2000). On the other hand, in 
systems with a high density of ionisable groups, such as chitosan which could form 
polyelectrolyte complexes (at pH < 6) with negatively charged mucins and 
consequently stronger mucoadhesion (Andrews et al., 2009). 
 
1.3.2.6 Initial contact time 
Another important factor affecting the mucoadhesive strength of polymeric 
components is initial contact time. It has conclusively been shown that mucoadhesive 
strength increases with the longer initial contact time between the bioadhesive 
polymer and mucus layer. Contact time between bioadhesive polymer and mucus 
layer determines the degree of chain interpenetration (Lee et al., 2000, Carvalho et al., 
2010). 
 
1.3.2.7 Degree of hydration 
Hydration is important for the relaxation and interpenetration of bioadhesive polymer 
chains. However, super hydration of system would lead to decreased mucoadhesion 
due to the formation of moist slippery mucilage. In addition, it has been suggested 
that cross-linked polymers permit a certain degree of hydration which would  provide 
a prolonged mucoadhesive effect (Andrews et al., 2009). 
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1.3.3 Advantages of mucoadhesive delivery systems 
If bioadhesive molecules can bind with the active drug pharmaceutical formulation, 
the formulation will be remain longer on the biological surface. Then the drug will be 
released close to the absorptive membrane, resulting in an improved bioavailability of 
the drug. Moreover, when using specific bioadhesive molecules such as chitosan, it 
will allow the possible targeting of a tissue or particular site for example the 
gastrointestinal tract. In addition, mocuadhesion is very important in the reduction of 
drug degradation during the first-pass metabolism (Andrews et al., 2009). 
 
1.4 Drug delivery system 
A drug delivery system (DDS) is a formulation or a device that enables the 
introduction of a therapeutic material to the body. Drug delivery systems are used to 
maintain a drug which has been administered using the therapeutic product for a 
determined period of time and the release of the active ingredients by the product 
across the biological membranes to the site of action. The concentration of drug must 
remain between the minimum and maximum blood values. This means, at high level, 
drugs could cause side effects and at lower levels the drug no longer provides a 
therapeutic effect (Winstanley et al., 2007). Due to chitosan’s efficiency in the 
entrapment of specific drugs and its ability to control drug release, it is one of the 
most widely used polymers in drug delivery systems (Table 1.1). Chitosan 
demonstrates promising properties as support agent in drug delivery. Chitosan is the 
only naturally occurring positively charged biopolymer rendering it unique among all 
other biodegradable polymers. This cationic character based on its primary amino 
groups is responsible for several properties and consequently for its use in drug 
delivery systems. Chitosan is generally used in the several forms including tablets, 
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powder, film, micro/nanocapsules and micro/nanospheres in drug delivery 
applications (Banerjee et al., 2002, Boonsongrit et al., 2006, Tang et al., 2003, Calvo 
et al., 1997b, Liu et al., 1997, Meshali and Gabr, 1993, Patel Jayvadan et al., 2009, 
Bhardwaj et al., 2010). 
 
1.5 Nanotechnology  
In 1974, Prof. Taniguchi first used the word “nanotechnology”. In addition, in 2000 
National Nanotechnology Initiative (NNI) was initiated by US President Bill Clinton 
(Agarwal et al., 2015). Nanotechnology can be defined as the design, which focuses 
on the characterisation and production of organic or inorganic compounds, structures, 
fabrication, manipulation, devices and systems by controlling their size and shape 
within the scale of sub-micron dimensions. Therefore, it refers to structures that are 
up to several hundred nanometres in size (Farokhzad and Langer, 2009). In 1959 the 
physicist Richard Feynman discovered that the possibility of manipulating substances 
at the nanoscale and also stated a process through which scientists might be able to 
manipulate the individual atoms or molecules as a more powerful tool of scientific 
chemistry than those used at that time. Therefore nanotechnology has applied in a 
variety of fields such as the electronics physical, material science and manufacturing 
at molecular or submicron level (Agarwal et al., 2015).  
 
1.5.1 Advantages of nanoscale drug delivery system 
Drug delivery is defined as the method of releasing a bioactive agent at a specific site 
and at a specific rate. The most important advantages of nanotechnology offers is 
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targeted drug delivery to the site of disease (Torchilin, 2000). The many advantages 
of nanoparticles include (Parveen et al., 2012): 
 Easier to penetrate cells and tissue to arrive at target organ(s) (Yih and 
Al‐Fandi, 2006, Monsky et al., 1999) 
 Protects the drug from degradation (Danhier et al., 2010) 
 Increases the aqueous solubility of the drug (Van Eerdenbrugh et al., 2010) 
 Prolonged release of the drug (zur Mühlen et al., 1998) 
 Improved utility of the drug (Brown et al., 2010) 
 Reduction undesired side effects of the drug (Mitra et al., 2001) 
 Rapid-formulation development (de la Escosura-Muñiz et al., 2009)  
 Offers suitable forms for all routes of administration (Parveen et al., 2012) 
 Improves the bioavailability of the drug (Wang and Zhang, 2012) 
 
 
1.5.2 Polysaccharide nano/microparticles  
Nanoparticles are defined as solid colloidal particles that are frequently composed of 
insoluble polymers and have a minimum of one dimension that is ranging from 10 – 
1000 nm in diameter. Nano size also, refers to one thousand millionth (one billionth) 
of a metre (Sahoo et al., 2007). On the other hand, microparticles, called microspheres 
or microcapsule, are defined as spherical microscopic particles that range from 1-1000 
µm in diameter (Figure 1.18).  
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Figure 1.18: An example of (a) TEM of a carbon black nanoparticle showing particle 
diameters ranging from 30 to 100 nm (b) SEM of NMC microparticles showing an average 
particle size of 10 µm (Morelly et al., 2017),  (c ) SEM image of black granular fingerprint 
powder, the elemental carbon has a particle size of 5-10 mm (Bandey and Gibson, 2006). 
 
 
Nanotechnology is one of the most interesting areas of biopolymer research which 
finds exciting applications in drug delivery systems and food technology. Biopolymer 
particles can be formed by self-association or aggregation of single biopolymers or by 
inducing phase separation in mixed biopolymer systems. Nanoparticles have a small 
size and are therefore used in or have been evaluated for use in, many fields and 
applications.  
 
Chitosan, alginate and glucomannan are examples of polysaccharides which have 
been used to produce nanoparticles for different applications in the pharmaceutical, 
medical, food and cosmetic industries (Zhang and Kosaraju, 2007, Alonso-Sande et 
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al., 2006, Janes et al., 2001, Liu et al., 2008b). The properties of substances may 
change when formulated into nanoparticles, hence the surface chemistry of a 
nanoparticle is unusually different from that of the original substances (Christian et 
al., 2008). Microparticles, for example, have a lower surface area to volume ratio the 
nanoparticles. The higher surface area of nanoparticles allows them to be more 
reactive to certain other molecules. As a consequence, nanoparticles have a high 
carrier capacity to allow numerous drug molecules to be combined in the particle 
matrix, this includes the ease of combination of both hydrophilic and hydrophobic 
molecules. In addition, the advantage of their small size  allows nanoparticles to be 
more readily taken up by the human body, to cross biological membranes then enter 
cells, tissue and finally organ, whereas the larger size particles such as microparticles 
cannot (Panyam et al., 2003, Desai et al., 1997, Desai et al., 1996). 
 
1.5.2.1 Methods of preparation of chitosan micro/nanoparticles 
(cross-linking of chitosan)  
Cross-linking is the development of primary bonds that form between polymer 
molecules, and it occurs when a chemical substance, known as a cross-linking agent, 
cross-links between polysaccharide macromolecules or introduces intermolecular 
bridges (Sinha et al., 2004, Shweta and Sonia, 2013). Moreover, cross-linking of 
chitosan is based on the addition of a cross-linker. The amino and hydroxyl groups 
which exist on chitosan are active sites that lead to the formation of a number of 
linkages, including amide and ester bonding as well as Schiff base formation. 
Chitosan can be physically cross-linked with polyanoins (Berger et al., 2004, Jonassen 
et al., 2012). In addition, this cross-linking may be achieved at different pH values: 
acidic, neutral or basic pH, depending on the method applied. Therefore, cross-linked 
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chitosan is very important in many applications, particularly in the pharmaceutical 
field for the formulation of several novel drug delivery systems such as microspheres, 
nanospheres, hydrogels and films/membranes. Some methods using chemical 
crosslinking agents such as glutaraldehyde, ethylene glycol diglycidyl ether and 
sodium hydroxide have been used to prepare particles. These chemical crosslinking 
agents may cause of undesirable effects. Glutaraldehyde for example, can cause 
irritation to mucosal membranes due to its toxicity (Mi et al., 2001, Mi et al., 1999, 
Chandy and Sharma, 1996, Ko et al., 2002). On the other hand, sodium 
tripolyphosphate (TPP) is a multivalent polyanion which is non-toxic and available at 
low cost (Sezer and Akbuǧa, 1995, Bodmeier et al., 1989, Mathur and Narang, 1990) 
and it is an inorganic compound of the sodium salt of the polyphosphate penta-anion. 
Sodium tripolyphosphate (molecular formula Na5P3O10) is the conjugate base of 
triphosphoric acid (molecular formula H5P3O10). 
 
Various techniques have been developed to prepare chitosan micro/nanoparticles, 
including emulsion crosslinking, coacervation/precipitation, spray drying, emulation 
droplet coalescence method, ionic gelation, reverse micellar method and sieving 
method. Selection of any of the methods depends on factors such as particle size 
requirement, chemical stability of the active agent, reproducibility of the release 
kinetic profiles, stability of the final product, the nature of the active molecule and the 
type of the delivery device (Agnihotri et al., 2004). Different methods of preparation 
of micro/nanoparticles of chitosan are summarised in Table 1.4. These methods are 
based on dropwise addition of chitosan under constant stirring to the cross-liking 
agent. 
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Table 1.4: Different methods of preparation of micro/nanoparticles of chitosan (Agnihotri et al., 2004). 
Method Process Crosslinking agent Reference 
Emulsion cross-
linking 
Emulsion of chitosan aqueous solution in the 
phase water (w/o) 
Glutaraldehyde (Kotadiya et al., 2009) 
Coacervation/ 
precipitation 
Sodium sulfate solution is added to an 
aqueous acidic chitosan solution 
Glutaraldehyde (Berthold et al., 1996) 
Spray drying Drug is dispersed in an chitosan acidic 
aqueous solution 
Vitamin D (Shi and Tan, 2002) 
Emulsion droplet 
coalescence 
method 
Both emulsion cross-linking and precipitation. 
emulsifying chitosan aqueous solution in an 
oil phase with 
Emulsifying chitosan aqueous 
solution in NaOH 
(Tokumitsu et al., 1999) 
Ionotropic 
gelation 
The complexation between  oppositely 
charged (polycation chitosan acidic solution) 
TPP, sodium 
Alginate 
(Kleine-Brueggeney et al., 2015, Severino et al., 
2016) 
Reverse micellar 
method 
Surfactant dissolved in organic solvent then 
mixed with an aqueous solution of chitosan 
and drug 
Glutaraldehyde (Mitra et al., 2001) 
Sieving method An aqueous acidic chitosan solution. 
Microparticle obtained passed through sieve 
Glutaraldehyde (Agnihotri and Aminabhavi, 2004) 
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1.5.2.1.1 Ionotropic gelation 
Among the methods above, the ionic gelation method (also known as ionotropic 
gelation) is the most widely used approach to ionic physical cross-linking. This 
method has been applied using a variety of polymers, including chitosan, alginates, 
gellan gums, and carboxymethyl cellulose, to form micro- and nanoparticles for 
encapsulation and controlled release of therapeutic agents (Patil et al., 2010, Liu et al., 
1997, Kawashima et al., 1985a, Calvo et al., 1997b, Sezer and Akbuǧa, 1995, Shu and 
Zhu, 2000). Moreover, this technique provides several advantages, such as its simple 
and mild method of preparation without the use of organic solvents or high 
temperatures. As well as decreasing the possible toxicity effect of reagents products 
which come with chemical cross-linking (Tiyaboonchai, 2003, Agnihotri et al., 2004). 
Electrostatic interactions can occur inside the network via interactions between the 
negative charges of the cross-linker TPP and the positively charged amino groups of 
chitosan molecules (Kawashima et al., 1985a, Kawashima et al., 1985b). For this 
process, as depicted in Figure 1.19, chitosan is dissolved in acidic solution such as 
dilute acetic acid. Then it is added dropwise to TPP solution, where chitosan 
undergoes ionic gelation and precipitation to form particles due to the presence of an 
oppositely charged species (Aydin and Akbuǧa, 1996, López-León et al., 2005). 
 .. 
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Figure 1.19: Scheme of the preparation of chitosan particles by ionotropic gelation 
 (Agnihotri et al., 2004). 
 
Calvo and co-workers (1997) first stated use of ionic gelation method to form of 
hydrophilic chitosan-polyethylene oxide nanoparticles. It was observed that the 
particles had a great entrapment capacity and allowed for continued release of bovine 
serum albumin for up to seven days. The size of nanoparticles ranged from 200 – 
1000 nm and the zeta potential ranged from +20 mV and +60 mV depending upon the 
concentration polyethylene oxide, TPP and chitosan; as well as chitosan molecular 
weight and degree of deacetylation of the chitosan (Calvo et al., 1997a). Finally, 
ionotropic gelation was selected as the method of micro/nanoparticle production for 
this thesis because of the process’s mild effective conditions, simplicity, previous 
encapsulation results with other therapeutic agents and CS: TPP particles may also 
interact with fingermarks (Il Dueik and Morris, 2013) Figure 1.20. 
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Figure 1.20: Schematic of chitosan: TPP particle formation process of by ionotropic gelation 
process (Ponnuraj et al., 2015). 
 
 
 
1.6 Fingerprints 
Fingerprints are made up of groups of various whirling lines including hills and 
valleys. These lines are made by features that are called ridges (hills), while the 
narrow spaces between them are called furrows (valleys), also ridges and furrows 
together form the unique character of a fingerprint (Wilshire, 1996). Fingerprints or 
fingermarks are left behind when fingers come into contact with a surface. The 
functions of the friction ridge skin is to assist the sense of touch, act as friction ridges 
in gripping, and raise the openings of the sweat glands to the surface for the discharge 
of sweat and to assist in temperature regulation (Junqueira and Carneiro, 2003). In 
forensic science, the revealing of traces on crime scenes or related substances 
represents a continuous challenge for scientists working on the enhancement or the 
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development of new detection techniques (Becue et al., 2008). Fingermarks are 
recovered from a crime scene, while, fingerprints are taken from suspect under 
controlled conditions such as inked elimination prints. Therefore, the identification of 
each fingermarks located at crime scenes is one of the most important of forensic 
examination (Knowles, 1978). In 1892 Galton reported that friction ridge was unique 
to each person and persistent (Galton, 1892). Hence, fingermark recognition is very 
important in any forensic investigation, because there are no two humans possess 
identical fingerprints, also it is characterized by stability from birth to death 
(uniqueness and persistent) (Faulds, 1880). In addition, different fingerprints will be 
found even in identical twins (White, 2010, Sun et al., 2010). As DNA is the same in 
both individuals in a pair of identical twins, in the case fingerprints are stronger for 
identification purposes (Kong et al., 2005, Kong et al., 2006). In a previous study 
(Jain et al., 2002) collected ninety four pairs of identical twins and reported that the 
fingerprint recognition system is able to discriminate them as different individuals 
based on fingerprint features (ridge details). The friction ridge skin (fingerprint) 
remains the same throughout an individual’s life, and it has not been found to have 
changed from birth until death (Lee and Gaensslen, 2001). Therefore, fingerprints are 
one of the best methods of identification which can be used during the life of person, 
and even remains useful for a period after death prior to decomposition. However, if 
there was some serious damage to the skin, such as a severe burn, a deep scar or cut 
which reaches the dermis layer this may alter the fingerprint's features (Lee and 
Gaensslen, 2001). 
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1.6.1 History of Fingerprints 
Evidence exists on the use of fingerprints in ancient culture as a means of personal 
identification (Ashbaugh, 1999, Berry and Stoney, 2001). Herschel (Herschel, 1916), 
Henry (Henry, 1905), Galton (Galton, 1892), and Faulds (Faulds, 1880) pioneered 
work succeeded in establishing ways by which the recognition of humans on the basis 
of their fingerprints is possible. Sir William Herschel and Dr Henery Faulds were the 
first two individuals, who, in nineteenth century, systematically explored the use of 
friction ridge skin as a method of making personal identification (Faulds, 1880). Dr 
Henery Faulds also undertook a study in friction ridges and also succeeded in 
realising their value as a method in making identification. Faulds (1880) also came to 
understand the persistency of the friction ridge arrangements. The realisation that the 
perpetrator of crimes could be identified through the fingerprints they left at the crime 
scene is credited to Faulds (Faulds, 1880). It was Faulds who also succeeded in 
recognising that fingerprint patterns make it possible for identification. Years later, 
Sir Edward Henry (1905) succeeded in developing a classification system for 
fingerprints storage and retrieval (Henry, 1905). Moreover, Sir Francis Galton earned 
the distinction of being known as the father of fingerprints as a result of the seminal 
text “Finger prints” which he wrote in 1892 (Galton, 1892). Galton explained that this 
was achieved through friction ridge systematic study detail, building upon Faulds 
work. Nonetheless, Herschel, the first individual to discover fingerprint’s lifelong 
consistency, conceded in 1917 that the idea of using fingerprints as a way of 
implicating people in crime and equally exonerating innocent parties was first 
conceived by Faulds (Lee and Gaensslen, 2001). It was only during the latter part of 
the 19th century that the discovery of the fingerprints permanence was made and the 
unique idea was given a sound practical basis (Maltoni et al., 2009). In fact, Herschel 
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and Faulds had both devised classification methods (Berry and Stoney, 2001). Sir 
Francis Galton, one other British contemporary, developed an identical system to that 
of Henry and was thus, the first to provide definitions to precise specific minutiae 
details (Galton’s Points), thereby giving recognition in terms of their role for 
individualisation (Polson, 1950). Starting from the first known case in central police 
department in Argentina in 1893 where acceptance as evidence of the fingerprints 
discovered at the crime scene was used in convicting a suspect (Hawthorne, 2008), 
friction ridge analysis has turned out to become one of the most important methods in 
worldwide crime scene investigations. 
 
Artefacts recovered from archaeological excavations of ancient civilisations indicate 
that fingerprint and handprint patterns used as means of personal identification 
thousands of years ago. Early potters may have used them to sign their work, and 
records indicate the use of fingerprints and handprints as marks of validity in China at 
least 2000 years ago (Xiang-Xin and Chun-Ge, 1988). In addition, fingerprint 
detection has been used as identification evidence for more than 100 years (Henry, 
1905). Fingerprint detects subjects through their unique natural characteristics 
comprising the pattern of ridges on fingers (Lee and Gaensslen, 2001). It is suggested 
that fingermark development techniques were in use even prior to the seminal works 
of Galton (1882) and Faulds (1890) where iodine was used to enhance latent marks in 
the 1860s, and in the following 150 years many different techniques have been 
proposed for fingermark enhancement (Quinche and Margot, 2010). 
 
  49 
 
1.6.2 Classification of Fingerprints 
The skin is the largest organ of the body. The friction ridge skin forms various 
patterns on the fingers and toes (and to an extent on the palms and soles of the feet). 
There are levels used to describe features visible in the fingerprint. The Henry system 
uses three basic fingerprint patterns (Figure 1.21), with several subdivisions (Figures 
1.22-1.23) (Rao and Balck, 1980). First: an arch is a type of fingerprint in which 
ridges across the fingerprint and rise in the middle then flows out on the other side; 
including plain arch and tented arch. Arch patterns contain no delta and account for 
about 5 % of all fingerprint patterns. Secondly a loop is pattern in which one or more 
of the ridges exit and enter on same side of the impression, and it has a stronger curve 
than arches these include: radial loop where the ridges slant towards right in case of 
left hand fingers or towards left in right hand fingers; and the ulnar loop, where the 
ridges about the core slant towards left in the case of left hand fingers or right in right 
hand fingers (Rao and Balck, 1980). Thirdly a whorl is any pattern which has two 
deltas and usually makes a spiral pattern around a centre of point and includes the 
plain whorl, which involves one or more ridges that make a complete circuit and 
comprises two deltas; the central pocket loop whorl, which comprises at least one 
ridge that recurves an obstruction at a right angle to the line of flow, and contains two 
deltas; the double loop whorl, which contains two separate loop patterns which 
encompass two distinct and separate sets of shoulders and deltas; and the accidental 
whorl, is comprised two or more deltas (Rao and Balck, 1980). Additionally there is 
another fingerprint type called the composite pattern which is a combination two or 
more patterns types within one fingerprint (Sam et al., 2015, Knowles, 1978). 
Characteristic fingerprint features are mostly categorized in three different levels: 
Level 1 (patterns), which are useful for classification and exclusion. Level 2 (minutia) 
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and level 3 (features), in order to classify fingerprint records into primary groups, so 
simplifying any consequent ridge detail (minutiae) comparisons. These features (three 
levels) are used to compare between the fingermarks recovered form a crime scene, 
and fingerprints taken from suspect to decide whether they are or are not from the 
same source. Due to the flexibility of skin, level 1 features may be wholly distorted 
(Ashbaugh, 1999) and appear relatively different in a print than in the comparable 
mark, therefore level 1 features is not unique and refer to  the macro details of the 
fingerprint such as pattern and ridge flow (Jain et al., 2007). Level 2 refer to ridge 
characteristics or minutiae of the fingerprint, such as ridge bifurcations which may be 
split into two ridges; and endings where some of this ridge terminates at a point; and 
the ridges may be a short in length called dot (Jain et al., 2007). In addition, it may be 
form an island by two bifurcations facing one another. Level 2 are the most 
commonly used for identification purposes because they provide specific rides and 
more detailed information of fingerprint such as the ridge interruptions, endings and 
bifurcations Therefore they have sufficient discriminating power to establish the 
individuality of fingerprints (Pankanti et al., 2002, Stosz and Alyea, 1994). When the 
Level 1 and Level 2 features present in the fingerprints are not adequate to make a 
decision of fingerprint matching, level 3 features are claimed to contain suitable 
details to compare fingerprints, and it can provide discriminatory information for 
human identification of individuality of fingerprints based on attributes of the ridge 
such as sweat pores and shapes, ridge path deviation, width, pores, edge contour, 
scars, incipient ridges, breaks, etc. (Ashbaugh, 1999, Jain et al., 2007). 
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Figure 1.21: Different types of fingerprint patterns (a) Arch (b) Loop (c) Whorl       
(Knowles, 1978). 
 
 
 
 
Figure 1.22: Each type of level 1 pattern (Figure 1.21) can be subdivided in to eight 
fingerprint sub-pattern types (Level 1 features): (a) plain arch, (b) tented arch, (c) right 
slanted loop (ulnar), (d) left slanted loop (radial), (e) plain whorl, (f) central pocked loop 
whorl, (g) double-loop whorl and (h) accidental whorl (Jain et al., 2007). 
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Figure 1.23: An examples of level 2 and level 3 fingerprint ridge pattern features details used 
for the classification and individualisation of fingerprints (Jain et al., 2007, Champod et al., 
2004). 
 
 
The basics of the discovery of Edward Henry together with more modern systems 
depending on ridge flow features still work in the current international computerised 
fingerprint identification systems (AFIS) (Jain and Feng, 2011). Those systems are 
used to perform two major types of forensic search known as latent search and ten 
print search. The ten print search includes a plain or rolled impression prints from 
every one of the ten fingers of individuals being searched against a database of 
identified persons. For the reason that plain and rolled impression prints are 
controllably collected, they are invariably of appropriate quality to give the entire 
information needed for a match (Komarinski, 2005). This is a four-step method 
referred to as ACE-V or analysis, comparison, evaluation and verification in the UK 
and several other countries (Jain and Feng, 2011). Analysing is the first stage of 
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assessing if the latent has adequate ridge detail and is of appropriate quality for 
identification, if the required characteristics are noted (Ashbaugh, 1999). The second 
step includes comparing the three levels of characteristics with paired print so as to 
measure their similarity level. Evaluation is the arrangement of latent paired 
fingermark and fingerprint as personal match or identification, non-match/exclusion 
or not conclusive depending the previous comparisons (Vanderkolk, 2001). Lastly the 
verification step is fundamentally a repetition of the first 3 steps and includes 
independent re-examination of latent print by one or two extra fingerprint experts 
(Druce and Bristow, 2010, Jain and Feng, 2011). At least sixteen of the fingerprint 
characteristics are required by the courts in the United Kingdom to describe the 
uniqueness of a fingerprint, consequently, the fingermark found at a crime scene is 
useful as proof identification and only if it is able to distinguish sixteen features of 
comparison with a fingerprints taken from a suspect (Knowles, 1978, Evett and 
Williams, 2015). 
 
1.6.3 Fingermark composition  
Many chemical compounds found in fingermarks can have three different sources 
(Champod et al., 2004). These compounds are a complex mixture of natural secretions 
of the body, and external contaminations from the environment (Champod et al., 
2004). The dermis, which is the bottom layer of the skin, contains three types of 
secretory glands including eccrine, apocrine and sebaceous glands (Thomas, 1978), 
whose secretions reach the skin surface through epidermal pores (Figure 1.24).  
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Figure 1.24: Friction ridge skin diagram of longitudinal section 
 (James and Nordby, 2003). 
 
 
1.6.3.1 Eccrine glands 
Eccrine secretions, which are located on the hands, play an important role in 
fingermark composition (Light and Cooley, 2004). Eccrine glands produce the main 
compound of their secretions is water (99 %), while several other inorganic 
compounds such as sodium chloride and organic compounds such as amino acids, 
lactic acid, urea and sugar can be secreted (Scruton et al., 1975, Wargacki et al., 
2007). 
 
1.6.3.2 Apocrine glands 
Apocrine glands are found in the breast, genital, inguinal and axillary regions. 
Apocrine secretions are found less in latent fingermarks (Choi et al., 2008). Apocrine 
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secretions include organic compound such as carbohydrates and proteins (Knowles, 
1978). 
 
1.6.3.3 Sebaceous glands 
Sebaceous glands are found all over the body except on soles of the feet and the palms 
of the hands. The major compound, which sebaceous glands secrete, is oil (the sebum) 
and often found in latent fingermarks. Organic compound (fat soluble) such as fatty 
acids, wax esters, cholesterol and glycerides are found in the secretions from 
sebaceous glands (Figures 1.25 - 1.28) (Bramble, 1995, Thomas and Reynoldson, 
1975). Sebum is transferred onto fingertips after contact with other parts of the body 
such as face and hair (Weyermann et al., 2011, Lewis et al., 2001). 
(a)
(b)
(c)
(d)
OH
OH
OH
OH
 
 
Figure 1.25: Molecular structure of fatty acids identified in fingermark residues: (a) 
Dodecanoic acid, 12: 0; (b) Myistoleic acid, 14: 1 (Tetradecenoic acid); (c) Palmitic acid, 
16:0 (Hexadecanoic acid); (d) Oleic acid, 18: 1 (Octadecenoic acid) (Girod et al., 2012). 
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Figure 1.26: Molecular structure of a wax ester (myristyl palmitoleate) (Girod et al., 2012). 
 
 
 
OH
 
 
Figure 1.27: Cholesterol molecular structure (Wydro et al., 2007). 
 
 
 
 
Figure 1.28: Triglyceride molecular structure (Girod et al., 2012). 
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1.6.4 Types of fingerprints/fingermarks 
There are three general categories to describe the fingermark evidence which may be 
found at a crime scene or on an item of evidence to a criminal matter: visible 
fingermarks,  impression  fingermarks and latent fingermarks (Knowles, 1978) 
(Figure 1.29) . 
 
 
 
 
Figure 1.29: Types of fingermarks (a) visible fingermarks, (b) plastic marks and (c) latent 
fingermarks. 
 
 
1.6.4.1 Visible (patent) fingermarks 
Visible fingermarks (Figure 1.29a) are often more readily visible without processing 
any treatment to be clearly recognizable as a fingerprint. Such marks may be formed 
by fingers contaminated with blood, dark oil, grease and dirt (positive image) or when 
some substances such as dust removed from the surface by contact (negative image) 
(Bobev, 1995, Champod et al., 2004).  
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1.6.4.2 A plastic marks (alternatively called an impression or 
indented) 
It may be detectable and left in a soft surface or malleable substances, such as wet 
paint, candle wax, butter, and silly putty (Figure 1.29b). These fingermarks should be 
immediately recognizable, and often needs no further processing (Thomas, 1978). 
 
1.6.4.3 Latent fingermarks 
Latent fingerprint is mark which left when a person touches a surface or an item with 
unprotected hands (Thomas, 1978). The latent fingermark (Figure 1.29c) is not 
readily visible (it is “latent”) and it is commonly found at crime scenes (Wilshire, 
1996). The latent fingermark is the usual form of fingerprint evidence and is invisible, 
so it requires the use of detection techniques such as physical (e.g., powdering), or 
chemical (e.g., ninhydrin), or optical (e.g., ultraviolet imaging) to develop (enhance) 
in order for a readily visible fingermark to be recovered that can be used for 
comparison purposes (Almog et al., 2000, Lee and Gaensslen, 2001, Sodhi and Kaur, 
2001). Selection of the technique for fingermark development/visualisation is 
dependent on the composition of latent print residue (Choi et al., 2008).  
 
In latent fingerprint visualisation it is now accepted that particles adhere to 
fingermarks due to the mechanical attraction with the fingerprint residues (Wilshire, 
1996). The factors with influence this interaction are particle size, particle charge, 
particle shape and relative surface area (James et al., 1991b, Yamashita and French, 
2011) all of which could be controlled by processing parameters such as chitosan 
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concentration, pH and ionic strength of the dissolution media, temperature of cross-
linking, stirring rate, etc (Wang et al., 2011).  
 
1.6.5 Surface characteristics 
Fingerprints can be left at a crime scene, when the fingers touch a solid surface. The 
various glands in the skin produced mixture of natural secretions, and these are set 
down by the ridges details on the surface of the skin. These secretions are transferred, 
depending on a number of factors including temperature of the surface, surface 
structure, electrostatic forces of the receptor surface, and humidity. These factors play 
significant roles in the visualisation or development latent fingermarks (Baniuk, 
1990). A sebaceous compound adheres better to a surface that is cooler than the 
human body. Moreover, a rough surface will have more adhesion forces (Champod et 
al., 2004).  
 
Many different techniques have been used for developing a latent print, the method of 
choice depends on the surface. There are three types of surfaces are considered to 
choice suitable detection methods, because they influence the composition of 
fingerprints (Champod et al., 2004).  
 
1.6.5.1 Porous surfaces 
Porous surfaces tend to absorb the latent fingerprint deposit very quickly (normally 
within seconds) such as paper, cardboard, cloth, and wood (Champod et al., 2004). 
The water-soluble compounds are quickly absorbed on the surface. During absorption, 
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water will be evaporated, and then leaving a mixture of residues behind on the 
surface. The residues include amino acids, urea, and sodium chloride (NaCl). As the 
fingermark ages, the amino acids will remain relatively stable provided that the 
surface of the substrate is stored under normal environmental conditions (relative 
humidity < 80%). On the other hand, other components such as urea and sodium 
chloride will tend to migrate continuously, depending on the environmental 
conditions. The higher the relative humidity, the faster is the movement. Thus, older 
marks will tend to alter in appearance significant due to diffusion of urea and sodium 
chloride  (Champod et al., 2004). The fat-soluble compounds (non-water-soluble) 
remain longer period on the surface (Champod et al., 2004) (Figure 1.30). 
 
 
 
Figure 1.30: Aging of latent fingermark on a porous substrate (Champod et al., 2004). 
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1.6.5.2 Semi porous surfaces 
The surface absorbs the water-soluble compounds, but more slowly than for porous 
surfaces (from minutes to hour), whereas, the fat soluble compounds (non-water-
soluble) stay much longer (from one day to several days) than it does on porous 
surfaces. A small amount of the fat soluble compounds may stay on the surface for a 
significant period. Semi-porous surfaces include metal, paints, and plastics (Champod 
et al., 2004). 
 
1.6.5.3 Nonporous surfaces 
This surface does not absorb any compounds deposited with the latent fingermarks 
(water-soluble and non-water-soluble compounds), and they will therefore remain on 
the surface (several weeks/months) unless they are removed, or are degraded. Usual 
examples of nonporous surfaces are plastics, glass, and shiny metal surfaces, mirrors, 
tiles, and glossy paints (Figure 1.31) (Weyermann et al., 2011).  
 
 
 
Figure 1.31: Aging of latent fingermark on a non-porous substrate (a) cross section of latent 
deposit immediately after deposition (b) numerous weeks/months after deposition 
(Champod et al., 2004). 
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1.6.6 Detection of fingerprints 
The detection of fingermarks represents an important interest in forensics, because it 
plays a significant role in individual identification (Wang et al., 2009). Several of 
techniques have been used to develop the visibility of latent fingermarks deposition 
on various surfaces. These techniques commonly employed may be broadly divided 
into four groups (Mohamed, 2011).  
 
1.6.6.1 Physical methods 
Physical methods, including powdering, small particle reagents (SPR) (Cuce et al., 
2004, Haque et al., 1989), and vacuum metal deposition (VMD) (Theys et al., 1968, 
Kent et al., 1976), but do not involve any chemical reaction (Cantu, 2001, Champod 
et al., 2004, Schnetz and Margot, 2001). The process of powder dusting is physical 
one, which the powder particles adhere to the latent residue (humid, sticky, or fatty 
compounds) in the latent fingerprint deposit. Fingerprint powders are most commonly 
reserved for crime scene use on objects which cannot be readily transported back to 
the laboratory. Small-particle reagent is usually applied by spraying or immersion in 
an aqueous suspension (the most common molybdenum disulfide) followed by rinsing 
with water. The powder suspension is normally referred to as small-particle reagent. 
The particles adhere to the lipid components of the residue on the fingerprint deposit. 
SPR technique is effective on surfaces that have been recovered from adverse 
conditions such as snow, rain, or high humidity (Haque et al., 1989). 
 
  63 
 
1.6.6.2 Chemical methods 
In these methods, various techniques for revealing a latent fingerprint through 
chemical reactions with the organic and inorganic components will be investigated. 
These techniques include ninhydrin and its analogues (Odén and Von Hofsten, 1954), 
metal complexation after ninhydrin treatment, diazafluorenone (DFO) (Pounds et al., 
1990), 1,2-indanedione (Hauze et al., 1998), sliver nitrate  (O'Neill, 1937) and genipin 
(Champod et al., 2004). Chemical methods of fingerprint development have the 
potential advantage that the non-moisture components may, under certain conditions, 
remain unaltered for a period of several days/weeks. Ninhydrin reacts with amino 
acids to give a dark purple product known as Ruhemann’s purple (Ruhemann, 1910).  
In addition, the ninhydrin reaction is slow unless accelerated by heat in the presence 
of humidity.  As the eccrine component of a latent mark deposit contains amino acids, 
therefore the small amount of amino acids in sweat (0.3-2.59 mg/L) can be used as a 
means of developing fingermarks on porous surfaces such as paper and cardboard 
(Hansen and Joullié, 2005). Ninhydrin is applied by spraying, painting, or dipping. 
Silver nitrate reacts with the chloride ions (Cl-) contained in secretion residue of 
fingermark to procedure silver chloride (AgCl). When silver chloride upon exposure 
to light, it decomposes to procedure metallic silver, resulting in a black fingermark. 
 
1.6.6.3 Physical/chemical methods 
Classically, the physical/chemical methods are physical developer, multi-metal 
deposition (MMD), iodine (O'Neill, 1937, Trowell, 1975) and cyanoacrylate 
(Karlinszky and Harkai, 1990, Menzel et al., 1983). Physical developer (PD) is a 
fingermark processing technique for porous surfaces like paper, and it is the most 
effective to visualise water insoluble components of the latent fingerprint deposit 
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(Cantu, 2001). PD is a photographic physical developer process based on the 
deposition of silver (Ag) onto latent fingerprint residue (Phillips et al., 1990) from an 
aqueous solution (at low pH) containing a ferrous/ferric redox (reduction/oxidation) 
system, citric acid (as a buffer) and silver salt mixture in solution  The mechanism is 
that the ferrous ions (Fe2+) in an aqueous solution reduce the silver  ions (Ag+) to 
silver metal (solid) (Ag). The silver particles (as colloids) deposit along the ridges, 
giving dark grey/black prints (Cantu, 2001). 
 
1.6.6.3.1 Multi-metal deposition (MMD) 
The comprises of two steps: the first is the immersion of the object (porous and non-
porous surfaces) in a solution counting gold nanoparticles as the active component; 
and the second is visualisation of the detected fingermarks using a silver physical 
developer (AgPD). So the silver deposit onto the surface of the gold nanoparticle 
(Schnetz and Margot, 2001). 
 
1.6.6.3.2 Iodine fuming method 
Iodine crystals are heated to transform into vapour (sublimation) that physically 
adsorbs onto the greasy substances of a fingermarks to produce brown coloured 
prints. The iodine fuming method can be used of porous and nonporous surfaces. In 
contrast, due to its limited sensitivity, the iodine fuming technique works best on fresh 
marks no more five days old. One disadvantage is that the developed print will 
disappear with time and so needs to be either fixed or photographed as quickly as 
possible. (O'Neill, 1937, Trowell, 1975). 
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1.6.6.3.3 Cyanoacrylate fuming (Super-glue method) 
Super-glue is a mixture of 98-99 % of methyl, ethyl, or butyl-2-cyanoacrylate 
(Kendall and Rehn, 1983). The polymerisation reaction, which makes the glue set, is 
easily catalysed by basic compounds, including water. The object and super glue are 
placed in the enclosed cabinet. The residues of moisture, amino acids, fatty acids, and 
proteins in found on the fingerprints is the reason that the super glue fume can stick 
latent finger ridge together fast to give a white colour on latent print. Super-glue 
fuming technique is most effective for a non-porous substrate (Kendall and Rehn, 
1983, Wood, 1991, Tissier et al., 1999). Previous research developed this method 
using cyanoacrylate fuming  followed by a thin layer of gold and zinc particles is 
deposited on fingermarks (VMD) (Jones et al., 2012). 
 
1.6.6.3.4 The combination of optical methods 
The combination of optical methods includes absorption, diffuse reflection, 
luminescence, ultraviolet absorption and reflection (Champod et al., 2004). 
Luminescent techniques are usually preferred due to their a high sensitivity and their 
ability to get rid of the pattern or the colour of the support on which the fingerprint 
lies (Dalrymple et al., 1977, Sears et al., 2012). Moreover, the most common 
important techniques that were mentioned, there still are numerous methods which 
can be used to develop or enhance the fingerprints. Each method is used according to 
number of factors; the cleanliness of surface, if it porous or non-porous, the 
environment, weather conditions, amount of contaminant, pressure applied, 
movement during transfer and condition of the friction ridge detail (Dilag et al., 
2013).  
  66 
 
In recent years, in forensic science research, one of the main achievements is the 
application of nanoparticles in fingerprint detection. In this period, numerous forensic 
science research has been done on the advancement in detection methods that depend 
on the application of nanoparticles in fingermark detection (Choi et al., 2008). One 
such attempt was undertaken to design new powders that acted as dusting agents with 
more potential than the classical methods. A previous study suggested the use of gold 
nanoparticles which had been grafted with aliphatic chains would improve the affinity 
of the powder towards sebaceous secretions (Choi et al., 2006). The same 
development was put in use with titanium dioxide nanoparticles, whereby they were 
grafted with aliphatic chains and a fluorescent dye. These new powders were applied 
using a brush (Choi et al., 2007). Similarly, two types of molecules; hydrophobic 
chain and Eosin Y (fluorescent dye) were used to coat aluminium oxide nanoparticles 
(Sodhi and Kaur, 2006), and in order to ensure latent fingermark detection on 
different surfaces a fluorescent dye was used in combined with silica nanoparticles 
(Theaker et al., 2008). Alternative research strategies include an attempt to improve 
existing physico-chemical methods utilising on nanoparticles. Research from other 
authors indicate the possibility of using gold nanoparticles, in increasing the silver 
deposition during the physical development process (Sametband et al., 2007). On the 
other hand, other researchers have modified classical multi-metal deposition methods 
through replacing the silver on gold nanoparticles with zinc oxide, to create 
luminescent fingermarks (Becue et al., 2008). Studies on gold nanoparticles are 
mainly motivated by the need to improve multi-metal deposition, a technique that 
depends on the application of colloidal gold in the fingermark detection on various 
substrates (Table 1.5) (Schnetz and Margot, 2001). In addition, studies have 
suggested multi metal deposition of luminescent materials where zinc oxide 
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deposition was used instead of silver coating (Becue et al., 2008). It has also been 
suggested that the application of a one-step multi metal deposition like process in 
fingerprint detection which can be operated on a wide pH range and uses glucose 
capped gold nanoparticles (Gao et al., 2009). Some authors used glutamate-capped 
gold nanoparticles trapped in polycation chitosan, which implies to develop latent 
fingerprint after immersion for several hours. The appearance of the fingermarks in 
this case is because of oil enriched fingerprints (Islam et al., 2007). Over the past 
decade, the application of fluorescents nanomaterials in detection of latent 
fingerprints has yielded much interest in forensic science because of their excellence 
in physical and chemical characteristics such as high intensity in fluorescent and 
larger surface area (Liu et al., 2008a, Becue et al., 2008, Ma et al., 2011). Currently, 
the widely investigated fluorescent nanomaterials in fingerprint development are 
quantum dots (QDs), which are excited by ultraviolet to produce strong visible 
fluorescence (Jin et al., 2008, Becue et al., 2009, Dilag et al., 2009, Wang et al., 2009, 
Liu et al., 2010). QDs are one to ten nanometres diameter extreme luminescent 
nanoparticles that can be solubilized and functionalized in either organic or aqueous 
solvents. The strong fluorescent emission lowers the background interference and 
increases contrast in the nanomaterials fingerprints development. Furthermore, over 
the past years, the uncommon earth fluorescent nanomaterials that have the merit of 
tiny particles size, high quantum yield, large surface area, good optical stability, 
narrow emission peak, and high fluorescent intensity (Shen et al., 2008) are the most 
efficient in fluorescent labels for fingerprint development (Wang et al., 2015a, Wang 
et al., 2015b). Some studies relied on the application of QDs in the fingermark 
detection. In the latent secretion detections there are three methods of integrating QDs 
that is; as an aqueous solution, as a dry powder, or as embedded as polymer which can 
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bond covalently with the secretion. For the detection of freshly marked fingerprints on 
aluminium foil, cadmium sulfide (CdS) encapsulated in a matrix of biopolymetric 
chitosan functioned as the dusting powder. The later detects luminescent fingermarks; 
however, using nanoparticles that are cadmium based poses a serious safety and 
health issues (Dilag et al., 2009). Alternative cadmium selenide (CdSe) quantum dots 
that are water soluble were synthesized for the detection of fresh fingerprints on 
adhesive surface tapes including black electrical tape, yellow electrical tape, blue 
electrical tape and yellow sealing tape; as a result, it was found to be successful 
(Wang et al., 2009). In the detection of bloody fingerprints on different non porous 
surfaces for instance, glass transparent polypropylene, black polyethylene, aluminium 
foil, cadmium telluride (CdTe) quantum dots produced in aqueous solution can be 
used. Quantum dots have an attraction to blood, due to of the presence of 
haemoglobin (Becue et al., 2009). A comparison of QDs with acid yellow 7 which is 
among the best blood reagents used in non-porous substrates showed that they are 
superior and more effective on aluminium than acid yellow 7. For detection of 
fingermark on non-porous substrates, it was proposed that samples should be 
immersed in an aqueous CdTe solution (Cheng et al., 2008, Liu et al., 2010), 
however, the immersion requires several hours. To improve the contrast of fumed 
fingerprints on non-porous surfaces, the QDs should be embedded in a 
polyamidoamine dendrimer (Jin et al., 2008, Wang et al., 2008b). In 2000, cadmium 
sulphide nanocrystals were used in staining cyanoacrylate though binding them with 
dendrimers (Menzel et al., 2000). Nonetheless, the immersion times took an entire 
day, destabilising the working solution; thus it did not offer an alternative method to 
the cyanoacrylate stains. In a recent improvement of this study, researchers grafted 
aliphatic chains on the surfaces of QDs in ether in an attempt to stabilise them and 
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used them in detection of sebaceous fingermarks on paper substrates and silicon 
wafers. This proved useful for the silicon surface but its high background 
luminescence makes it unsuitable for paper (Sametband et al., 2007). Moreover, silica 
nanoparticles refer to a different type of reliable nanocomposites used for fingerprint 
detection because it offers a great freedom in relation to dye doping and 
functionalism. According to previous research, there is entrapment of different 
fluorescent and coloured dyes including thiazole orange, rhodamine 6G, rhodamine B, 
oxazine perchlorate, methlene blue, flourescein, basic red 28, and basic yellow 40 
within the silica particles (Theaker et al., 2008). The obtained doped nanoparticles 
were applied in aqueous solution for fingermarks detection as dusting reagents. In 
both new fingermarks (twenty minutes old) and old fingermarks (forty days old) they 
produced an accurate definition after development. In addition, another study 
incorporated europium-based dye within silica nanoparticles and powdered further to 
acquire nanocomposites for fresh detection of latent fingermarks (six day old) on 
different substances such as green leaf, coloured paper, rubber glove, and plastic bag 
(Liu et al., 2008a). Silica nanoparticles enhanced with carbon black also function as 
fingerprint powder in the fingermark detection on metal and glass surfaces prior to 
lifting them using a lifting tape (Benton et al., 2010b, Benton et al., 2010a, Rowell et 
al., 2009). The powder particles improve adhesion on the fingerprint greatly 
depending on their shape and size. Large particles have a less adhesion than fine 
powder particles; hence, the powder is categorised according to sizes ranging from 1 
to 10 µm (Theaker et al., 2008). More recently (Dhall and Kapoor, 2016), studies 
formulations of titanium dioxide, zinc oxide, and zinc carbonate based fluorescent 
particle reagents and compared and analysed them in the formation of latent 
fingermarks affected by destructive conditions. Then the three compositions were 
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developed using fresh latent prints and prints affected by simulated or natural 
destructive crime scene situations such as burial in soil, explosion, arson, burial in 
snow and immersion in drainage water. Even after exposure to destructive crime 
scene simulations, the researchers successfully obtained the latent prints. Furthermore, 
the fresh prints with better quality prints were recovered from drainage water, soil 
burial, and arson; but for snow burial and explosion conditions the results were 
relatively poor. Titanium dioxide, has a 205.8 nm average particle size, circular shape; 
and the morphology of particles is uniform in size and shape and it forms soft 
agglomerates. For zinc carbonate, it has a 13.57 µm average particle size, spherical to 
irregular shape; and the morphology of particles is porous spherical grains with 
extensive variation in shape and size of particles. For zinc oxide it has a 464.7 nm 
average particle size, characteristic nanorods shape; and its morphology of particles is 
typical of nanorods with soft agglomerate formations and clumpings. The study 
concludes that latent fingerprints exposed to destructive crime scene conditions 
should not be neglected. Fluorescent SPR compositions based on titanium dioxide or 
zinc carbonate are suitable reagents for the development of fingermarks exposed to 
destructive crime scene conditions. Wet powder based suspensions were found 
suitable for development of fingerprints exposed to destructive conditions and the 
efficiency of the reagents was found in the order: titanium dioxide > zinc carbonate > 
zinc oxide (Dhall and Kapoor, 2016). Reynolds’ (2008) study concluded that powder 
particles comprised of titanium dioxide particles of an average size 300 nm in 
diameter and have a rich coat of silicon or aluminium. This coating is loosely packed 
in Sirchie powder and in titanium dioxide the coating is 100 nm thick. Conversely, 
Stan Chem powder has a thinner, denser coating that covers titanium dioxide 
irregularly with a 20 nm thickness. The composition and existence of a coating that 
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adheres to titanium dioxide particles may be related to the cause of different powder 
performance in the development of fingerprint (Reynolds et al., 2008). In terms of 
background staining and ridge quality numerous studies shown that the commercially 
available powder suspensions differ in effectiveness. Previous research has made a 
comparison of Wet Powder™ white, titanium dioxide grade RG-15, Adhesive side 
Powder light Cat No. ASP50L – Sirchie, and Wetwop™ white #1-0078 (Jones et al., 
2010a). Then, the white powder suspensions (WPS) formulations were smeared on a 
black insulating tape and the outcome was investigated using X-rays photoelectron 
spectroscopy and electron microscopy.  For all 200 – 500 nm particles the distribution 
of particle size was similar with insignificance influence on effectiveness. However, 
with respect to WPS formulations chemical composition and morphology, the particle 
coating is different and is responsible for the variation in the performance of different 
brands (Reynolds et al., 2008). In a different study, a similar situation applied 
scanning electron microscopy and atomic force microscopy to study surface 
smoothness categorized as non-porous which refers to unplasticised polyvinyl 
chloride, polyethylene, and formica. Afterwards, they attempted to compare the iron 
oxide powder suspension effectiveness with these analytical measures in the 
fingerprints detection on those substrates (plastic formica, polyethylene and 
unplasticised polyvinyl chloride) using 18 hour old sebum. They proved that both 
topographical feature and average roughness substantially affect the latent finger 
marks processing (Jones et al., 2010b). In addition, there are more studies which 
development of fingerprint using different substance and different surfaces (Table 
1.5).   
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Table 1.5: An examples of chemical compounds used to detect of fingerprint. 
Substance Method Surface Interaction Reference 
Colloidal gold/ silver MMD Porous (white paper), Non-porous 
(white polythene plastic bag) 
Gold particles (pH 2.5-2.8)  as active 
component attract to some components of 
fingermark residue then develop print with 
PD (silver) 
(Schnetz and 
Margot, 2001) 
Polycyanoacrylate/  
gold and zink   
CA fuming and 
BY40 dye 
followed by VMD 
of gold and zink 
Low-density polyethylene Polymerisation CA around pores in 
fingermarks, subsequent additional areas 
(not coated with CA) development by 
VMD. 
(Jones et al., 2012) 
Turmeric (Curcuma 
longa). 1,7-bis-(4-
hydroxy- 
3-methoxy-phenyl)-
hepta-1,6-diene-3,5-
dione 
Powder dusting Porous and non-porous surfaces 
including normal paper, bond 
paper, thermal paper, transparency 
sheet, aluminium foil, wooden 
surface (sun mica-glossy), plastic 
sheet, painted steel and top as well 
as writing surface of CD. 
Formation of hydrogen bonds between the 
lipid residue (fatty acids) of sebum and the 
carbonyl and hydroxyl group of the 
curcumin component of the turmeric 
powder 
(Garg et al., 2011) 
Titanium dioxide 
particles. Acid 
yellow, acid violet 
and acid black) 
Wet powder 
suspensions/or 
small particle 
reagent (SPR) 
Dark coloured, smooth non-porous 
surfaces 
 
Titanium dioxide primarily interact with 
the non-bloodied part of the mark, thus 
producing a contrasting effect with the 
background and acid dyes 
(Au et al., 2011) 
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Traditionally the most widely used techniques for latent fingerprint development are 
powder dusting, ninhydrin dipping and iodine fuming and their effectiveness will 
depend upon the surface on to which the latent fingerprint has been deposited. 
However, these traditional methods for latent print detection are not always effective 
and researchers and practitioners are continually trying to improve upon these existing 
techniques. In recent years, there has been an increasing interest to detect and develop 
latent fingerprints using modern instrumentation. For example gas chromatography-
mass spectrometry (GC/MS) to determine the natural composition of fingerprints such 
as cholesterol, fatty acids and wax esters for aging (Weyermann et al., 2011, Bailey et 
al., 2012); X-ray photoelectron spectroscopy (XRP), X-ray fluorescence (XRF), 
transmission electronmicroscopy (TEM) (Jones et al., 2010a); time-of-flight 
secondary ion mass spectrometry (ToF-SIMS) (Attard-Montalto et al., 2014, Montalto 
et al., 2013) and SEM analysis (Bacon et al., 2013, Jones et al., 2010b, Jones et al., 
2012, Wei et al., 2017). 
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1.7 Research aims and objectives 
The aim of this research was to prepare chitosan particles at different CS: TPP ratios 
then investigation the potential of these particles for forensic and pharmaceutical 
applications. To achieve this aim the following objectives will be followed: 
 
 Study the effect of different variables of three independent variables (pH, ionic 
strength and CS: TPP ratio) on formulation parameters of chitosan 
microparticles using the mathematical models obtained to predict the relative 
viscosity, zeta potential and particle size under different preparation 
conditions. 
 Illustrate the optimisation of different chitosan- TPP microparticles using a 23 
factorial factor design with eight experiments to use in latent fingermark 
visualisation. Development of aged latent fingermarks and the evaluation of 
the effectiveness of CS: TPP microparticles in samples with a decreased 
amount of fingermark residue in either individual depositions or in a split 
depletion series.  
 Preparation and optimisation parameters produce chitosan-TPP nanoparticles 
for the delivery of poorly water soluble drug ibuprofen for potential 
pharmaceutical applications. 
 in vitro release studies of the ibuprofen from chitosan-TPP nanoparticles 
 Evaluate the mucoadhesion properties of chitosan-TPP nanoparticles and how 
these nanoparticles may interact with mucin through viscosity, particle size 
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and zeta potential measurements performed on chitosan nanoparticles alone 
and their mixture with mucin. 
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1.8 Publications and Presentations 
Publications from this thesis are as follows: 
Journal Publications: 
 Ezzeddin, M. A. Hejjaji, Alan M. Smith and Gordon A. Morris. (2017). 
"Designing chitosan-tripolyphosphate microparticles with desired size for 
specific pharmaceutical or forensic applications." International Journal of 
Biological Macromolecules, 95: 564-573. This publication forms part of 
chapter 3. 
 Ezzeddin, M. A. Hejjaji, Alan M. Smith and Gordon A. Morris. (2017). "The 
potential of chitosan-tripolyphosphate microparticles in the visualisation of 
latent fingermarks." Food Hydrocolloids, 71: 290-298. This publication forms 
part of chapter 4. 
 Ezzeddin, M. A. Hejjaji, Alan M. Smith and Gordon A. Morris. (2018). " 
Evaluation of the mucoadhesive properties of chitosan nanoparticles prepared 
using different chitosan to tripolyphosphate (CS: TPP) ratios." International 
Journal of Biological Macromolecules, 120: 1610–1617. This publication 
forms part of chapter 6. 
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Conference Presentations:  
The potential of chitosan-tripolyphosphate microparticles for forensic and 
pharmaceutical applications. 
 13th International Conference on Chitin and Chitosan. Munster - Germany 
(2015): Poster 
 2nd UK Hydrocolloids Symposium, Birmingham - UK (2015): Flash Oral 
Presentation 
 19th European Carbohydrate Symposium EUROCARB. Barcelona - Spain 
(2017): Poster  
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Instrumental techniques 
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2 Instrumental techniques (background theory) 
 
The main purpose of this chapter is to give a general background to the theory of the 
techniques which will be applied in this thesis to characterise chitosan particles. 
2.1 Zeta potential 
Zeta potential is the potential that exists at the boundaries of the outer diffuse layer 
surrounding charged particles. Under the effect of an electric field, the particles 
migrate in the direction which has the opposite charge. In colloids, zeta potential is 
the electrical potential difference across the ionic layer around a charged colloid ion 
(Hunter, 1981) (Figure 2.1). 
 
 
 
Figure 2.1: Schematic representation of zeta potential: ionic concentration and potential 
differences as a function of distance from the charged surface of a particle suspended in a 
medium (Liese and Hilterhaus, 2013). 
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The zeta potential is important, since it plays a major role in the stability of 
suspensions. If suspended particles have large negative or positive zeta potential 
values, they tend to repel each other, minimizing flocculation. When the zeta potential 
is low the electrical repulsion between the particles does not exceed the attractive van 
der Waals forces and the dispersion will break and flocculate or precipitate (Figure 
2.2). However, if the zeta potential is high, this leads to a high value of the electrical 
double-layer thickness, and the solution will resist aggregation (Avadi et al., 2010). 
 
 
 
Figure 2.2: Evaluation of dispersion stability by zeta potential/particle size 
(Liese and Hilterhaus, 2013). 
 
 
Generally, the higher the zeta potential, the more stable the colloid becomes. 
Therefore, particles which have zeta potential greater than +30mV or less than -30 
mV are considered stable (Müller et al., 2001, Hu et al., 2008). 
 
The Zetasizer instrument can also quantify the size of the particles at nanoscales using 
a process called Dynamic Light Scattering (DLS) that measures Brownian motion and 
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relates it to the particles size. Brownian motion is defined as the constant movement 
of particles in liquid due to the random collision with the molecules of the liquid 
which surrounds the particle. The relationship between the particle size and its speed 
(diffusion) due to Brownian motion is related via the Stokes-Einstein equation.   
 
RH = KBT / (6π η D)                                                                              Eq. (2.1) 
 
Where RH is the hydrodynamic radius, KB is the Boltzmann's constant (1.381×10
−23 
J/K), T is the temperature (K), D is the diffusion constant and η is the viscosity of the 
solvent in which the particles are suspended.  
 
The laser is used to provide a light source to illuminate the sample particles. Most of 
the laser beam passes straight through the sample, however some are scattered by the 
particles within the sample. A detector measures the intensity of the scattered light. 
Therefore, when large particles are being measured, the large particles move slowly 
and the intensity of the pattern will also fluctuate slowly. Whereas, the small particles 
move more quickly and the intensity of the speckle pattern will also fluctuate quickly. 
The instrument software uses algorithms for a number of size classes to produce a size 
distribution. The particle size distribution can be reported as the intensity of the 
scattered light (y-axis) against the distribution of size classes (x-axis). The particle 
size distribution graph is characteristic and can be shown in Figure 2.3. 
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Figure 2.3: Particle size distribution of chitosan nanoparticle CS-TPP at (4:1) ratio,         
216.0 ± 1.9 nm. 
 
 
2.2 Particle size analysis 
The Malvern Mastersizer 2000 can be used to determine the particle size distribution 
at the microscale. Laser diffraction (LD) is the method used for measuring the light 
scattering which is dependent on particle size. Particle sizes can be measured by laser 
diffraction analysis from 0.02 to 2000 µm. The LD technique uses the fact that the 
laser beam is scattered by the particles and this scattered laser light is registered on 
detectors (Figure 2.4). The light sources of the laser beam are helium and neon 
having two different wavelengths. The blue laser is used for measuring the amount of 
back scattering from the sample (small particles), whereas the red laser detects the 
larger particles, for which the diffraction pattern is measured by a series of detectors. 
The angle at which the beam is scattered is inversely proportional to the particle size. 
The pattern is characteristic of the particle size and using mathematical analysis the 
result is transformed into an accurate, repeatable picture of the size distribution 
(Stojanovic and Markovic, 2012). 
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Figure 2.4: Models for determination of particle size distribution 
 (Stojanovic and Markovic, 2012). 
 
 
2.3 Rheometry (Rheology) 
Rheometry is a technique to determine the rheological data that consists of measuring 
systems, instruments, test and analysis methods (Mezger, 2006). In addition, rheology 
is the scientific study of the deformation and flow properties of substance. Therefore, 
the word ‘rheology’ comes from the Greek words rheo (ʹʹto flowʹʹ) and logos 
(ʹʹscienceʹʹ). Rheology can be defined as the relationship between strain and stress 
within a material as a function of temperature, time, and frequency. Stress and strain 
are important parameters in studying rheological properties of hydrocolloid systems. 
The term ‘strain’ refers to the deformation as a result of the applied stress whereas, 
the term ‘stress’ refers to the force (F) per unit area (A) applied on a system (Picout 
and Ross-Murphy, 2003). Rheometry gives information about the physical and 
mechanical properties of a sample, as well as it is important to use rheometry 
measurements to evaluate the viscoelastic properties of pharmaceutical formulations 
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as this behaviour can have an effect on all the stages of dosage form development 
right through to administration. Compounds are classified according to observed 
physical behaviour i.e. liquid (viscous) or solid (elastic) with the two extremes of 
behaviour corresponding to a perfect (Newtonian) liquid or and a perfect (Hookean) 
solid. Bipolymers such as polysaccharides have properties that are both viscous and 
elastic, therefore, are referred to as viscoelastic (Figure 2.5) (Mezger, 2006). 
 
 
 
Figure 2.5: Classifications of materials in sample shear. Where 𝛾 represents strain rate, η 
represents viscosity, σ represents stress, µ, expressed as the coefficient of viscosity and G 
represents the constant of proportionality or elastic modulus (Partal and Franco, 2010). 
 
Another important parameter as the change in strain over the time is known shear rate 
or strain rate (𝛾); it is essential parameter and its unit the reciprocal of seconds (1/s) 
(Mezger, 2006, Rao, 2010). 
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2.3.1 Viscosity 
Viscosity is a measure of a liquid's resistance to flow. The higher the viscosity, the 
greater a liquid's ability to resist flow (the friction between the internal molecules of a 
material). All fluids become less viscous as the liquid's temperature increases and 
more viscous as the fluid gets cooler. The viscosity of a liquid is an important 
parameter which can be used to predict the behaviour of products, on application and 
storage, as well as can have an impact of drug release (Lewis, 1990). 
 
The flow of  Newtonian liquids is directly proportional to the stress applied which 
expresses in Equation 2.2 (Barbosa-Canovas and Ibarz, 2014).  
 
Viscosity (η) = Stress (σ)/rate of shear (γ)                                                     Eq. (2.2) 
 
If shear is applied in Newtonian liquids system such as water, alcohols and oils, at 
temperature constant, there is no change in viscosity as a linear relationship between 
the shear stress and shear rate (Chhabra and Richardson, 2008). On the other hand, if 
shear is applied to non-Newtonian fluids system, there is change in viscosity as there 
is a non-linear relationship between the shear stress and shear rate. There are 
numerous common types of non-Newtonian flow behaviour such as dilatant, pseudo-
plastics and Bingham plastic (Figure 2.6) which can be estimated by plotting shear 
stress vs. shear rate. 
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Figure 2.6: Flow curves (shear stress vs shear rate) for Newtonian and non-Newtonian flow 
behaviour with yield stress region shown (Miri, 2011). 
 
 
Several factors such as concentration, temperature and pH may effect flow properties 
(Koliandris et al., 2008). Dissolution of chitosan molecules will increase the viscosity 
of a solution because it disrupts the streaming of the flow. The polymer conformation 
and the polymer–solvent interactions depend on the number of positive charges (-
NH3
+) on chitosan (Kasaai et al., 2000).  
 
2.4 Powder X-Ray Diffraction (p-XRD)  
X-Ray Diffraction has been used to characterise microparticles. XRD pattern is quite 
characteristic and usually used to determine crystallographic, molecular structure of 
material. A monochromatic beam of X-rays may be diffracted by atoms in a crystal. 
The angle θ that intense reflections are detected is governed by interferences between 
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X-ray beams reflected by neighbouring planes of atoms in the crystal. These angles θ, 
the spacing between the several planes of atoms can be determined. The intensity of 
reflections against 2θ, where θ is both of the incident and reflect angle between the X-
ray beam and the planes of the atoms, are called diffraction patterns. The diffraction 
pattern is recorded for individual crystalline substances and can be interpreted in 
terms of the crystal structure of substance (Figure 2.7). 
 
 
Figure 2.7: X-ray diffraction, lattice planes (1, 2 and 3 are incident X-rays; 1`, 2`, and 3` are 
reflected x-rays) (Bahl and Tuli, 2010). 
 
 
Reflated X-ray from a set of planes interfere constructively when the Bragg condition 
is met (Equation 2.3) 
 
nλ = 2d sin θ                                                                                             Eq. (2.3) 
 
where n is an integer, the order of reflection; λ is wavelength of beam; d is the spacing 
between the planes;  θ is the angle between either incident and reflected beams and 
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the plane. The Bragg equation is useful to determine the lattice d-spacing of crystals. 
Each peak in the diffractogram therefore results from the d-spacing in the crystal 
(Atkins and De Paula, 2011). 
 
2.5 Fourier Transform Infrared – Attenuated Total Reflectance (FTIR-ATR) 
Spectroscopy 
(FTIR-ATR) Spectroscopy was used in this thesis for qualitative study the 
spectroscopic behaviour of the particles prepared. It is a surface sensitive technique 
and it is depending the interaction of electromagnetic radiation with sample within 
4000 – 400 cm-1 region of the electromagnetic spectrum. This interaction excites the 
molecules making their covalent bonds vibrate by stretching or bending 
(deformation). Infrared spectra can be reported as the infrared intensity against the 
wavenumber of light (cm-1). The advantages to use FTIR-ATR as follows: 
- It uses the sample without any further preparation e.g. diluting it with an IR 
transparent salt such as potassium bromide.  
-  ATR is the very thin sampling path length and depth of penetration of the 
electromagnetic infrared beam into the sample.  
The basic principle of operation in a typical FTIR-ATR technique is described 
according to Figure 2.8. 
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Figure 2.8: Schematic of infrared- Attenuated Total Reflection Spectroscopy (IR-ATR) 
(Pavia et al., 2008). 
 
 
The infrared light passes through a sample which is placed in close contact with a 
transmitting crystal e.g. diamond, zinc selenide (ZnSe) or germanium (Ge) which has 
a relatively high refractive index. Then this light reflects from the internal surface and 
penetrates the sample with each reflection along the top surface. This process 
eventually generates an evanescent wave which produces some energy that gets 
absorbed by the sample and reflected radiation that attenuates and goes into the 
detector and converts to infrared spectrum by the Fourier Transform. Different 
crystals have different refractive indices depending on the material used and are 
applied to different transmission ranges for example ZnSe for 20,000 - 650 cm-1, Ge 
for 5,500 - 800 cm-1). 
 
2.6 Ultraviolet—Visible Spectrometry (UV-Vis) 
The interaction of radiation with matter is the subject of the science called 
spectroscopy. Ultraviolet and visible spectrometers have become the most important 
tool in analytical chemistry. This technique can give both qualitative and quantitative 
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analysis in many fields such as in chemistry, biology, forensic science, engineering, 
agriculture, clinical chemistry, and many other fields. Different molecules absorb 
radiation of different wavelengths and the amount of light absorption can be measure 
as a function of wavelength. Furthermore, most organic molecules absorb ultraviolet 
or visible light that is the regions where wavelengths range from 190 nm to 700 nm. 
The absorbance of a solution increases as the beam increases. On the other hand, the 
absorbance of a solution increases, the transmittance decreases. The relationship 
between transmittance and absorbance is shown Figure 2.9 (Pavia et al., 2008). 
 
 
 
Figure 2.9: The larger arrow on the incident beam indicates a higher radiant power P0 than 
that transmitted by the solution P. The path length of the absorbing solution is b and the 
concentration is c (Skoog et al., 2013). 
 
 
In spectrometric technique, the sample solution absorbs electromagnetic radiation 
from a suitable source, and the amount absorbed is related to the concentration of the 
sample. UV-VIS spectrum is usually recorded as a plot of absorbance against 
wavelength (Figure 2.10) (Christian and O'Reilly, 1988). 
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Figure 2.10: The visible absorption spectrum respond to wavelengths from about 390 to 700 
nm. The visible spectrum is the part of electromagnetic spectrum which is visible to the 
human eye (Pavia et al., 2008). 
 
 
2.7 Scanning electron microscopy (SEM) 
Scanning Electron Microscopy (SEM) is indeed one of the most powerful and 
efficient characterization techniques that scientific inquiries can utilize. SEM utilizes 
a shorter wavelength high-energy electron beam instead of light photons, as is the 
case in optical microscopy. SEM has been identified as the most efficient and 
versatile tool in performing the analysis of chemical composition characterizations 
and surface morphology. Consequently, the SEM is crucial in looking at the surface 
topographic details due to its high resolution (Goldstein and Harvey, 1975). 
Therefore, thorough SEM, high levels of magnification allow the visualization of how 
the fingermarks, developmental techniques and deposition surfaces interact with each 
other and also with various external factors.     
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Figure 2.11: Shows SEM setup’s schematic representation as well as features within the two 
main areas: the specimen chamber and the electron column (Barron et al., 2012). 
 
 
As indicated by Figure 2.11, the typical SEM setup schematic representation has two 
main areas namely the specimen chamber and the electron column (Barron et al., 
2012). The electron gun source is instrumental in forming a stream of electrons that 
are accelerated, by use of a positive electrical potential, towards the specimen. 
At the top of the electron column, the electron gun or electron beam source is located. 
In the modern Scanning Electron Microscopy, there are two main kinds of guns, 
described as field emission or thermionic guns (Leng, 2009). The thermionic gun is 
usually a twisted tungsten, which works through high temperature heating of the 
cathode filament to provide strong kinetic energy for the escape of electrons. In 
addition, a brighter beam results from the lanthanum hexaboride as compared to 
tungsten having the same accelerating power or voltage (kV) (Goldstein and Harvey, 
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1975). When the beam passes the anodic terminal, two condenser lenses 
(electromagnetic condenser lenses) forces the beams to converge and thus passing 
through a focal point. Depending on the changes on the column’s magnetic fields, the 
lenses work by having some beams of electron selectively deflected, thus effectively 
creating focal points of varied lengths in each lens (this is digitally controlled in the 
modern SEM software in focusing the beam on the selected sample) (Goldstein and 
Harvey, 1975). In order to improve resolution, the beam is directed through the 
aperture, which functions to exclude electrons that are not part of the optical axis.          
One the electron beam strikes the sample’s surface; there are a number of signals that 
are emitted due to the interaction with the beam of the sample. In the case of two 
major imaging modes as well as a number of emissions’ characteristics, the emissions 
include secondary electrons and the primary backscattered electrons (BSE) (Stokes, 
2008). Often, the sample’s atom nucleus can collide with the electron beam thus 
bouncing to yield a backscattered electron as indicated in Figure 2.12. 
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Figure 2.12: Schematic diagram of the positioning of the two SEM detectors. 
 
 
The image is produced from the backscattered electrons. According to (Scrivener, 
2004), the lighter atoms backscatter less electrons than the heavy ones and thus image 
formed is blurred. Therefore, the heavy atoms, due their ability to backscatter more 
electrons produces brighter images. In SEM, the image can also be produced through 
detection of secondary electron. As indicated in Figure 2.12, the atom in the sample 
can collide with the electron beam leading to one being knocked out as a secondary 
electron, which in turn may also collide with other atoms producing numerous 
secondary electrons. These secondary electrons are also utilized to produce images. 
The accelerating voltage utilized has been identified to affect the penetration of the 
electron beam into the sample and that penetration would be determined by the 
voltage used (the higher the voltage the higher the penetration). The E-T (Everhart-
Thornley) scintillator detector is the most common SEM electron detector, because 
the electrons emitted from the sample are usually less than 50 eV). The E-T detector 
easily attracts the SEs due to their low energy. The positive charge on a grid in front 
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of the detector attracts the electrons and captures them prior to amplifying them 
through a photo-multiplier and then digitising and sending them to a screen. This 
gives a signal, which is then transferred to a viewing screen as a beam that is scanned 
to create an image (Leng, 2009). However, there may be a selective bias on the BSE 
collection by the E-T detector thus leading to a reduction of voltage’s collector grid to 
a negative voltage (-50V) and thus limiting low energy.             
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2.8 Summary 
This chapter highlighted the main techniques which are applied in this thesis 
including: Zetasizer, Mastersizer, rheology, viscometry, FTIR, UV-Vis and SEM. 
Zetasizer identifies zeta potential (surface charge) which is a very important factor in 
the characterization of chitosan particles. Moreover, zeta potential can provide 
information on the stability of chitosan particles in suspension. High zeta potential, 
which is greater than +30 mV or less than -30 mV, indicates high stability of chitosan 
particles. Measuring of chitosan surface charge can help to obtain an understanding as 
to how well the particles will interact with fingerprints. Additionally, this could also 
be used to help understand how well the nanoparticles would interact with the 
different membranes present in the body and give an indication as to how well these 
would perform in terms of drug delivery.  
 
Another key parameter providing size are Mastersizer and Zetasizer. It is important to 
be able to evaluate particle size and polydispersity index (size distributions) as this 
enables the cell membrane interactions to be better understood and also how well the 
physiological drug barriers can be penetrated by the drug. As well as, this could 
potentially enable the fine tuning of chitosan particles size for forensic applications 
(visualisation of latent fingermarks) and to help understand suitable particle size to 
attach between ridges in fingermarks. Viscometry (rheology) can provide useful 
information about mechanical properties of a chitosan which in turn is important in 
physical characterisation. Evaluation of the relative viscosity is a vital parameter for 
the testing of polymers in solution. For example, if the viscosity is too low, the 
chitosan particles will not exhibit prolonged contact time with the mucosal epithelium 
as it will either be excreted with the clearance of the mucus, or the entire drug 
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complex will be absorbed. This is because the chitosan particles will flow straight in 
to the stomach contents rather than interact with the mucin on the stomach walls. An 
XRD study is a valuable in investigating the crystallinity of chitosan in the cross-
linked with TPP and through chemical modification in the arrangement of molecules 
in the crystal lattice. The FT-IR of chitosan is characteristic of chitosan structure due 
to determine the molecular changes in the resulted cross-linked chitosan particles. 
Studies of surface morphology of particles is important using SEM, due to the surface 
characteristics being dependent on the process parameters such as CS: TPP ratio. 
Additionally, SEM is useful technique used on to study fingermark development. 
Knowledge of viscosity, zeta potential, particle size and shape has an influence on 
potential applications of CS: TPP particles in drug delivery (Wang et al., 2011) or in 
forensic applications (Il Dueik and Morris, 2013) and can therefore enable the 
investigations of the aims outlined in Section 1.7. 
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Factors Affecting the Physico-
Chemical Properties of Chitosan-
Tripolyphosphate Microparticles 
Formed by Ionotropic Gelation 
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3 Factors Affecting the Physico-Chemical Properties of Chitosan-
Tripolyphosphate Microparticles Formed by Ionotropic Gelation 
3.1 Introduction 
 
Cross-linking of chitosan is based on the addition of a cross-linker, for example 
chitosan can be physically cross-linked with polyanions such as TPP. There are 
numerous of experimental parameters which can be controlled in the preparation of 
chitosan particles including: type of chitosan (molecular weight, DD and 
concentration), chitosan to TPP (CS: TPP) ratio, pH, ionic strength, temperature and 
stirring rate. These will all have an influence on for example, the particle size, particle 
surface charge, particle shape, relative surface area, colloidal stability, etc (Hu et al., 
2008, Wang et al., 2011). It is therefore the purpose of the present study to investigate 
the systematic manipulation of three independent processing parameters (pH, ionic 
strength and CS: TPP ratio) on three important physicochemical properties (relative 
viscosity, zeta potential and particle size) during the preparation of CS: TPP 
microparticles loaded with dye (for visualisation purposes) by the ionotropic gelation 
method. This will then enable the use of mathematical models obtained to predict the 
relative viscosity, zeta potential (net surface charge) and particle size under different 
conditions to obtain predicable and programmable microparticle properties in relation 
to, for example, latent fingerprint enhancement, drug release kinetics or 
mucoadhesion. 
 
3.2 Design of experiments (Factorial Design) 
In statistics, design of experiments (DOE) is a powerful tool for improving and 
controlling experiments which all levels of one independent variable (I.V), which are 
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also sometimes called factors, are combined with all levels of another (Altekar et al., 
2007). In a full factorial experiment, the response dependent variables (Y) are 
measured at all combinations of the independent factor levels. The combinations of 
independent factor levels represent the conditions at which responses dependent 
variable (Y) will be measured. A dependent variable is a variable with a value which 
depend on that of the independent variable. Whereas, independent variable is variable 
which value do not depend on the value of another variable. Factorial design is used 
to statistically optimise the formulation parameters. Moreover, factorial design allows 
the investigator to perform many experiments involving the simultaneous study of the 
effects of two or several factors on the response dependent variable (Y), also the 
effects of interactions between factors on the response dependent variable (Y). In 
other words, design of experiment for predicting response by varying the different 
factors at a specific level, factorial designs are most efficient for this type of 
experiment (Shah and Londhe, 2011). Use of experimental design allows for testing a 
large number of factors simultaneously and precludes the use of a huge number of 
independent runs. Procedures are then carried out through the selection of an 
objective function and finding the most important or contributing factors. In the 
present study, Minitab® 17.1.0 software 23 factorial design was carried out to find 
optimised conditions for response (Y), and eight experimental runs were constructed. 
A run is each experimental condition. Linear regression model equations were 
employed for fitting the response surface in the following form:  
 
Y = A0 + A1 X1 + A2 X2 + A3 X3 + A4 X1
2 + A5 X1X2 + A6 X1X3 + A7 X2
2 + A8X2X3 + 
A9X3
2 + A10 X1X2X3                                                                Eq. (3.1)  
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Where Y is the measured response with each factor level combination; A0 is an 
intercept; A1 to A10 are regression coefficient of the respective independent variable; 
and X1, X2 and X3 are the coded levels of independent variables. The terms X1 X2 X3 
and Xi
2 (i = 1, 2 or 3) represent the interaction and quadratic terms, respectively. 
 
3.3 Materials 
Chitosan of medium molecular weight (MMW ∼295,000 g/mol) was obtained from 
Sigma–Aldrich (Gillingham, UK) and reported to have an average degree of 
deacetylation (DD) of ∼75–85%. In addition, chitosan of low molecular weight 
(LMW ∼ 50,000 – 190,000 g/mol) was purchased from Sigma–Aldrich (Gillingham, 
UK) and was reported to have an average degree of aeacetylation of ∼75–85%. 
Glacial acetic acid, sodium acetate trihydrate and tripolyphosphate (TPP) sodium salt 
were obtained from Sigma–Aldrich (Gillingham, UK) and red food colouring was 
from Silver Spoon (Peterborough, UK). All materials were used without any further 
purification. 
3.4 Experimental 
3.4.1 Sample preparation   
Nine different acetate buffers (AB) coded AB-1, AB-2, AB-3, AB-4, AB-5, AB-6, 
AB-7, AB-8, and AB-9 were prepared (Table 3.1, further details on their preparation 
are in Appendix A) in order to investigate the effect of three independent variables: 
pH value, ionic strength and volumetric ratio of chitosan to TPP on the 
physicochemical properties of CS: TPP microparticles. According to literature 
chitosan is soluble in acidic solution (pH < 6.0), so the pH (3.3 – 5.3) were chosen to 
cover a good range of pHs (Dyer et al., 2002). 
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Table 3.1: Acetate buffers of varying ionic strength and pH. Buffers AB-1 to AB-9 were used 
to create generate model equations and buffers AB-10 to AB-13 were used in model 
validation (pKa of acetic acid is 4.75). 
Acetate buffer (AB) pH Ionic strength (IS) 
AB-1 3.3 0.1 M 
AB-2 3.3 0.3 M 
AB-3 3.3 0.5 M 
AB-4 4.3 0.1 M 
AB-5 4.3 0.3 M 
AB-6 4.3 0.5 M 
AB-7 5.3 0.1 M 
AB-8 5.3 0.3 M 
AB-9 5.3 0.5 M 
   
AB-10 3.8 0.2 M 
AB-11 3.8 0.4 M 
AB-12 4.8 0.2 M 
AB-13 4.8 0.4 M 
 
 
3.4.1.1 Preparation of chitosan and TPP samples with different 
ionic strengths and pH value (Acetate buffers AB-1 to AB-
9) 
2.0 mg/mL of nine different chitosan medium molecular weight solutions were 
dissolving in acetate buffers (AB-1 to AB-9). The chitosan solutions were stirred 
overnight at room temperature using a magnetic stirrer. The solutions were then 
filtered using Gooch crucible (AG 1 X 3) vacuum filtration to remove residues of 
insoluble chitosan molecules and the solutions were collected for further analysis. 
0.84 mg/mL of nine different TPP solutions were dissolved in the acetate buffers 
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(AB-1 to AB-9). A previous study observed that the optimal concentrations of 
chitosan and TPP solutions were 2 mg/ml and 0.84 mg/ml respectively to form 
chitosan particles (Dyer et al., 2002). In addition, another recent research used 
chitosan and TPP solutions at concentrations of 2 mg/ml and 0.84 mg/ml respectively, 
and obtained chitosan microparticles which were successfully applied in fingerprint 
enhancement (Il Dueik and Morris, 2013), although in a very small-scale preliminary 
experiment. Therefore, these concentrations were subsequently used for the 
preparation of particles.  
 
3.4.1.2 Preparation of CS: TPP microparticles 
Chitosan microparticles were prepared according to ionotropic gelation procedure 
(Figure 3.1) (Morris et al., 2011, Dyer et al., 2002). To prepare the CS: TPP 
microparticles, an appropriate volume of the TPP solution was added drop wise to the 
appropriate volume of the chitosan solution to make seven ratios of CS: TPP 
microparticles (6:1, 4:1, 2:1, 1:1, 1:2, 1:2, 1:4 and 1:6), and the samples were then 
stirred at 600 rpm for 60 min at room temperature. The resultant microparticles 
spontaneously formed due to the ionic crosslinking of chitosan by sodium 
tripolyphosphate. Then 30 drops (∼2 mL) of red dye added to all ratios to make the 
particles clearly visible and more amenable in latent fingerprint visualisation. The 
resultant microparticle solutions were left standing overnight at room temperature, 
prior to centrifugation (Thermo Fisher Scientific Biofuge Primo R, Germany) for 90 
minutes at 8500 rpm, the supernatant was discarded, and the microparticles were 
rinsed with deionized water for further analysis. 
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Figure 3.1: Procedure of chitosan microparticle formation, where V represents the 
appropriate volumes of TPP and chitosan respectively. 
 
 
3.4.1.3 Model validation (prediction method)  
Chitosan medium molecular weight solutions were prepared by dissolving 2 mg/mL 
of polymer in a further four different acetate buffers (AB-10, AB-11, AB-12 and AB-
13) (Table 3.1) and TPP solutions were prepared by dissolving TPP at a concentration 
of 0.84 mg/mL in the same acetate buffers (AB-10, AB-11, AB-12 and AB-13). The 
resultant solutions were prepared as per Section 3.4.1.2 to give CS: TPP volume ratios 
(v/v) of 6:1,4:1, 2:1, 1:1, 1:2, 1:4 and 1:6 respectively.  
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3.4.2 Characterisation of chitosan microparticles 
3.4.2.1 Fourier transform infrared (FTIR)  
Spectroscopy FTIR spectra of chitosan, TPP and chitosan microparticles were 
recorded using a Fourier transform infrared spectrophotometer (Thermo Nicolet 380 
FT-IR spectrometer, Thermo Electron Corporation). FTIR depends on the interaction 
of electromagnetic radiation with sample and it is a surface sensitive technique. The 
ATR (Attenuated total reflectance) crystal was cleaned with Isopropyl alcohol. A 
background check was performed before to obtain samples spectra. A powdered small 
amount of samples were placed on the crystal using micro spatula and force applied 
by twisting top of the arm of sample stage. The test sample spectra was collected from 
4000 to 500 cm-1. Each sample was run in triplicate. 
 
3.4.2.2 Powder X-ray diffraction (p-XRD) 
A crystallinity study was carried out by comparing XRD spectrum of microparticles 
using Bruker AXS diffractometer (D2 PHASER) with Cu Kα radiation to characterise 
chitosan, TPP and CS: TPP microparticles. Powdered sample (chitosan, TPP and CS: 
TPP microparticles) was placed in a stainless steel holder then the surface of powder 
was levelled manually to make appropriate a flat surface for analysis. The sample was 
exposed to X-ray Cu Kα radiation with a wavelength of 1.5406 Å. An electron beam 
is directed across a field of high voltage in a vacuum which is sealed and it hits a solid 
anode target that is either rotating or stationary, thus X-rays are emitted. Collisions 
with atoms in the target causes the electrons to decelerate hence X-ray streams are 
continuously generated. Some elements such as Cr, Co, and Cu are the most common 
X-ray tube targets that are used and they emit 14 keV X-rays that have a wavelength 
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of 0.8 Å, and 8 keV X-rays that have a wavelength of 1.54 Å. Peaks in a pattern of an 
X-ray diffraction are related directly to atomic distances. The data was recorded at 2θ 
range of 5°–80° at a scanning rate of 4°/min. Each sample was run in triplicate. 
 
3.4.2.3 Determination of relative viscosities 
All samples were analysed using a Bohlin Gemini HR Nano Rheometer (Malvern 
Instruments, Worcestershire, UK). Rheological measurements give information about 
the viscoelastic properties of a sample. 5 mL of sample (acetate buffer, chitosan 
solution and CS: TPP particles in suspension) was placed into 55 mm parallel plate 
geometry using 1mm gap at a constant shear rate of 500 s−1 under precise temperature 
control (25.0 ± 0.1°C). All measurements were performed in triplicate.  







0

rel
                                                                                        Eq. (3.2) 
 
where η is the average (n = 3) viscosity of chitosan, the CS: TPP microparticles and, 
ηo is the viscosity for the appropriate acetate buffer (Harding, 1997). 
 
3.4.2.4 Determination of zeta potential  
Zeta potential was measured for chitosan, TPP and CS: TPP microparticles of 
different ratios using a Malvern Zetasizer NANO-Z (Malvern Instruments Limited, 
Malvern, UK). All Measurements were performed in the appropriate buffers using a 
folded capillary cell and refractive index of the CS: TPP microparticles was set at 
1.6–1.8 (Azofeifa et al., 2012) and no significant effect of refractive index was 
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identified. To determine the zeta potential approximately 1.0 mL of sample was 
pipetted into a folded capillary cell by using a syringe and measurements were 
performed at 25 ± 0.1 °C in triplicate to obtain data value an average of ten 
measurements. Doppler electrophoresis is the phenomenon of taking place during zeta 
potential measurements. The laser is divided to give a reference and an incident beam. 
The latter (incident beam) goes through the sample cell centre, then the forward angle 
is used to spot and observe scattered light. Immediately the measurement of zeta 
potential commences, the reference beam’s intensity is taken. This technique takes 
into account the speed with which particles can move in liquids after an application of 
electric field (its velocity). As soon as the applied electrical field  and the particle`s 
velocity are known in advance and by use of sample constants; dielectric and 
viscosity constant,  zeta potential  now becomes determinable. 
 
3.4.2.5 Determination of particle size 
The particle size distributions of the resultant chitosan particles were measured 
directly by a dynamic light scattering (DLS) using a Malvern Mastersizer 2000 
(Malvern Instruments Ltd., Malvern, UK). The microparticles were dispersed in 
deionized water. Refractive index of particles and dispersion medium (water) was set 
to 1.8 and 1.330, respectively. Before the analysis was started, apparatus was left to 
warm-up for not less than one hour after it was turned on. Alignment of the optics was 
performed after addition of dispersant to the cell sample and subsequently the 
background measurements were observed and recorded. Particle samples were added 
to reach an obscuration ranging from 10 to 30%. This process was repeated prior to all 
sample measurements. The analysis was performed with a constant stirring rate of 
1500 rpm. The apparatus was rinsed well between each experiment to get rid of any 
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contamination. The average particle size was described using the volume-weighted 
mean diameter D[4,3]. The intensity of scattered light was transformed into the 
diffusion factor, the mean value of ten measurements of the particle size was obtained 
and each formulation and was repeated three times. 
 
3.4.2.6 Scanning electron microscopy (SEM) 
The surface microparticle morphology was characterised using scanning electron 
microscopy (SEM). The samples of chitosan particle powders were mounted on 
aluminium stubs using double sided carbon adhesive tape attached to stub. Then the 
samples were vacuum dried, coated with gold-palladium and observed 
microscopically (JEOL JSM 6060 LV – Oxford instruments, Abingdon, UK). 
Scanning electron microscope refers to the surface of the sample examination using a 
beam of electrons of high energy. Backscattered electrons are produced as a result of 
interaction between the atoms and the electrons and they carry information about the 
topography of the surface of the sample. Images were taken by applying an electron 
beam accelerating voltage of 10 kV. This accelerating voltage was chosen to improve 
surface sensitivity and obtain high quality images (Bacon et al., 2013). Images were 
also analysed using Image J software (version 1.42q, National Institute of Health, 
Bethesda, USA) to estimate the particle surface areas. 
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3.4.3 Effect of cross-linker TPP concentration and chitosan molecular weight 
using acetic acid at different conditions to formulate CS: TPP 
nanoparticles 
Chitosan low and medium molecular weight and varying concentrations of TPP 
solutions were made up as shown below in Table 3.2. Chitosan of a suitable weight 
(LMW and MMW) were then dissolved in dilute acetic acid (0.3 %) and this were left 
stirring overnight at room temperature on a magnetic hot plate at 800 rpm. The 
following day this solution was then filtered under vacuum filtration and pH was 
adjusted to 5.3 using dilute sodium hydroxide (0.1 N). However, the pH of TPP 
solution was controlled by adding dilute hydrochloric acid (0.1 N) until a final pH of 
5.3 was obtained to make sure that H2P3O10
3− ions exist in solution, this is also 
beneficial in producing less polydisperse nanoparticles. TPP when dissolved in water 
numerous anions could be present in solution depending on the pH, which is 
undesirable as they can competitively react with the protonated ammonium groups of 
chitosan solution (pH 5.3), the hydroxide ion will also effect of pH of solution. Thus, 
the pH of TPP was adjusted to 5.3 (Sullivan et al., 2018).  
 
Table 3.2: Summaries the different concentrations required to make CS: TPP particles 
Chitosan (mg/mL) TPP (mg/mL) 
3 0.84 
3 1.0 
3 1.25 
 
A water bath was created using a beaker on a hot plate and the temperature was 
regulated. An appropriate volume of TPP was added to a sample vial and this was 
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placed in the water bath for half an hour to allow the temperature to equilibrate at 30 
°C. A magnetic stirrer was included and the required volume of chitosan was added to 
ratio of CS: TPP at (5:1) particles. This ratio was chosen as it gives the smallest 
particle size and highest zeta potential. Thermometers were also placed in the samples 
to ensure the correct temperature was reached. This was checked periodically and 
adjusted if required. The magnetic hot plates were then adjusted to the correct speed 
at 750 rpm and samples were left stirring for an hour. The resultant (CS: TPP) 
particles spontaneously formed due to the ionic crosslinking of chitosan by TPP. All 
samples were sonicated for 5 min (the cycle and amplitude was adjusted to 0.5 and 80 
% respectively; Hielscher Ultrasonics GmbH, Teltow, Germany) before being 
subjected to further analysis. 
 
Measurement of the mean particle diameter, polydispersity and zeta potential of CS-
TPP nanoparticles in the suspension were performed using Malvern Zetasizer NANO-
Z (Malvern Instruments Limited, Malvern, UK) on the basis of DLS techniques. The 
dispersion medium (water) and refractive index of particles was set at 1.330 and 1.6 
respectively. To determine particle size a glass cuvette was used and an angle 
scattering of 173o was utilized. Approximately 1.0 mL of sample was pipetted into the 
cuvette and three readings were taken. The laser is used to provide a light source to 
illuminate the sample particles. Some of the laser beam scattered by the particles 
within the sample then the detector measures the intensity of the scattered light.  An 
average of these readings was then recorded. Zeta potential of samples was measured 
using the same instrument used to determine particle size. Measurements were 
performed using a folded capillary zeta cell. Approximately 1.0 mL of sample was 
pipetted into a folded capillary cell by using a syringe and measurements were 
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performed at 25 ± 0.1 °C in the same method as described earlier. The data value of 
an average of three measurements of the zeta potential were obtained. 
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3.5 Results and discussion 
3.5.1 FTIR analysis 
The FTIR spectrum of pure TPP (Figure 3.2a) showed characteristic bands at 1217 
cm−1 which indicates P=O stretching (Dudhani and Kosaraju, 2010), 1138 cm−1 which 
indicates symmetrical and asymmetric stretching vibration of the PO2 groups 
(Gierszewska-Drużyńska and Ostrowska-Czubenko, 2010), 1094 cm−1 which 
indicates symmetric and asymmetric stretching vibration of the PO3 groups and 892 
cm−1 (P-O-P) asymmetric stretching (Martins et al., 2012). As ca be seen in Figure 
3.2b the spectrum of CS shows characteristic absorption bands at 3424 cm−1 indicates 
the combined broad non-symmetric band of the N-H and O-H group stretching 
vibration of functional groups involved in hydrogen bonds, and the peak at 2873 cm−1 
indicates the –C-H stretching vibration (Ali et al., 2011, Dudhani and Kosaraju, 2010, 
Pierog et al., 2009). The peak at 1650 cm−1 indicates C=O stretching in amide I 
vibration group (CONH2), and 1560 cm
−1 which indicates N-H deformation in amide 
II group vibration (NH2) (Wang and Liu, 2014, Gierszewska-Drużyńska and 
Ostrowska-Czubenko, 2010). Peaks at 1377 cm−1 and 1322 cm−1 might be attributed 
to O–H deformation of –CH2–OH and –CH–OH, and absorption bands at 1151 cm−1 
indicates asymmetric bridge oxygen (C–O–C) stretching (Wang and Liu, 2014).  
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Figure 3.2: FTIR spectrum of (a) TPP, (b) CS, (c) CS: TPP (6:1), (d) CS: TPP (4:1), (e) CS: 
TPP (2:1), (f) CS: TPP (1:1), (g) CS: TPP (1:2), (h) CS: TPP (1:4), (i) CS: TPP (1:6) in buffer 
AB-1. 
 
 
The CS: TPP particles were characterized through FTIR spectroscopy, and the spectra 
are presented in Figures 3.2c – 3.2i. Crosslinking process in the spectra of all CS:TPP 
ratios samples the band of 3424 cm−1 becomes wider,  this indicates that hydrogen 
bonding is enhanced (Wu et al., 2005). In addition, in microparticles the band of 1650 
cm−1 disappears and there appears a new band at 1635 cm−1. This band can be 
assigned to anti-symmetric deformation N‑H bond vibrations in NH3+ ion. The 1560 
cm−1 peak in pure chitosan shifts to a new sharp peak at 1532 cm−1 (Wu et al., 2005). 
These two new peaks as mentioned above (1635 cm−1 and 1535 cm−1) show that a 
linkage has been formed between the ammonium ions and phosphate ions (Bhumkar 
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and Pokharkar, 2006). In other words, the new NH3
+– PO- bond is formed due to one 
hydrogen atom of the amino group in chitosan is substituted by the phosphate group. 
It further proves that the amino group is the only reactive functional group chitosan. 
Moreover, the characteristic peaks of the hydroxyl groups at 1377 cm-1 and 1322 cm-1 
mentioned above do not change (Wang and Liu, 2014). The cross-linked 
microparticles also show a new peak at 1217 cm-1 which may be attributed to the P=O 
stretching from TPP (Qi and Xu, 2004). Therefore, clearly indicating that the 
protonated amino groups of chitosan are linked with negatively charged 
tripolyphosphate groups of TPP, clearly demonstrating the formation of CS: TPP 
particles. 
 
3.5.2 Crystallographic characterisation  
Crystallographic structures of chitosan powder and chitosan microparticles were 
determined by X-Ray Diffraction (XRD). The XRD spectra of the chitosan 
microparticles were characteristic of amorphous structures. As can be seen in Figure 
3.3 there are two strong characteristic peaks in the diffractogram of chitosan powder 
at 2θ = 10° (amine I “–N-CO-CH3” of chitosan)  and 2θ = 20° (amine II “–NH2” of 
chitosan), indicating the high degree of crystallinity of chitosan chains (Liu et al., 
2012, Moharram et al., 2012). The peak at 10° is due to the integration of water 
molecules into the hydrated chitosan crystal structure and the latter peak at 20° is 
assigned to the crystal lattice of the chitosan orthorhombic unit cell (110) (Matet et 
al., 2013), moreover there is no indication of impurities in the chitosan formulation 
(Lad et al., 2013). It is known that the width of X-ray diffraction peak is related to the 
size of crystallite and an increase in the amorphous nature of the material (Rhim et al., 
2006). Imperfect crystals usually lead to a broadened peak (Jingou et al., 2011). After 
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ionic cross-linking with TPP, a shift of peak positions, significant reduction in the 
intensity of characteristic peaks of chitosan (at 2θ = 20°), and broadness of peaks 
were observed, reflecting the destruction of the native chitosan packing structure, 
which is in agreement with the results reported by (Wan et al., 2003, Shah et al., 
2009). Figure 3.3 also highlights similarity between the CS: TPP ratios 2:1, 1:1, 1:2, 
1:4 and 1:6. Consequently the broad peak of the chitosan microparticles may have 
been caused by ionic cross-linking interaction between amino groups on chitosan and 
the TPP, which is known to destroy the crystalline structure of chitosan (Shah et al., 
2009).  
.  
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Figure 3.3: X-ray diffraction pattern of TPP, chitosan and of CS: TPP microparticles of seven 
different ratios in buffer (a) AB-10 (b) AB-11 (c) AB-12 and (d) AB-13. 
 
Integration of the two crystalline peaks (2θ = 10° and 20°) as a proportion of the total 
integrated area gives an approximate estimate of the degree of crystallinity in each of 
the samples. Based on this calculation the degree of crystallinity was calculated from 
the areas under the two peaks at 2θ = 10° and 20° relative to the total area using the 
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in-built area under the curve (AUC) function in Origin version 6.1 (OriginLab, 
Northampton, USA). Therefore, the degree of crystallinity of the native chitosan was 
∼30 % and the degrees of crystallinity of the TPP-chitosan microparticles are all ∼10 
%, this is almost entirely due to the decrease in the chitosan orthorhombic unit cell 
reflection (110) at ∼20°. Other than for 6:1 and 4:1 the reflection (020) at ∼10° 
remains unchanged during ionotropic gelation with TPP. Changes in chitosan 
crystallinity is important in terms of polymer degradation, tensile strength, moisture 
content, cell responses in in vivo applications and contact angles, which are important 
during hydration. All of these are factors are important to consider when developing 
novel chitosan-based formulations for forensic or pharmaceutical applications. The 
cross-linked chitosan with lower concentrations of TPP show less intense and broader 
crystalline peaks (6:1 and 4:1) which may be due to a greater amorphisation as 
compared with those of less 2:1, 1:1, 1:2, 1:4 and 1:6 (Moharram et al., 2012, 
Hosseini et al., 2013). The distinct differences in the diffractogram of chitosan and 
cross-linked chitosan might be attributed to chemical modification in the arrangement 
of molecules in the crystal lattice (Bhumkar and Pokharkar, 2006) and this is also in 
agreement with FT-IR as to the absence of native chitosan. In addition, in chitosan 
cross-linked with TPP at AB-13 (Figure 3.3 d) more suppressed peaks at 10 degree 
(2θ) and 20 degree (2θ) were observed, which might be due to more amorphization. 
 
3.5.3 Relative viscosity and zeta potential for varying chitosan solutions 
Chitosan when in solution is a polycation which is influenced by the presence of 
electrolytes (Smidsrød and Haug, 1971). Therefore, the effect of ionic strength and 
pH value on nine different solutions of chitosan was studied. It can be seen from 
Figure 3.4 that the relative viscosity of nine chitosan solutions, with fixed pH 
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including AB-1, AB-2 and AB-3; AB-4, AB-5 and AB-6; AB-7, AB-8 and AB-9 
decreased with increasing ionic strength solution.  
 
 
 
Figure 3.4: Relative viscosities of nine different chitosan solutions (using AB-1 to AB-9) at 
varying ionic strength and pH values at 25.0 ± 0.1 °C.  (Mean ± SD, n = 10). 
 
 
The chain flexibility of chitosan molecules in solution can be manipulated by using 
chitosan with differing solution pH and/or ionic strength. Furthermore, it is known 
that in acidic media the amino groups of chitosan, NH2, are protonated to NH3
+ 
groups. This causes electrostatic repulsion between chitosan molecules; meanwhile, 
there also exists inter-chain hydrogen bonding interactions between chitosan 
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molecules. The hydrogen bonding occurs between the amino and hydroxyl groups 
(Fan et al., 2012, Huang et al., 2009).  
In low ionic strength solutions (0.1 M), the intramolecular electrostatic repulsion 
effect, also called the third electroviscous effect, dominates in which the chitosan 
molecule exists in an extended conformation (Fan et al., 2012, Abodinar et al., 2014). 
Therefore, more inter-molecular hydrogen bonding occurs in low ionic strength 
solution (Figure 3.5) (Qun and Ajun, 2006). This causes a high resistance to the flow 
or mobility of the polymer molecules and consequently a high relative viscosity is 
observed.  
 
 
Figure 3.5: Schematic representation of chitosan in (a) low ionic strength and (b) high ionic 
strength solution (Fan et al., 2012). 
 
 
However, in high ionic strength solutions (0.5 M), the concentration of acetate ions 
(CH3COO
-) is raised which neutralises more NH3
+ groups. This leads to less 
  120 
 
dissolution of chitosan and weaker intermolecular electrostatic repulsion, causing the 
chitosan polymer chains to become more contracted and lowers the resistance to the 
flow or mobility of the polymers, resulting in a lower relative viscosity (Hu et al., 
2008, Jonassen et al., 2012). In addition, the relative viscosity of chitosan also 
decreased with increasing pH in solutions with fixed ionic strength. The number of 
positive charges on CS at I.S 0.1 M will be greater at pH 3.3 of the solvent, leading to 
a higher degree of expansion of chitosan and a rigid conformation due to electrostatic 
repulsions (Kasaai et al., 2000). Information on chain expansion of chitosan used in 
the formulation of microparticles enables the possibility to better control microparticle 
properties by selecting suitable preparation conditions or starting polymer (Bellich et 
al., 2016). Because of this, the chitosan molecules disrupt the streamlining of the flow 
and increases viscosity, which will have an influence on the particle size and particle 
shape of any chitosan microparticles formed under these conditions (Kawadkar and 
Chauhan, 2012).   
 
Zeta potential measurement is important to gain knowledge on the surface charge. 
This charge can affect the interaction between chitosan polymer chains in phenomena 
such as swelling characterisation, in the interaction with TPP during gelation (Gan et 
al., 2005) or during the interaction with oily subcutaneous residues (Yamashita and 
French, 2011). The ionic strength and pH value of the chitosan solution affect this 
interaction. The effect of pH value and ionic strength of the chitosan solution on zeta 
potential may be seen: 
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(i) At variable pH value and fixed ionic strength 
It can be seen from Figure 3.6 that the zeta potential decreases as the pH value 
increases from 3.3 to 5.3. At pH 3.3, the primary amine groups NH2 of chitosan are 
more strongly protonated as NH3
+ in acetate buffer solution and therefore increased 
zeta potential. On the other hand, at an increased pH value of 5.3 the NH3
+ on the 
chitosan molecules were more neutralised resulting in a decreased zeta potential. 
 
 
Figure 3.6: Zeta potentials of nine different chitosan solutions (using AB-1 to AB-9) at 
varying ionic strength and pH values at 25.0 ± 0.1 °C (mean ± SD, n = 10). 
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(ii) At the fixed pH value and variable ionic strength (0.1, 0.3 and 0.5 M) 
It can be seen from Figure 3.6 that the zeta potential decreased with an increase in the 
ionic strength from 0.1 M to 0.5 M. At ionic strength 0.1 M, the primary amine 
groups NH2 of chitosan are protonated as -NH3
+ in acetate buffer solution and 
therefore an increased zeta potential is seen. Conversely, with an increased ionic 
strength at 0.5 M, the NH3
+ on the chitosan molecules were more neutralised by 
acetate ions (CH3COO
-) leading to a decreased zeta potential. This is important in 
terms of the conformation of chitosan chains and how that might influence their 
interactions with TPP polyanions during ionotropic gelation where the change in zeta 
potential of chitosan (and indeed all polyelectrolyte biopolymers) can be used to 
estimate chain stiffness (Abodinar et al., 2014).  
 
3.5.4 Analysis of different ratios of CS: TPP microparticles using scanning 
electron microscope (SEM) 
In this study CS: TPP microparticles formed by ionotropic gelation, were prepared at 
various ratios, (loaded with red dye for visualisation purposes), by the mixing CS 
solution with TPP solution under stirring. The particles formed at each ratio were 
shown to have different chemical and physical properties (Figure 3.7a–g). As can be 
seen in Figure 3.7, microparticles prepared with AB-12 at the higher CS: TPP ratios 
and therefore at higher viscosity and surface charge had more porous surfaces than 
those of microparticles prepared with the lower CS: TPP ratios which had irregular 
angular surfaces, this is expected to have an influence strength of interaction and 
therefore integrity of the particle “walls” and therefore their size and shape (Ponnuraj 
et al., 2015). The availability of TPP is of course limited at high chitosan ratios and in 
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excess in those with lower chitosan ratios and this influences the cross-linking density 
which again has an effect on size, shape and morphology of the particles (Ponnuraj et 
al., 2015). Furthermore, although it may appear as though some of the particles are 
fragments of precipitated chitosan this is not the case as this inconsistent with both the 
FT-IR and XRD data above. 
 
 
Figure 3.7: Example of SEM images of chitosan microparticles CS: TPP using AB-12 (a) 
6:1, (b) 4:1, (c) 2:1, (d) 1:1, (e) 1:2, (f) 1:4 and (g) 1:6. Where the scale bar is 100 µm and the 
estimated total surface areas (based on the measurement of the sizes and areas of the particles 
using Image J, version 1.52a (National Institute of Health, Bethesda, USA)) of the particles 
are approximately ∼31000, 14000, 25000, 24000, 10000, 11000 and 12000 µm2, respectively. 
 
In terms of potential applications of non-spherical particles, it has been previously 
reported that flake-like metal particles (aluminium, copper, etc.) are more effective 
than spherical particles in latent fingerprint development (James et al., 1991b) due to 
increased surface: volume ratios (Yamashita and French, 2011), therefore samples 
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with a 2:1 CS: TPP ratio were used for further forensic studies in latent fingerprint 
visualisation with encouraging results, this will depend on total particle surface area, 
which ranges from ∼10000 µm2 (Figure 3.6e) to >31000 µm2 (Figure 3.7a) and on 
the number of particles per unit area. ImageJ was used to measure surface area of 
particles. In brief, in the toolbar of ImageJ the line tool has selected to determine how 
many pixels correspond to scale bar (100 μm). A straight line has drawn along the 
length of the scale bar of the image. The analyse tool and then set scale has selected. 
A number 100 was entered in the known distance field and the unit μm has entered in 
the unit of length field. On the toolbar of ImageJ, file menu has opened, then SEM 
image of particles has selected. An irregular shape tool has selected then free hand 
drawn around each of the particles. Under the “analyse tab” measure was selected and 
the average of surface area was estimated. Measurements were repeated with three 
another images then the average of surface area was obtained. As the surface area of 
nanoparticles are greatly influenced by their size similar factors are important in 
determining the surface area for example: the CS: TPP ratio, the initial chitosan 
concentration and the degree of de-acetylation of the chitosan (Sreekumar, et al., 
2018), the nature (ionic strength, pH, salt content, etc.) of the solvent in which the 
nanoparticles are prepared is also important (Hejjaji, et al., 2017; Sreekumar, et al., 
2018). In addition, the drying method is an important parameter which affects the 
particle size and surface area of chitosan nanoparticles (Kumar and Kar, 2014). 
Several studies (Gan et al., 2005, Janes and Alonso, 2003, Deng et al., 2006, Yang 
and Hon, 2009) have concluded that increasing molecular weight of chitosan had a 
direct effect of chitosan nanoparticles by increasing of particle size, this  may be 
attributed to the increase of chitosan viscosity which led to less solubility of chitosan 
in acetic acid solution (Bugnicourt et al., 2014) and may form an outer membrane and 
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leading to effect particle size and surface area (Sarmento et al., 2007a, Sarmento et 
al., 2007b). Furthermore, previous studies reported that there were differences in the 
particle size and surface areas of chitosan nanoparticles between SEM/TEM and DLS 
techniques due to the fact that particles swell in aqueous media (through being 
surrounded solvent molecules). Using DLS, the hydrodynamic diameter of particles is 
measured, however SEM or TEM provides the dry particle’s diameter, where any 
water or solvent in shell would evaporate and particles therefore shrink in the dry state 
(Fan et al., 2012, Domingos et al., 2009, Komalam et al., 2012). 
In the case of the irregular particles previous research has shown that the shape of 
chitosan particles depends on the pH at which chitosan and TPP are mixed and the 
molecular weight (viscosity) of the chitosan (Ko et al., 2002), furthermore in terms of 
pharmaceutical applications irregular particles with angular features have been shown 
to decrease drug dissolution (Mosharraf and Nyström, 1995), have a higher drug 
loading efficiency (Uskokovic et al., 2012), influence phagocytosis (Champion et al., 
2007) and to have a greater probability of adhering to cancer cell surfaces (He and 
Park, 2016) which suggests that chitosan particles formed in this way may be have 
potential in drug delivery formulations.  
 
The relative viscosity of the CS: TPP microparticle suspension is shown in Figure 
3.8, which indicates that neither pH nor ionic strength have a large influence the 
relative viscosity at ratios CS: TPP 1:6, 1:4, 1:2, 1:1 and 2:1. It can be attributed to its 
lesser resistance towards flow due the relatively low charge on chitosan 
microparticles. At higher ratios (4:1; 6:1), the relative viscosity is higher with an 
increase in the CS: TPP ratio in the mixture. Moreover, at the fixed pH value and 
different ionic strength (0.1, 0.3 and 0.5 M), the relative viscosity increased with a 
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decrease in ionic strength. This behaviour may arise because of the decrease in the 
repulsion force between charges for the solvent and polymers and not unsurprisingly 
is dominated by the amount of chitosan in the microparticles. 
 
 
Figure 3.8: Relative viscosities of chitosan (green columns) and CS: TPP microparticles (blue 
columns) solutions (using AB-1 to AB-9) at varying ionic strength and pH values at 25.0 ± 
0.1 °C (mean ± SD, n = 10). 
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The effect of ionic strength and pH value on the zeta potential of nine chitosan 
microparticle formulations was investigated as shown in Figure 3.9. When chitosan 
and TPP were mixed with each other in an acetate buffer, they spontaneously formed 
microparticles (diameters were in the range 28–445 µm) with an overall positive 
surface charge which are at least partially within the size range of particles which 
have been demonstrated to be effective in latent fingerprint visualisation ∼1–50 µm 
(James et al., 1991b) and may have potential in pulmonary or colonic drug delivery 
systems (Bellich et al., 2016). The more positively or negatively charged the particles, 
the more they repel each other and therefore at values of ± 30 mV are required for 
optimal stability (Tang et al., 2013). As the CS: TPP ratio decreased from 6:1 to 1:6 
the zeta potential values decreased from for example +36.4 mV to +5 mV in buffer 
AB-1 or from +13.5 mV to +3.0 mV in buffer AB-9 (Figure 3.9).  
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Figure 3.9: Zeta potentials of chitosan (green columns), TPP (red columns) and CS: TPP 
microparticles (blue columns) solutions (using AB-1 to AB-9) at varying ionic strength and 
pH values at 25.0 ± 0.1°C (mean ± SD, n = 10). 
 
 
It was also observed that with a decrease in the concentration of chitosan the 
appearance of the system changed from clear viscous liquid to milky dispersion prior 
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to precipitation. It was demonstrated that, there was no significant difference in the 
zeta potential values of CS: TPP from 1:2 to 1:6, indicating neutralization of the 
protonated amino groups on the surface of chitosan microparticles and subsequent 
loss of repulsive force which led to precipitation of the particles. On the other hand, as 
the CS: TPP ratio increased from 1:2 to 6:1 the zeta potential increased almost 
linearly. The large positive surface charge due to the high degree of deacetylation and 
protonation causes the chitosan molecules to have a large number of potential cross-
linking sites. The presence of higher positive charge on the particles indicated that 
free (non-cross-linked) amino groups remained on the particle surface (Zhang et al., 
2004, Fan et al., 2012) which is consistent with an increased viscosity in solution. 
When the CS: TPP ratio was high at 6:1 and 4:1 (the available quantity of TPP was 
small) the reaction solution was clear, indicating that the amount of phosphate groups 
was inadequate to lead to the full cross-linking with the chitosan amino groups (Li 
and Huang, 2012). As the CS: TPP ratio decreased from 6:1 to 1:1, the particle size 
decreased due to increased intramolecular and intermolecular cross-linking density 
between chitosan amino groups and the TPP groups (Figure 3.10), this is also due to 
the decrease in viscosity (Figure 3.8) which leads weaker networks and therefore 
assuming there is no change in shear forces (stirring rate was constant at 600 rpm in 
all cases) smaller particles (Kawadkar and Chauhan, 2012). It can be inferred that 
chitosan molecules were almost fully cross-linked at CS: TPP (1:1), which coincided 
with the smallest particle size range measured. As the CS: TPP ratio decreases further 
from 1:1 to 1:6 the particle size increased, as more TPP molecules are involved in the 
formation of the microparticles. This increased concentration of TPP promotes 
aggregation due to inter-particle cross-linking (bridging effects) which leads to a 
lower surface charge density of the particles resulting in precipitation (Li and Huang, 
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2012, Ponnuraj et al., 2015). As we can see in Figure 3.7 the CS: TPP microparticles 
are in some cases non-spherical, with aspect ratios ranging from 1:1 to 13:1 and as 
particle size analysis treats particles as equivalent spheres there is potential for minor 
discrepancies in the absolute particle sizes, these are expected to be minimal although 
this will depend on the type of material being measured (Polakowski et al., 2014). 
 
 
Figure 3.10: Particle size (D[4,3]) of CS: TPP microparticles solutions (using AB-1 to AB-9) at 
varying ionic strength and pH values at 25.0 ± 0.1°C (mean ± SD, n = 10). 
  131 
 
Using multiple regression analysis, the responses (relative viscosity, zeta potential and 
particle size) were correlated with the three variables studied using second-order 
polynomials. The coefficients of the model equation and their statistical significance 
were evaluated using Minitab®17.1.0 software (Minitab Inc., Philadelphia, U.S.A.). 
The regression model for the responses to relative viscosity (Y1), zeta potential (Y2) 
and particle size (Y3) in terms of coded factors is given by Eqs. (3.3) – (3.5) 
respectively. 
 
Viscosity (Y1) = −0.251 + 0.575 X1 − 0.136 X2 + 0.3315 X3 − 0.0631 X12 + 0.008 X1X2 − 
0.0676 X1X3 + 0.232 X22 − 0.178 X2X3 + 0.01397 X32 + 0.0213 X1X2X3                     Eq. (3.3)                                  
 
Zeta potential (Y2) = −25.54 + 14.89 X1 − 35.8 X2 + 15.00 X3 − 1.812 X12 + 6.88 X1X2 − 
1.606 X1X3 + 16.5 X22 + 2.32 X2X3 − 0.5282 X32 − 1.446X1X2X3                                Eq. (3.4)                                                      
 
Particle size (Y3) = 299 − 98.3 X1 − 271 X2 − 9.9 X3 + 12.4 X12 + 54.5 X1X2 + 4.23 X1X3 + 
167 X22 − 12.2 X2X3 + 5.50 X32 + 7.1 X1X2X3                                                               Eq. (3.5)                                                                                  
 
The equations were applied to the responses (Viscosity, Zeta potential and Particle 
size), to describe the principal effects and interactions amongst the identified variables 
pH (X1), ionic strength (X2) and ratio (X3). The coefficients with one factor including 
pH, ionic strength or ratio represent the statistical effect of the particular factor, while 
the coefficients with two factors (such as X1X2), three factors (such as X1X2X3), and 
those with second order terms (such as X3
2) represent the interaction between the two 
factors, three factors and quadratic effect, respectively. The positive sign in front of 
the terms indicates synergistic effect, while negative sign indicates antagonistic effect 
on the response.  
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3.5.5 Model validation of relative viscosity, zeta potential and particle size 
Four different chitosan microparticle formulations were prepared in different acetate 
buffers: AB-10, AB-11, AB-12 and AB-13. The relative viscosities, zeta potential and 
particle size of the four chitosan microparticles were measured (Table 3.3). The 
regression equations were obtained for Eqs. (3.3) – (3.5) which suggests the empirical 
relationship between the value of response and the independent variable. Therefore, 
the predicted values were calculated using mathematical model from Eqs. (3.3) – 
(3.5). For validation of relative viscosity, zeta potential and particle size results, the 
experimental values of the responses were compared with that of the predicted values 
(Table 3.3 and Figures 3.11). 
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Figure 3.11: Linear correlation plot (scattergram) between the experimental and predicted of 
relative viscosity (a), zeta potential (b) and practical size (c) for validation data. 
 
 
Model validation through the analysis of the scattergram plots of expected versus 
predicted values in Figures 3.11 were studied. Firstly, with respect to all three 
scattergram plots, it is clear that these scattergrams exhibit discernible positive 
correlations from left to right, with all the points more or less adhering to this pattern. 
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As such, it can be said that the expected responses and predicted values are all 
positively correlated (Montgomery, 2017). This implies that although not all the 
points fall precisely on the linear plot itself, there is still a definite correlation that 
persists between the expected responses and the predicted values (Montgomery, 
2017). The outliers are less at lower viscosities because the particle size is low and the 
density of intramolecular and intermolecular cross-linking between chitosan and TPP 
is high. Therefore, the viscosity is more predictable for chitosan nanoparticles with 
small size (Figure 3.11a). The experimental zeta potential and predicted zeta 
potential exhibited a linear relation and outliers were not observed. Such findings 
suggested that the chitosan nanoparticles were appropriately produced and the surface 
properties were predictable as a function of the presence of protonataed groups. In 
addition, the findings of the zeta potential were complemented by the findings of the 
regression line of predicted particle size with experimental particle size. The 
scattergram reflected strong goodness of fit. Although at the low particle sizes there 
were certain outliers. However, those outliers were near the goodness of fit (Figure 
3.11b and Figure 3.11c). Secondly, the correlation coefficient (R2) values for the 
plots in Figures 3.11 – 3.13, which are 0.91, 0.96, and 0.85, respectively, are all 
above the minimum acceptable value of 0.85 and all approach unity. As such, the 
models that were generated during this experiment can be said to be highly linear in 
addition to exhibiting positive correlations between the x- and y-axes (Montgomery, 
2017, Singh and Agarwal, 2002). In turn, the models can be said to be useful for 
future studies that entail the development of chitosan nanoparticles for a certain 
application. Furthermore, the variations between the experimental responses and the 
predicted values have seen in Table 3.3. The least frequent variations between 
experimental responses and predicted values may be observed for the relative 
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viscosity measurements. In particular, two of the runs for which percent error 
relatively high, which were, namely, runs 1 and 3, exhibited a pH of 3.8, an ionic 
strength of 0.2, and a CS: TPP ratio of 6:1 and 2:1, respectively. The other run for 
which percent error relatively high, which was run 10, differed from the previous runs 
in that the ionic strength was 0.4, but it was similar to run 3 in that the CS:TPP ratio 
was 2:1. Based on these findings, it can be said that higher proportions of chitosan 
relative to TPP may increase relative viscosity. In support of these results, (Al-
Shammari et al., 2011) revealed that polymer concentration significantly affects 
relative viscosity. Thus, it can be concluded that high concentrations of chitosan may 
have caused the variations in percent error for the relative viscosity measurements. 
This could be due to repulsion force decrease between the polymers and the solvent 
(Harding, 1997). It is observed in Table 3.3 that the values of zeta potential decreased 
with decrease in the CS: TPP ratio from 6:1 to 1:6. There is no significant difference 
between the expected and predicted values by runs 1 – 23. This is a clear indication of 
protonated amino group neutralization on the chitosan micro-particles’ surface and 
hence, there is repulsive force loss that results to particle precipitation. 
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Table 3.3: Observed (Exp.) responses and predicted (Pred.) values and percent error (biasa %) 
for relative viscosity (Y1), zeta potential (Y2) and particle size (Y3). 
X1 X2 X3 Particle size    [D4,3] (µm)
Run pH I.S (CS:TPP) Exp. Pred. Bias (%) Exp. Pred. Bias (%) Exp. Pred. Bias (%)
1 3.8 0.2 6:1 1.66 ± 0.01 1.85 11.4 35.2 ± 1.3 34.2 -2.8 354 ± 40 351 0.85
2 3.8 0.2 4:1 1.34 ± 0.01 1.46 9.0 29.7 ± 1.1 28.2 -5.1 226 ± 21 223 1.33
3 3.8 0.2 2:1 1.07 ± 0.01 1.18 10.3 19.0 ± 1.6 18 -5.3 135 ± 6 139 -2.96
4 3.8 0.2 1:1 1.11 ± 0.01 1.08 -2.7 11.8 ± 0.9 11.3 -4.2 111 ± 3 113 -1.80
5 3.8 0.2 1:2 1.05 ± 0.01 1.04 -1.0 8.5 ± 1.3 7.6 -10.6 119 ± 2 104 12.6
6 3.8 0.2 1:4 1.04 ± 0.01 1.03 -1.0 6.1 ± 0.9 5.6 -8.2 124 ± 3 101 18.5
7 3.8 0.2 1:6 1.04 ± 0.01 1.02 -1.9 5.8 ± 0.4 5 -13.8 128 ± 6 100 21.8
8 3.8 0.4 6:1 1.66 ± 0.01 1.74 4.8 32.6 ± 2.9 30.4 -6.7 379 ± 49 376 0.79
9 3.8 0.4 4:1 1.45 ± 0.01 1.38 -4.8 27.0 ± 2.7 25.7 -4.8 248 ± 41 242 2.42
10 3.8 0.4 2:1 1.04 ± 0.01 1.15 10.6 17.0 ± 0.6 16.8 -1.2 146 ± 5 152 -4.11
11 3.8 0.4 1:1 1.00 ± 0.01 1.07 7.0 10.0 ± 0.7 10.8 8.0 121 ± 2 123 -1.65
12 3.8 0.4 1:2 1.02 ± 0.01 1.04 2.0 8.0 ± 1.2 7.3 -8.8 129 ± 5 113 12.4
13 3.8 0.4 1:4 1.02 ± 0.01 1.03 1.0 6.0 ± 1.4 5.5 -8.3 132 ± 4 109 17.4
14 3.8 0.4 1:6 1.02 ± 0.01 1.02 0.0 4.3 ± 0.7 4.9 14.0 135 ± 5 108 20.0
15 4.8 0.2 6:1 1.45 ± 0.01 1.5 3.4 21.3 ± 0.4 23.5 10.3 407 ± 50 404 0.74
16 4.8 0.2 4:1 1.24 ± 0.01 1.24 0.0 19.9 ± 0.8 21.3 7.0 267 ± 31 265 0.75
17 4.8 0.2 2:1 1.09 ± 0.01 1.08 -0.9 14.3 ± 0.6 14.9 4.2 171 ± 4 169 1.17
18 4.8 0.2 1:1 1.03 ± 0.01 1.05 1.9 9.7 ± 0.5 10.1 4.1 135 ± 2 138 -2.22
19 4.8 0.2 1:2 0.98 ± 0.01 1.04 6.1 8.0 ± 0.1 7.3 -8.8 138 ± 2 126 8.70
20 4.8 0.2 1:4 1.07 ± 0.01 1.04 -2.8 6.9 ± 0.4 5.8 -15.9 139 ± 2 122 12.2
21 4.8 0.2 1:6 0.97 ± 0.01 1.04 7.2 4.8 ± 0.1 5.4 12.5 142 ± 6 120 15.4
22 4.8 0.4 6:1 1.38 ± 0.01 1.42 2.9 18.6 ± 0.6 19.4 4.3 451 ± 31 445 1.33
23 4.8 0.4 4:1 1.21 ± 0.01 1.18 -2.5 17.3 ± 0.1 19 9.8 306 ± 29 300 1.96
24 4.8 0.4 2:1 1.06 ± 0.01 1.06 0.0 10.3 ± 0.3 14.5 40.8 194 ± 11 196 -1.03
25 4.8 0.4 1:1 1.02 ± 0.01 1.04 2.0 9.0 ± 0.5 10.6 17.8 158 ± 8 161 -1.90
26 4.8 0.4 1:2 0.98 ± 0.01 1.05 7.1 6.8 ± 0.3 8.3 22.1 164 ± 10 147 10.3
27 4.8 0.4 1:4 1.02 ± 0.01 1.05 2.9 5.7 ± 0.2 7 22.8 167 ± 23 141 15.5
28 4.8 0.4 1:6 0.98 ± 0.01 1.05 7.1 4.2 ± 0.5 6.6 57.1 171 ± 15 139 18.7
Dependant Variables Y1 Y2 Y3
Relative viscosity Zeta potential (mV)
 
a  
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In general, the percent error variations with the largest magnitude can be discerned at 
a pH level of 4.8, an ionic strength of 0.4, as well as ratios of chitosan and TPP that 
are not proportionate, as seen in Table 3.3. In fact, it seems that the latter factor has 
the most significant effect on zeta potential when pH and ionic strength remain 
unchanged at 4.8 and 0.4, respectively. This trend is best exemplified by runs 26, 27, 
and 28, wherein the obtained percent error values were 22.1, 22.8, and 57.1, 
respectively. Such large magnitudes of percent error may be attributed to the changes 
in CS: TPP, as these runs exhibited polymer: crosslinking agent ratios of 1:2, 1:4, and 
1:6, while pH and ionic strength remained constant. Importantly, in their study on the 
effects of concentration, ionic strength, and pH on zeta potential, (Carneiro-da-Cunha 
et al., 2011) found that zeta potential increases with increasing chitosan concentration, 
which was indeed observed for runs 26, 27, and 28. Consequently, it can be said that 
at the lower pH and the higher ionic strength implemented in this experiment, zeta 
potential is likely to be decreased with increasing crosslinking agent concentration, 
thereby resulting in the variations in the zeta potential measurements. There is a 
decrease in the size of the particle as the ratio of CS: TPP dropped from 6:1 to 1:1 and 
also within this range, the bias ratio or the difference between the expected and 
predicted is relatively low. This could be because of increase in the density of 
intermolecular and intermolecular cross-linking between the TPP and chitosan amino 
groups; viscosity decrease could also to this (Kawadkar and Chauhan, 2012). It can be 
noted that there was increase in the particle size as the ratio of CS: TPP dropped from 
1:1 to 1:6 and as such, the percentage bias or the difference between the predicted and 
expected was seen to increase significantly as the ratio dropped from 1:1 to 1:6. The 
reason for this could be because more molecules of TPP participate in microparticle 
formation (Li and Huang, 2012). Additionally, as seen in Table 3.3, the magnitude of 
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the variation in percent error increases as the concentration of TPP increases while 
that of chitosan remains unchanged or constant. To illustrate, for runs 5, 6, and 7 
wherein the CS: TPP ratios were 1:2, 1:4, and 1:6, respectively, the obtained percent 
error values were 12.6, 18.5, and 21.8, respectively. This result appears to imply that 
greater amounts of a crosslinking agent tend to produce smaller particle sizes. This 
may occur because the volume of chitosan is lowered when that of TPP is increased. 
Such a finding is corroborated by the study conducted by (Gan et al., 2005), who 
explained that controlling the chitosan and TPP weight ratio can lead to the 
achievement of nanoparticles that possess the desired particle size. Specifically, it was 
found that smaller volumes of chitosan produced nanoparticles of smaller sizes, while 
bigger nanoparticles were obtained for larger volumes of chitosan (Choi et al., 2002, 
Gan et al., 2005, Katas and Alpar, 2006). A possible explanation for this occurrence is 
that smaller particles form when the unoccupied functional groups are in 
stoichiometric proportion, whereas large particles tend to form when polymer 
concentrations are large due to aggregation of polymer molecules (Douglas and 
Tabrizian, 2005, Quong and Neufeld, 1998, Mandlik and Ranpise, 2017). Thus, it is 
likely that the CS: TPP ratio caused the variations in the particle size measurements. 
Finally, Table 3.3 indicates that ionic strength, pH and CS: TPP ratio are suitable in 
predicting viscosity, zeta potential and particle size and can therefore be used in future 
studies to design tuneable microparticles for specific applications.  
 
3.6 Effect of chitosan molecular weight and TPP concentration in acetic acid to 
formulate CS: TPP nanoparticles 
The size of the CS: TPP particles depend basically on molecular weight of chitosan, 
either concentration of TPP or chitosan and conditions of mixing, i.e. chitosan-TPP 
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volume ratio, stirring speed, pH, sonication or temperature (Giri et al., 2012). The 
conditions required for these experiments were determined to be (5:1) CS: TPP ratio, 
30 ℃, 750 rpm (Section 3.4.3). These conditions were selected due to a previous 
studies described that the particle size of CS: TPP at 5:1 decreases with increased 
temperature (Jain et al., 2016, Tsai et al., 2008), this is attributed to decrease in 
intrinsic viscosity and hydrogen bonded water of hydration in chitosan, resulting in an 
increase in chitosan chain flexibility (Chen and Tsaih, 1998). As a result chitosan 
chains form a compact structure during cross linking (Fan et al., 2012). Additionally, 
another previous studies reported that the particle size decreased with increasing 
stirring speed (Jain et al., 2016, Hassani et al., 2015, Tsai et al., 2008). It can be 
observed from Table 3.4 that the concentration of TPP could influence of the particles 
size. At a fixed concentration of chitosan at 3 mg/mL but different the concentrations 
of TPP from (0.84 – 1.25, mg/mL), resulted in an increase in particle size for both 
LMW and MMW samples when TPP concentration was increased. It was noted that 
the initial increase in TPP concentration (0.84 mg/mL) high degree of cross-linking of 
chitosan chain, therefore a significant reduction in particle size were formed. Further 
increase in TPP concentration led to increases in the particles size, this could be due 
to excessive of interparticle cross-linking (bridging effects) (Li and Huang, 2012). 
The size of chitosan nanoparticles prepared by different molecular weight chitosan 
was also studied. Table 3.4 indicated that the particle size has slightly increased with 
the molecular weight chitosan due to increased viscosity which led to less solubility 
of chitosan in diluted acetic acid (Bugnicourt et al., 2014). Therefore, less amino 
groups on chitosan could be protonated. This could lead to inefficient interaction 
between positively charged chitosan and negatively charged TPP (Katas and Alpar, 
2006). This result is similar to previous studies with reported increases in the particle 
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size with increases in chitosan molecular weight (Yien et al., 2012, Gan et al., 2005, 
Janes and Alonso, 2003). The polydispersity index (PDI) reflects the size distribution 
of nanoparticles and it is documented that the higher PDI value, the wider the range of 
particle size. The PDI, also, is used to indicate the uniformity of the nanoparticles. As 
can be seen in Table 3.4 the PDI ranges from 0.24 ± 0.01 to 0.43 ± 0.01. This 
indicates that a narrow size range of nanoparticles, and it in an acceptable range as 
PDI less than 0.50 indicates a relatively homogenous dispersion (Jardim et al., 2015). 
PDI of the LMW and MMW samples range from 0.24 ± 0.01 to 0.26 ± 0.01 and 0.34 
± 0.04 to 0.43 ± 0.01 respectively. This suggests that as molecular weight increases 
the polydispersity of samples also increases, this is due to an increase in particle size 
distribution, and therefore a homogenous dispersion of chitosan nanoparticles were 
prepared (Hu et al., 2008). It has been reported in a previous study that the particle 
size was related to the polymer chain length, and the PDI would tend to procedure 
particles with a large size range (Bugnicourt et al., 2014) as the molecular weight 
increases. 
Zeta potential of these samples also decreased as the concentration of TPP was 
increased. Charge ranged from +36.3 ± 3.6 mV to +34.4 ± 1.7 mV. This can be 
explained by the fact that at a higher concentration of TPP, there are more negatively 
charged phosphate ions which can form cross linkages with free positively charged 
amino groups on chitosan. Therefore, the positive charge of these nanoparticles 
decreases (Dyer et al., 2002, Hassani et al., 2015, Shah et al., 2016). In addition, 
MMW of chitosan has higher zeta potential than LMW of chitosan. This was due to 
the MMW of chitosan has more available cationic groups, resulting in the higher 
positive zeta potential (surface charge) (Hu et al., 2008). Therefore, all chitosan 
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nanoparticles are stable as a surface charge greater than + 30 mV is in the ideal range 
(Jardim et al., 2015). 
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Table 3.4: Change in particle size and zeta potential as concentrations of TPP and molecular weight of chitosan are changed 
 LMW Chitosan MMW Chitosan 
Chitosan 
(mg/mL) 
TPP 
(mg/mL) 
Particle 
Size (nm) 
PDI Z.P 
(mV) 
Particle 
Size (nm) 
PDI Z.P 
(mV) 
3 0.84 231.3 ± 7.9 0.26 ± 0.01 36.3 ± 3.6 237.4 ± 1.8 0.36 ± 0.02 38.7 ± 1.4 
3 1.00 280.3 ± 2.9 0.26 ± 0.01 35.3 ± 1.7 293.7 ± 3.3 0.43 ± 0.01 36.5 ± 1.2 
3 1.25 290.6 ± 6.1 0.24 ± 0.01 34.4 ± 1.7 294.7 ± 10.3 0.34 ± 0.04 35.3 ± 1.7 
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3.7 Summary 
In this study, chitosan microparticles of different morphologies were successfully 
formed by the ionotropic gelation method at method at different CS: TPP ratios and 
pH/Ionic strength conditions. The particles were characterized by relative viscosity, 
zeta potential, particle size, FTIR spectroscopy, SEM and XRD. Using experimental 
design, the relative viscosity, particle size and zeta potential of CS: TPP 
microparticles under different conditions could be predicted using the mathematical 
models. The mathematical models obtained showed good relationships between 
independent variables (pH, ionic strength and CS: TPP ratio) and dependent variables 
(relative viscosity, zeta potential and particle size) for prediction. This gives us the 
ability to design tuneable CS: TPP microparticles for specific pharmaceutical or 
forensic applications more specifically latent fingerprint visualization (see Chapter 
4).  
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Chapter 4 
 
The potential of chitosan-
tripolyphosphate microparticles in the 
visualisation of latent fingermarks 
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4 The potential of chitosan-tripolyphosphate microparticles in the 
visualisation of latent fingermarks 
4.1 Introduction 
 
Chitosan has been investigated widely for its potential in the development of food and 
drug delivery systems and pharmaceutical applications, however it has not generally 
been considered in forensic applications for example fingerprints (fingermarks). The 
identification of fingerprint evidence is widely used in forensic investigations (Becue 
et al., 2008, Choi et al., 2008). Latent fingerprints are a very common form of 
physical evidence (Kabklang et al., 2009, Roux et al., 2000). Some new techniques 
have been enhanced for latent fingerprint identification however, the traditional 
fingerprint identification technique for treating latent prints is powdering method 
(metal powders and magnetic powders). The most traditional methods usually used 
for latent print development are powder dusting (Jones et al., 2010a), iodine fuming, 
ninhydrin spraying and silver nitrate soaking which are quite effective for numerous 
surfaces (Garg et al., 2011, Lee and Gaensslen, 2001). On the other hand, these 
traditional techniques for latent fingermarks detection are not always effective. 
Therefore, forensic scientists have attempted to improve the existing techniques for 
the visualization of latent fingermarks (Garg et al., 2011). The most commonly used 
procedure for revealing the ridge pattern is powder dusting, which relies on the 
mechanical adherence of fingerprint formulation to the fatty components of the skin 
deposit that are secreted by sweat pores that exist on friction ridges (Yamashita and 
French, 2011). Chitosan can form particles by ionic interaction between positively 
charged amino groups of chitosan and negatively charged counter ions of TPP. 
Knowledge of viscosity, zeta potential and particle size will have an influence on the 
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bioadhesion of chitosan: TPP microparticles and hence potential applications in 
forensic applications such as the development of fingermarks (Il Dueik and Morris, 
2013). The factors which effect this interaction are particle size, particle charge, 
particle shape and relative surface area (James et al., 1991b, Jones et al., 2010b, 
Yamashita and French, 2011) all of which are controlled by processing parameters 
such as chitosan concentration, pH and ionic strength of the dissolution media, 
temperature of cross-linking, stirring rate, etc (Wang et al., 2011). There are a number 
of different powders which have been used to detect fingermarks (Table 4.1) 
including for example, granular carbon particles, lead powder (Graham, 1969), Congo 
red dye (Sodhi and Kaur, 2001), eosin yellow dye (Sodhi and Kaur, 1999).  
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 Table 4.1: Various chemicals or powders used for development of latent fingerprints (Garg et al., 2011). 
Name of powder Advantages Disadvantages 
Metallic dusting such as grey powder (containing 
aluminium dust and kaeolin);  Silver powder 
(containing aluminium flake and quartz powder) 
They have longer shelf lives as compared to the 
organic-based powders (Sodhi and Kaur, 2001). 
Grey and silver powder used for dark metallic 
surfaces and  most smooth non-porous surfaces 
(James et al., 1993)  
 Silver powder may be hard to see on a reflective 
surface. 
Black powder (Charcoal) It can develop fingerprints on white and light 
coloured surfaces (Saferstein, 2004)  
Fingerprints may be dotty which more hard to see 
clear contentious details (Bandey and Gibson, 
2006). 
Magnetic powder (iron oxide)  It used magnetised rod and there is no 
conventional brushes such as fibres to touch the 
print and probably damage it (James et al., 1991a) 
Less effective on ferromagnetic surfaces such as 
steel and nickel metal (James and Nordby, 2003, 
Yamashita and French, 2011) 
Luminescent powders such as acidine yellow, Nile 
blue, crystal violet  
They can be used for developing weak prints and 
multicoloured surfaces that would present a 
contrast issues of developed with traditional 
powders (Menzel and Duff, 1979, Menzel, 1979, 
Menzel and Fox, 1980) 
They are not always suitable for use in a crime 
scene (Sodhi and Kaur, 2001). 
Sudan III It used primarily for contaminated wet surfaces 
with beverages, oil, grease, or foods 
It caused hazard to user in case of skin contact, 
and eye contact 
Phloxine B dye It can develop latent fingermarks on a wide  range 
of non-absorbent surfaces (Sodhi and Kaur, 2000) 
May cause eye irritation and cause damage to 
stomach through prolonged or repeated exposure 
Rhodamine B dye It useful for visualisation of latent marks deposited 
on multi-coloured surfaces (Kapoor et al., 2015) 
Hazardous in case of skin, and eye contact 
(irritant) 
Eosin-blue dye It may develop weak fingermarks under UV- It may cause eye, skin, and respiratory tract 
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light. It gave good fingerprint on laminated 
and polyethene surfaces (Hawthorne, 2008) 
irritation such as eosin dyes 
Azure I dye and azure II dye It can detect latent fingerprints on a wide range 
of surfaces, porous and non-pours; white 
and multicoloured (Sodhi and Kaur, 2004) 
Harmful 
Basic fuchsin dye It can detect latent fingerprints on 
wet non-porous surfaces with SPR (Rohatgi and 
Kapoor, 2016) 
Slightly hazardous in case of skin contact 
(sensitizer) 
Molybdenum disulfide It used for development latent fingerprint on non-
porous wet surface 
It can cause several irritations of the eyes and skin 
(Haque et al., 1989) 
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Other common development techniques as discussed in literature review (section 
1.6.6). Titanium dioxide, however, is a white inorganic compound and it is most 
important widely used in the industry as a white pigment. In addition, it has a higher 
refractive index than other white pigments (Yang et al., 2004). Furthermore, titanium 
dioxide for drug delivery have been investigated (Liang et al., 2011, Signoretto et al., 
2011, Park et al., 2014, Jia and Kerr, 2013). A previous study (Reynolds et al., 2008) 
reported that titanium dioxide regularly used in the development of latent fingerprints 
on dark surfaces, as it contrasts very well, is non-hazardous and nontoxic (Helmus et 
al., 2008, Pigments, 2008). Titanium dioxide also has a number useful properties such 
as  optical (absorbs ultraviolet light) and photocatalytic ability (it can show 
photocatalytic activity under ultraviolet light) (Choi et al., 2007, Chen and Mao, 
2007). Furthermore, according to literature titanium dioxide is effective for 
enhancement of bloody prints (Bergeron, 2003) and on wet surfaces. On the other 
hand, some of chemical substances, which have been used to detect fingermarks, have 
drawbacks such as high background interference, high toxicity and pose potential 
health and environment hazards, e.g. Congo red is a Group 1 carcinogen (Afkhami 
and Moosavi, 2010). Therefore, a novel powder for developing latent fingerprints me 
be used in order to try to minimise these issues, this study has proposed a new 
fingermark visualisation powder based on the naturally occurring positively charged 
polysaccharide chitosan which is cheap, readily available, non-destructive (Islam et 
al., 2007) and non-toxic (Aramwit et al., 2015). In the previous chapter, seven ratios 
formulations of CS: TPP microparticles (6:1, 4:1, 2:1, 1:1, 1:2, 1:2, 1:4 and 1:6), were 
prepared according to ionotropic gelation procedure in a four different acetate buffers 
(AB-10, AB-11, AB-12 and AB-13). In this chapter, theses formulations are 
optimisation using a 23 factorial factor design, with 8 experiments (in triplicate), to 
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analyse the effects of the three selected factors (pH, ionic strength and CS: TPP ratio), 
in order to design particles of defined properties for latent fingerprint visualization on 
glass microscope slide (non-porous surface) and on paper (porous surface). Lipids in 
fingermarks residue have an important role in forensic science investigations (Girod 
and Weyermann, 2014). This study will explore capacity of CS: TPP microparticles to 
associate organic lipid residues in fingermarks for forensic applications. Fingermarks 
were aged and stored under laboratory conditions, and the effectiveness of a CS: TPP 
microparticle enhancement method was assessed, following the methodology outlined 
in (Sears et al., 2012). Moreover, the purpose of using four different conditions of 
chitosan at various ratios was to find out the optimum conditions of attachment of 
microparticles to the ridges of latent fingermarks/fingerprint.   
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4.2 Materials 
All the materials that used in this chapter were described in Chapter 3 Section 3.3.  
4.3 Factorial design experiment 
The experimental design applied in this study. The effect of three different parameters 
on the ability of chitosan microparticles properties to enhance latent fingermarks were 
evaluated using a 23 factorial design composed of three factors (Table 4.2). These 
factors including: pH value, ionic strength, and CS: TPP ratio were selected as 
independent variables and set at two levels each (upper and lower). The quality of 
fingerprint were response parameter or the dependent variable (Y4). 
 
Table 4.2: Parameters used in the factorial design. 
 
Factors Symbol Lower level (-) Upper level (+) 
pH value X1 3.8 4.8 
Ionic strength X2 0.2 0.4 
CS: TPP ratio X3 1:1 2:1 
Dependent 
variables 
Y4 
Assessment quality fingerprint (Fairley et al., 2012) 
4: Over 2/3 clear ridge detail, which is similar to green 
magnetic powder (Figure 4.1) 
3: Between 1/3 and 2/3 clear ridge detail 
2: Less than 1/3 clear ridge detail 
1: Very few visible ridges, poor quality 
0: No evidence of fingermark  
  152 
 
   
Assessment of fingermark development quality is basically dependent on an 
individual’s background and experience (Fritz et al., 2015). Additionally, a subjective 
scale depends on the opinion of the fingerprint examiner to competently identify ridge 
details (minutiae) (Pounds et al., 1990, Stoilovic, 1993, Wallace-Kunkel et al., 2007, 
Humphreys et al., 2008) also they are dependent on the scale used (Becue et al., 2009, 
Fairley et al., 2012, Pulsifer et al., 2013). Previous studies have reported that the 
evaluation of the quality of a fingermark is difficult due to the subjectivity of the 
currently used grading systems (Pulsifer et al., 2013) and that these rely entirely on 
visual assessment. In the original Bandy scale to obtain top a grade of 4, this requires 
“a full development - whole mark clear with continuous ridges” (Bandey and Gibson, 
2006), 3 requires “more than two thirds of marks continues ridges” which can be used 
for identification, 2 requires about one third to two thirds of the ridge detail, 1 
requires signs of contact but without ridge detail. Therefore, it is possible to imagine 
two or more fingermarks being given the same grade, but not necessarily showing the 
same level of detail. However in other studies only over two thirds clear ridges details 
are required for a top grade of 4 (Fairley et al., 2012), and the fingerprint should be 
usable to identify a person from that fingerprint. The subjective grading system of 
Bandy is more coarse in comparison to the updated objective grading system 
presented (Fairley et al., 2012). In this study, following on from (Fairley et al., 2012), 
the fingermark development was assessed based on clarity ridge detail (de la Hunty et 
al., 2014), therefore a score of 4 represents over two thirds clear ridge details and can 
be characterised as potentially identifiable marks. Also, fingermarks with a grade of 3 
or 2 may be described as visible fingerprints, whereas finger marks which grade of 1 
can be termed as poor quality or very few visible marks (Table 4.2). In the present 
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study, the effectiveness of a development technique can be evaluated in collating and 
averaging the grade of the fingermarks. When evaluating and comparing methods a 
high proportion grade of 4 would indicate that the method was performing well 
(Fairley et al., 2012). 
 
 
 
 Figure 4.1: Latent fingerprint development using green magnetic powder consisting of iron 
(I,II) oxide as a control. (a) Donor 1, (b) donor 2, (c) donor 3, (d) donor 4 and (e) donor 5. 
 
 
4.4 Experimental 
4.4.1 Microparticle preparation (CS: TPP) 
Following preparation of chitosan, TPP and CS: TPP microparticles at different ionic 
strengths and pH values (Acetate buffers AB-10 to AB-13) as described in section 
3.4.1.3. Buffers AB-10, AB-11, AB-12, and AB-13 were chosen as they have 
previously been used in model validation in chapter 3 and cover a good range of pH 
and ionic strength. 
 
4.4.2 Samples preparation and fingermarks development 
Two different approaches were used in the experiments. The first approach, was 
whole fingermarks depletions. Natural latent fingermark were collected from five 
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donors during the study period. Donors (males and female aged 33-47 years) were 
asked not to wash their hands for at least thirty minutes prior to fingermark 
deposition, and rubbed their hands together. This allowed passable fingerprint residue 
to distribute over fingers, and minimises variability (Sears et al., 2012). Glass 
microscope slides were used as a “typical” non-porous surfaces during the 
experiments. The glass slides were washed with detergent and warm water, cleaned 
with ethanol, to remove any contaminations such as fat soluble or water soluble, and 
then left to dry prior to deposition (Bacon et al., 2013). Donors were asked to deposit 
fingermarks using their right thumb (except donor 3 who deposited their left thumb 
due to an injury to their right thumb) in positions 1, 2, 3, 4, 5 and 6 on glass 
microscope slides containing the odd numbered fingermarks in a depletion on the left 
and the even numbered fingermarks on the right, this will be referred to as stage 1. 
This was repeated but reversing the development process order used on the odd and 
even numbered fingermarks, referred to as stage 2 (Figures 4.2) (Sears et al., 2012, 
Bandey and Gibson, 2006). 
 
 
Figure 4.2: Schematic representation depletion method (first approach) (Sears et al., 2012, 
Bandey and Gibson, 2006). 
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After deposition, the fingermarks were aged for one day before development, due to 
the fact that fingerprints found at crime scenes are typically around one day old 
(James et al., 1991b). Three techniques have been used to develop latent fingermarks: 
a spray method, suspended chitosan particles in solution and powder method in order 
to investigate which method is more effective and sensitive for detecting latent 
fingermarks. 
 
4.4.2.1 First technique (spray) 
1- Fingermarks deposited on glass slides were sprayed with chitosan solutions 
using AB-10 at different ratios, slides were then placed in drying oven for 5 
minutes at temperature 60 °C. 
2- TPP solutions using AB-10 with red dye at different volumes were then 
sprayed on each slide. It was applied five times to confirm the results. 
3- Steps 1 and 2 were repeated for chitosan and TPP solutions using different 
acetate buffers (AB-11, AB-12 and AB-13). 
 
4.4.2.2 Second technique (microparticles in solution) 
1- Fingermarks deposited on glass slides were immersed into the seven working 
solutions of CS: TPP ratios (AB-10) at 6:1, 4:1, 2:1, 1:1, 1:2, 1:4 and 1:6, for 
30 min, 1 hour, 2 hours and 3 hours.  
2- Slides were then dried at room temperature. It was applied five times to 
confirm the results. 
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3- Steps 1 and 2 have applied for chitosan microparticles using different acetate 
buffers (AB-11, AB-12 and AB-13). 
 
4.4.2.3 Third method (microparicles as powder)   
The 28 CS: TPP microparticle mixtures prepared using buffers AB-10, AB-11, AB-12 
and AB-13 were precipitated by centrifugation (Thermo Fisher scientific - Heraeus 
biofuge primo R) at 8500 rpm for 60 minutes and then supernatant (liquid) was 
discarded. The recovered microparticles (remaining solid) were washed three times 
using deionised water, followed by freeze drying for 24 hours (Alpha 1e4 LD2 freeze 
drier (Martin Christ GmbH, Osterode am Harz, Germany). Deposited prints were 
developed with seven different chitosan particles ratios of CS: TPP (6:1, 4:1, 2:1, 1:1, 
1:2, 1:4 and 1:6) formulation for each acetate buffer (AB-10, AB-11, AB-12 and AB-
13). The process was repeated five times per formulation (Figure 4.3). To confirm 
these results a further split depletion series (second approach) consisting of six latent 
fingermarks made by the deposition of prints of three fingers (index, middle and ring 
finger) from each of the donors were applied as described in section 4.4.2.3.1. 
 
 
 
Figure 4.3: An example of CS: TPP particles at ratio of 2:1 using buffer AB-12. 
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In addition, to further investigate different surfaces, fingermarks were collected from 
donors on the paper (porous surfaces), then aged for one day and developed using 
chitosan microparticle powder as described earlier. 
 
4.4.2.3.1 Split print depletion series 
1- Five donors were asked not to wash their hands for at least thirty minutes 
before fingermark deposition and they rubbed their fingertips together prior to 
deposition to minimise variability and distribute sweat evenly in all ridges. To 
determine the relative sensitivity and limitation of the method, six split 
depletion series (second approach) of fingermarks were obtained by requesting 
that each donor deposit fingermarks on the middle of two clean glass 
microscope slides side-by-side from the index, middle and ring fingers of right 
hand. The fingermarks were aged for one day before developing (Figure 4.4) 
(Sears et al., 2012).  
2- Then each fingermark was split into halves. One half slide print of the 
depletion (left) was developed with CS: TPP at 2:1 ratio using AB-10, while 
the other half slide print (right) was developed with different CS: TPP at 1:1 
ratio using AB-10 for comparison. These two formulations were chosen as 
they gave satisfactory results in initial experiments (section 4.5.1). 
3- Step 2 was repeated for CS: TPP at 2:1 and 1:1 ratio using different acetate 
buffers including AB-11, AB-12 and AB-13. The process was repeated ten 
times for each of the eight formulations per donor’s finger. Bisected slides 
were placed side by side and imaged together. 
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Figure 4.4: Schematic representation of the deposition of a fingermarks the split depletion 
series (second approach) for four different acetate buffers (AB-10, AB-11, AB-12 and AB-
13) at CS:TPP ratios of 2:1 and 1:1 (two techniques per four formulations).  
 
 
For the aged latent fingermarks study, latent fingermarks deposited in split depletion 
were collected from each donor (index, middle and ring fingers of their right hand) on 
cleaned glass microscope slides fingermarks as described earlier and were stored 
(variable humidity and temperature 20 – 25 oC) for 7 and 14 days respectively in an 
open tray on the lab bench, where the windows kept closed at all times. Then each 
fingermark was split into halves, and the first half (left) was aged for 7 days whereas 
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the other half (right) was aged for 14 days. Both halves were then developed with 
chitosan particles as powder CS: TPP at 2:1 in buffer (AB-12).  
 
4.4.3 Photography of Samples 
All fingermark samples were visually evaluated and imaged using a Nikon D3100 
digital camera (Tokyo, Japan), equipped with an AF-S Micro-NIKKOR 60 mm lens 
and the camera was mounted on Firenze Mini Repro tripod. Samples, were 
photographed using a shutter speed of 1/30 seconds, focus mode of AF-S and an ISO 
sensitivity of Auto. The photographic plane of camera was parallel to the plane of 
fingeremark, and the same angle of incidence, sample positioning and camera 
aperture. In addition, optical microscopy examination was conducted with two 
different microscopes (Leica stereo low powered microscope EZ4HD, and Leica high 
powered microscope DM 500, ICC50 HD) using the same intensity of lighting; Leica 
LAZ software for image manipulation (Leica Microsystems, Milton Keynes, UK).  
 
4.4.4 Scanning electron microscopy (SEM) 
The surface microparticle morphology was characterised using scanning electron 
microscopy (SEM). The developed fingerprints on glass slides were coated using a 
Quorum 7920 Sputter coater (Quorum Industries, Laughton, UK) by a thin layer of 
gold-palladium alloy, before placing onto aluminium stubs using carbon impregnated 
double sided adhesive tape. The images were obtained using a JEOL JSM 6060 LV 
Scanning Electron Microscope (Oxford instruments, Abingdon, UK) using the Back 
Scattered Electron mode at a beam accelerating voltage of 10 kV and under high 
vacuum. Accelerating voltage was chosen to improve surface sensitivity and obtain 
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high quality images (Bacon et al., 2013), powdered chitosan microparticles were 
mounted on aluminium stubs using double sided carbon adhesive tape attached to stub 
and coated in the same method as described earlier. Scanning electron microscope 
refers to the surface of the sample by examining it using a beam of electrons of high 
energy. Backscattered electrons are produced as a result of interaction between the 
atoms and the electrons and they carry information about the topography of the 
surface of the sample.  
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4.5 Results and discussion 
The ridge deposits of a fingermark comprise a complex mixture of natural secretion 
residues, such as fatty acids, cholesterol, triglyceride and amino acids (Bramble, 1995, 
Scruton et al., 1975). Lipids on the skin surface come from sebaceous glands 
(Nicolaides, 1974). Functionalised nanoparticles have drawn great interest over the 
last decade in forensic science to detect and as visualising reagents for latent 
fingermarks (Sametband et al., 2007, Becue et al., 2007). The fingermarks evaluated 
in these study were aged for 1 day prior to development when preliminary 
examinations were being conducted, and then for 7 days and 14 days during 
subsequent comparative studies. The first visualisation technique evaluated 
fingerprints left on 28 glass microscope slides. Chitosan as solution (AB-10, AB-11, 
AB-12 and AB-13) were sprayed on to the glass slides, then TPP as solution (AB-10, 
AB-11, AB-12 and AB-13) was sprayed. This technique did not work for any ratio 
(Figure 4.5a). The second technique was chitosan microparticles in acetate buffer 
solutions. The fingermarks were immersed into the different microparticle 
dispersions, removed from the solutions 30 minutes, 1, 2 and 3 hours later, and dried 
at room temperature. No clear ridges of prints were obtained. As a consequence, using 
all ratios as a solution, this technique has not yielded any satisfactory results (Figure 
4.5b).  
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Figure 4.5: An examples of latent fingerprint (donor 1) on glasses slides with different 
development method utilised, (a) first technique (spraying method), (b) second technique 
(particles in solution method) and (c) third technique (powder method) (n= 5). 
 
 
Both techniques (first and second) were unsuccessful, this could be due to low 
concentrations of chitosan (0.013% - 0.143%) and therefore only limited chitosan 
microparticles were available and could attached or provide coverage of the lipid 
residues in latent fingermark. This observation is similar to previous study which 
reported at low concentrations of chitosan (0.2% - 0.6%) poor quality fingerprints 
were obtained (Islam et al., 2007). In addition, in the same study it was demonstrated 
that at higher concentrations of chitosan (> 1.0 %) might cause high viscosity which 
leads to increased resistance to the flow of chitosan in furrows (between ridges 
fingermarks) and resulted in a thin chitosan layer over the whole fingermark area, 
which obscures the ridge details (Islam et al., 2007) and reinforces the importance of 
particle viscosity in fingermark visualisation. Moreover, in acidic media, some 
components such as proteins or amino acid within a fingermark can be protonated 
(Gao et al., 2009, Choi et al., 2008) and therefore become positively charged and will 
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repulse positively charged chitosan microparticles. As a result, chitosan 
microparticles were not deposited onto fingermark ridges. An alternative approach, 
latent fingerprint developed using third technique (chitosan microparticles as a 
powder) on glass microscope slides; obtained results which were better than first and 
second techniques (Figure 4.5c). Therefore, this method was used in further studies. 
However, fingermarks on paper (porous surface), which was developed using CS: 
TPP powder at ratio of 2:1 in buffer AB-12 was unsuccessful, this is most likely due 
to the paper absorbing fingermark residues (Figure 4.6). Therefore, the third 
technique could be sufficient or valid to use on non-porous surfaces (Figure 4.5c). 
 
 
 
Figure 4.6: An example of development of latent fingermark (donor 1) on paper using third 
technique (powder method) (n=5). 
 
 
4.5.1 Proposed mechanism for interaction 
Many researchers have investigated the ability of CS: TPP microparticles to associate 
with organic compounds such as peptides and proteins for pharmaceutical 
applications (Hu et al., 2008). However, they have not been widely considered in 
forensic applications (Il Dueik and Morris, 2013) and it is proposed that chitosan 
microparticles, which have long carbon chains, deposit on to fingermarks due to the 
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lipophilic interactions with the lipid residues in fingerprint ridges. Polycationic 
chitosan molecules with long carbon chains forms an ionotropic gel with the TPP 
polyanion which results in partially lipophilic microparticles. Then van der Waals 
interactions occur between the lipophilic (hydrophobic) ends of long carbon chain and 
the lipid residues of the latent fingerprint (Figure 4.7) (Islam et al., 2007). In addition, 
lipid residues in fingermarks have partially negative charge, whilst CS: TPP 
microparticles surfaces have positive charge, which can be controlled depending on 
processing conditions. Therefore, the binding of the chitosan microparticles with 
lipids may be facilitated by electrostatic and lipophilic interactions and hydrogen 
bonding (Muzzarelli, 1996, Wydro et al., 2007). Latent fingerprints developed using 
third technique (chitosan microparticles as a powder) on glass microscope slides (non-
porous surface) obtained satisfactory results (although this depends on the pH, ionic 
strength and CS: TPP ratio at which these particles were prepared). This technique 
relies on the chitosan microparticles in the fingerprint powder adherence to the oily 
component of the skin ridge deposits. The effectiveness with which the powder 
adheres to the ridge depends on the factors such as viscosity, particle size and the 
charge on the particles (Sodhi and Kaur, 2001). 
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Figure 4.7: Schematic representation of third technique (A) chitosan carbon chains with ionic 
ends and TPP anions (B) chitosan polycations attraction with TPP polyanions making them 
lipophilic (C) the hydrophobic (lipophilic) ends of long carbon chains from chitosan 
microparticles burying themselves into the lipid residues of the latent fingerprint (Islam et al., 
2007). 
 
 
A previous study was conducted using silver nanoparticles which slowly deposited on 
water insoluble component of sweat, resulted in a black or dark grey print (Burow et 
al., 2003). This technique is sensitive, however, some forensic laboratories have 
limited using this technique on a routine basis (Jaber et al., 2012) due to its 
disadvantages such as solution instability, complexity, and often poor contrast (Becue 
et al., 2007, Burow et al., 2003, Cantu et al., 2003). Another studies (Stauffer et al., 
2007, Schnetz and Margot, 2001) used gold nanoparticles stabilised by citric acid, 
followed by modification with a physical silver developer. At low pH, gold 
nanoparticles adhered to fingermark residues due to ionic interactions between 
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negative charged of gold particles and positive charged of fingermarks component 
residue (Choi et al., 2006). When using the same finger to deposit fingermarks 
sequentially the composition of the first deposition mark is different to the second 
mark, which is different to the third mark and fourth mark etc., this is known as a 
depletion series (Bandey and Gibson, 2006).  
This investigation (third technique) used chitosan microparticle powders prepared 
using buffers AB-10, AB11, AB-12 and AB-13 at all seven CS: TPP ratios at 6:1, 4:1, 
2:1, 1:1, 1:2, 1:4 and 1:6. The results were analysed according to quality of detected 
fingermarks and sensitivity of the method. The quality of the fingermark development 
on seven glass microscope slides (non-porous surface) were first evaluated by visual 
observation. The results demonstrated that CS: TPP ratios of 2:1 and 1:1 showed 
ridges than other ratios. Therefore, these ratios (6:1, 4:1, 1:2, 1:4 and 1:6) were 
withdrawn from the further investigations. Observations of each of the eight 
developments per donor using CS: TPP at 1:1 and 2:1 ratio as a powder on glasses 
microscope slides after preparation in the four different acetate buffers: AB-10, AB-
11, AB-12 and AB-13 are shown in Figures 4.8 and 4.9. The variation in the degree 
of ridge detail development between donors might be explained in terms of variations 
in the amount components of deposited residue in latent fingermarks being secreted 
by different donors (Ramasastry et al., 1970, Downing and Strauss, 1974), also 
differences in contact time, angle and pressure (Girod et al., 2012, Cadd et al., 2015). 
Previous studies have reported that the latent residues or the quantity of material 
deposited, depend on factors such as age (Ramasastry et al., 1970, Buchanan et al., 
1997), deposition force (Jasuja et al., 2009), gender (Asano et al., 2002), or diet 
(Croxton et al., 2010), the nature of the receiving surface, environment conditions, 
and the method used in the development of the fingermarks, and it is inevitable for 
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experimental results involved in fingerprints to reveal some degree of variation 
(Sauzier et al., 2013). There were a number of fixed parameters in this study:  
 all fingermarks collections were made on the same non porous surface (glass 
microscope slides) 
 the forces applied during deposition were carefully controlled throughout the 
experiments  
 dusting was performed under the same environmental conditions 
 the same method was used in their development.  
The microparticles aggregate on the fingermark ridges due to lipophilic and 
electrostatic interactions between the chitosan microparticles and the lipid residues of 
the latent fingermarks (Choi et al., 2008). These interactions rely on parameters which 
will be discussed later. In terms of CS: TPP ratios at 2:1 and 1:1, the 1:1 is not best 
for a good deposition of chitosan microparticles onto the fingermarks (Figure 4.8), 
and all of fingermarks ridges could not be seen clearly using any of four different 
chitosan microparticles irrespective of the buffer. Although chitosan microparticles 
cover some of the fingermark area, there is not enough ridge details for adequate 
identification (grade 1). Therefore, this method (CS: TPP ratio at 1:1) could not be 
accepted for identification work. 
 
  168 
 
 
Figure 4.8: Development of first depletion latent fingermarks of CS: TPP at 1:1 ratio as a 
powder on glass microscope slides (Naked eye) for five donors, using (a) AB-10 (b) AB-11 
(c) AB-12 and (d) AB-13. All are poor quality (grade 1) (n=10). 
 
 
 
However, as shown in Finger 4.9, when latent fingermarks were developed using the 
buffers (AB-10, AB-11, AB-12 and AB-13) for chitosan microparticles at ratio of 2:1. 
The images of fingermarks using AB-12 of chitosan microparticle (Figure 4.8c) were 
clear enough and have significant details for comparison and could be used for 
identification and produced grade 4 fingermarks.  
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Figure 4.9: Development of first depletion latent fingermarks of CS: TPP at 2:1 ratio as a 
powder on glasses microscope slides (Naked eye) for five donors, using buffers (a) AB-10 
(grade 2) (b) AB-11 (grade 3)  (c) AB-12 (grade 4) and (d) AB-13 (grade 1) (n=10). 
 
 
Additionally, latent fingermarks developed using AB-12 (pH = 4.8 and I.S = 0.2 M), 
CS: TPP ratio at 2:1 are shown in Figure 4.9c and had high capability to enhance the 
fingermarks for all donors (grade 4). It is thought that these microparticles adsorb 
more onto the ridges as a result of lipophilic and electrostatic interactions. Figure 
4.10 shows an example of two differences in the development of fingermark residue 
by different chitosan microparticles in a depletion series (first approach, section 4.4.2) 
which had high proportions of grades (3 and 4). As can be seen in Figure 4.10 that 
the stage 1 of CS: TPP ratio at 2:1 in buffer 12 (depletions of 1, 3 and 5) and CS: TPP 
ratio at 2:1 in buffer 11 (depletions of 2, 4 and 6) there is a sequential reduction in 
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development quality as the deposited fingermark residue depletes. This is due to 
decreases in the amount of fingermark residues on the finger throughout the series. 
The same observations were seen in stage 2 when repeated but development processes 
reversed, so that CS: TPP ratio at 2:1 in buffer 11 (depletions of 1, 3 and 5) and the 
CS: TPP ratio at 2:1 in buffer 12 (depletions of 2, 4 and 6). These observations were 
consistent with all donors (Figures 4.10 - 4.13). The depletion series describes the 
relative sensitivity or effectiveness of a technique and examination of whole or split 
fingermarks. Results obtained from 5 donors could give a realistic indication of the 
method. In addition, a CS: TPP ratio of 2:1 in buffer AB-12 can detect fingermarks 
until the third depletion, whereas CS: TPP ratio at 2:1 in buffer AB-11 technique can 
only detect fingermarks until second depletion. This is might be different surface 
charges on particles which leads to different attractions. 
 
Figure 4.10: Development fingermarks depletion series (donor 1). Stage 1 using CS:TPP at 
2:1 (a) in buffer AB-12 (left column), (b) in buffer AB-11 (right column). Stage 2 repeated 
but development reversed (c) in buffer AB-11 (left column), (d) in buffer AB-12 (right 
column). 
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Figure 4.11: Development fingermarks depletion series (donor 2). Stage 1 using CS:TPP at 
2:1 (a) in buffer AB-12 (left column), (b) in buffer AB-11 (right column). Stage 2 repeated 
but development reversed (c) in buffer AB-11 (left column), (d) in buffer AB-12 (right 
column). 
 
 
Figure 4.12: development fingermarks depletion series (donor 3). Stage 1 using CS:TPP at 
2:1 (a) in buffer AB-12 (left column), (b) in buffer AB-11 (right column). Stage 2 repeated 
but development reversed (c) in buffer AB-11 (left column), (d) in buffer AB-12 (right 
column). 
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Figure 4.13: development fingermarks depletion series (donor 4). Stage 1 using CS:TPP at 
2:1 (a) in buffer AB-12 (left column), (b) in buffer AB-11 (right column). Stage 2 repeated 
but development reversed (c) in buffer AB-11 (left column), (d) in buffer AB-12 (right 
column). 
 
 
 
Figure 4.14: Development fingermarks depletion series (donor 5). Stage 1 using CS:TPP at 
2:1 (a) in buffer AB-12 (left column), (b) in buffer AB-11 (right column). Stage 2 repeated 
but development reversed (c) in buffer AB-11 (left column), (d) in buffer AB-12 (right 
column).  
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To confirm above results, a further split print depletion series using three fingers from 
each donor was performed to assess the effect of each development technique and the 
sensitivity of techniques on the residue fingermarks (second approach, section 4.5.4). 
Based on those results obtained in preliminary experiments pH, ionic strength and CS: 
TPP ratio were selected to find the optimised conditions to obtain the best quality 
fingerprint visualisation using a 23 factorial design (Table 4.2). The formulations (F1 
- F8) (Figure 4.8 and 4.9) were prepared based on the ionic gelation of positively 
charged amino groups of CS with TPP anions (Table 4.3). An important parameter in 
the characterization of microparticles is the surface charge of the chitosan 
microparticles indicated by zeta potential. A higher zeta potential may be related to 
stronger positive charges of the amino group (NH3
+) of chitosan at high level in the 
factorial design experiment; and the remaining amine groups (non-interacting) would 
be responsible for the positive zeta potential on microparticles (Zhang et al., 2004). 
To determine the quality level of fingerprint development; a fingermarks quality scale 
assessment (0 - 4) was used Table 4.2 (Fairley et al., 2012). As shown in Table 4.3 
and Figures 4.8, 4.9, the optimum quality fingerprint was obtained for three 
formulations: F5 (Figure 4.8a), F6 (Figure 4.9c) and F7 (Figure 4.9b). Formulation 
F5 (Figure 4.9a) had limited development and less than about one third of ridge 
details were present, and therefore probably could not be used for identification 
purposes. While, formulation F7 (Figure 4.9b) had good development (grade 3) 
where between one third and two thirds of ridge detail were present. Finally, 
formulation F6 (Figure 4.9c) has the best development (grade 4), as more than two 
thirds of ridge details were present and it has the potential to be used for identification 
purposes (Rohatgi and Kapoor, 2016). 
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Table 4.3: Characteristics of the chitosan microparticles obtained by the factorial design 23 for different formulation F1 to F8. Fingerprint quality was 
assessed using chitosan microparticles on glass microscope slides 
 
Formulation 
code 
Dependent variables Independent variables, mean ± SD (N = 3)  
X1: 
pH 
X2: 
I.S 
X3: 
CS:TPP 
Ratio 
Y1: relative 
viscositya 
Y2: zeta 
potential (mV)a 
Y3:  particle size 
(µm) 
D[4,3]a 
Y4: average 
fingerprint 
qualityb 
(Grade) 
Fingerprint 
image 
(Donor 2) 
F1 (AB-10) 3.8(-) 0.2(-) 1:1(-) 1.11 ± 0.01 11.8 ± 0.9 111 ± 3 1 
 
F2 (AB-12) 4.8(+) 0.2(-) 1:1(-) 1.03 ± 0.01 9.7 ± 0.5 135 ± 2 1 
 
F3 (AB-11) 3.8(-) 0.4(+) 1:1(-) 1.0 0± 0.01 10.0 ± 0.7 121 ± 2 1 
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F4 (AB-13) 4.8(+) 0.4(+) 1:1(-) 1.02 ± 0.01 9.0 ± 0.5 158 ± 8 1 
 
F5 (AB-10) 3.8(-) 0.2(-) 2:1(+) 1.07 ± 0.01 19.0 ± 1.5 135 ± 6 2 
 
F6 (AB-12) 4.8(+) 0.2(-) 2:1(+) 1.09 ± 0.01 14.3 ± 1.1 171 ± 4 4 
 
F7 (AB-11) 3.8(-) 0.4(+) 2:1(+) 1.04 ± 0.01 17.0 ± 0.6 146 ± 5 3 
 
F8 (AB-13) 4.8(+) 0.4(+) 2:1(+) 1.06 ± 0.01 10.3 ± 0.3 194 ± 11 1 
 
aChapter 3.  
bY4: Assessment quality fingerprint: (Fairley et al., 2012)
  176 
 
All the chitosan microparticle formulations are positively charged, but the values of 
charges for F5 (Figure 4.9a), F6 (Figure 4.9c), and F7 (Figure 4.9b) (14.3 - 19.0 
mV) are higher than those of the other formulations (9.0 - 11.8 mV). The ionic 
strength of solution in formulation F7 (Figure 4.9b) was at a higher level (Table 4.3) 
and caused an increase in quality of fingerprint compared to F5 (Figure 4.9a). 
Moreover, with an increased ionic strength at 0.4 M, the ammonium ions (NH3
+) on 
the chitosan molecules are more shielded by acetate ions (CH3COO
-) leading to a 
decreased zeta potential (charge). Increased zeta potential diminished the electrostatic 
repulsion between the chitosan particles. In general, quality fingerprint increased with 
increased positive zeta potential (Table 4.3) and those samples with a zeta potential of 
less than +12 mV F1 (Figure 4.8a), F2 (Figure 4.8c), F3 (Figure 4.8b), F4 (Figure 
4.8d) and F8 (Figure 4.9d) produced prints of poor quality (1 on the Fairley scale) 
(Fairley et al., 2012). Of the three formulations which produced fingerprints of better 
quality F6 (Figure 4.9c) was the best performing (fingerprint quality of 4) and as this 
sample has a lower zeta potential than both F5 (Figure 4.9a) and F7 (Figure 4.9b) 
this suggests that the overall charge on the particles is not the only factor which 
affects fingerprint quality and that other interactions such as van der Waals 
interactions with lipid residues of the latent fingerprint are also important, as well as 
hydrogen bonding (Muzzarelli, 1996, Wydro et al., 2007). The hydrodynamic 
diameter of particles were measured and this was repeated three times (same 
formulations) on three different days (different preparations) to produce average 
values of particle size, and the standard deviations are relatively small therefore 
particles of similar sizes, at least after suspension in buffer, can be prepared easily 
with little variation in size (Domingos et al., 2009, Komalam et al., 2012). F6 (Figure 
4.9c) also had larger particle size (171 ± 4 µm) and great viscosity than both F5 (135 
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± 6 µm) (Figure 4.9a) and F7 (146 ± 5 µm) (Figure 4.9b), which leads to decreased 
surface area and van der Waals interactions between particles and therefore 
potentially stronger van der Waals interactions with lipid residues than either F5 
(Figure 4.9a) or F7 (Figure 4.9b). Although the size range of the microparticles are 
greater than those which have been demonstrated to be the most effective in latent 
fingerprint visualisation ~ 50 µm (Theaker et al., 2008). However, in the previous 
chapter the effect of temperature and stirring rates on particle size for example may 
improve visualisation (Chapter 3, Section 3.6).  
In addition, the main (the largest) effect on quality fingerprint (Y4) is the CS: TPP 
ratio (Figure 4.15a). The fingerprint quality increases as we move from low level 
(1:1) to higher level (2:1) of the factor (CS: TPP ratio). However, the main effects 
plot also indicates that ionic strength (I.S) has negative effect on quality fingerprint. 
The fingerprint quality decreases when we move from the low level to the high level 
I.S which indicates that the net charge on the particles (zeta potential) is important, 
which is evident from Table 4.3. However, pH has no effect on quality fingerprint as 
the line is horizontal. In brief, an interaction plot basically reveals whether there is an 
interaction between two different processing conditions for a certain response in the 
fingerprint quality. When the lines are parallel, interaction effects are zero. The more 
different the slopes, the more the influence the interaction effect has on the results 
(Israel et al., 2014). In Figure 4.15b the lines of pH and ratio are parallel indicating 
there are no interactions between them, however the interaction between pH and ionic 
strength is the most significant as the lines non-parallel and cross. The lines of I.S and 
ratio are non-parallel indicating there are interactions between the different processing 
conditions. The two factors interactions are -0.5, -0.25 and 0.0 for pH*I.S, I.S*Ratio 
and pH*Ratio, respectively. 
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Figure 4.15: (a) The main effect plots for quality fingerprint (Y4): pH; I.S and CS: TPP ratio. 
The reference line (1.75) is shown as dotted line and the steeper the slope the greater the 
effect of a particular parameter. (b) The interactions plot for quality finger. To visualize these 
effects, the Y-axis scale is always the same for each combination of factors. This graph shows 
that the pH*IS interaction effect is the largest. 
 
 
Moreover, the attachment of CS: TPP microparticles to fingermark residues can easily 
be seen, and revealed clearly visible marks at 2:1 ratio in buffer AB-12 resulting in a 
high quality fingerprint image where fingerprints are clear enough and have 
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appropriate details for comparison and identification (Figures 4.16 - 4.20). 
Considering the many features that can be seen when the fingermark is dusted with 
the chitosan microparticles and magnified using a low power optical microscope, 
there may be some potential in further evaluating thee materials.  
 
 
 
Figure 4.16: (a) A developed latent fingerprint (donor 1) on glass slide using chitosan 
microparticle as a powder at CS: TPP of 2:1 in buffer AB-12 (Naked eye), (b) chitosan 
microparticle adsorbed on fingerprint ridges under low power optical microscope, 
magnification 20x (grade 4). 
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Figure 4.17: (a) A developed latent fingerprint (donor 2) on glass slide using chitosan 
microparticle as a powder at CS: TPP of 2:1 in buffer AB-12 (Naked eye), (b) chitosan 
microparticle adsorbed on fingerprint ridges under low power optical microscope, 
magnification 20x (grade 4). 
 
 
 
 
 
Figure 4.18: (a) A developed latent fingerprint (donor 3) on glass slide using chitosan 
microparticle as a powder at CS: TPP of 2:1 in buffer AB-12 (Naked eye), (b) chitosan 
microparticle adsorbed on fingerprint ridges under low power optical microscope, 
magnification 20x (grade 4). 
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Figure 4.19: (a) A developed latent fingerprint (donor 4) on glass slide using chitosan 
microparticle as a powder at CS: TPP of 2:1 in buffer AB-12 (Naked eye), (b) chitosan 
microparticle adsorbed on fingerprint ridges under low power optical microscope, 
magnification 20x (grade 4). 
 
 
 
 
Figure 4.20: (a) A developed latent fingerprint (donor 5) on glass slide using chitosan 
microparticle as a powder at CS: TPP of 2:1 in buffer AB-12 (Naked eye), (b) chitosan 
microparticle adsorbed on fingerprint ridges under low power optical microscope, 
magnification 20x (grade 4). 
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These results are consistent to results obtained from previous study (Dilag et al., 
2009), which used cadmium sulphide/chitosan nanocomposites in the powder dusting 
method to develop latent fingermarks on non-porous surfaces (aluminium foil). To 
further compare this new chitosan microparticle formulation with the green magnetic 
powder (control), fingermarks were split into halves after the donor’s deposition on 
glass microscope slides, therefore that one half (right halves) were developed by 
green magnetic powder which consisted of iron (II, III) oxide, and the other half (left 
halves) were developed by CS: TPP particle at 2:1 in buffer AB-12. After 
development, the latent fingermarks are similar, in terms of quality, for chitosan 
particle method and the control green magnetic powder, with good details ridge 
patterns (Figure 4.21). 
 
 
 
Figure 4.21: Comparison of latent fingermarks development on microscope glass slides 
between chitosan particles at CS:TPP of 2:1 in buffer AB-12 (left halves) and green magnetic 
powder as a control (right halves), (a) donor 1, (b) donor 2, (c) donor 3, (d) donor 4 and (e) 
donor 5. 
 
 
The typical characteristics of three level features of fingermarks friction ridge 
developed on glass slides by CS: TPP microparticles using AB-12 at ratio 2:1 under 
low power optical microscope at different magnification are shown in Figure 4.22 - 
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4.26. Importunely, from five donors, first-level feature describes the classification of 
fingerprints pattern such as loops and whorl features are distinguishable; according to 
literature, the general information obtained from the level one features are not 
conclusive (Figure 4.22a - 4.26a). Therefore, it cannot be used for identification. The 
level two features include ridge characteristics and pattern minutiae such as 
bifurcations, ridge ending, hook, short ridge and enclosure (Figure 4.22b - 4.26b). 
Additionally, the level three features are related to the morphology of a ridge such as 
pores, and incipient ridges were identifiable (Figure 4.22c - 4.26c). As a result level 
two and three features become strong identification features and can be used in 
fingerprint matching due to their uniqueness (Ashbaugh, 1999). From Figure 4.22c, 
magnified images of latent fingermarks developed, exhibiting level three details, such 
as pores. With these images captured under magnification, level two details such as 
fingermark endings, ridge bifurcations and enclosures can be seen through the low 
power microscope(Figure 4.22b), and provided high evidential quality which could 
be used by forensic experts. Moreover, the clarity of the images was such that it is 
possible to use the level three details, especially the sweat pores (Figure 4.22c) 
running along the ridge pattern, which have been known to be helpful to the 
identification of partial or damaged fingermarks (Wei et al., 2017). 
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Figure 4.22: Representative examples of the three levels of features on latent fingermarks 
developed on glass slides under low power optical microscope (donor 1) using chitosan 
microparticles at 2:1 in buffer AB-12. Magnification (a) 8x, (b and c) 35x. 
 
 
 
In order to confirm these results, more donors donated their fingermarks for 
enhancement on glass microscope slides in order to observe all three levels. As shown 
in Figure 4.23 to donor 2, there are the details of short ridge, bifurcation and hook 
were observed (level 2 features) Figure 4.23b; incipient ridges were observed (level 3 
features) in Figure 4.23c which cannot be seen with naked eye. 
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Figure 4.23:  Representative examples of the three levels of features on latent fingermarks 
developed on glass slides under low power optical microscope (donor 2) using chitosan 
microparticles at 2:1 in buffer AB-12. Magnification: (a) 8x, (b and c) 35x. 
 
 
 
Moreover, Figure 4.24 from donor 3 showed a bifurcation, and ending and short ridge 
(level 2) Figure 4.24b, and incipient ridges (level 3) Figure 4.24c. 
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Figure 4.24: Representative examples of the three levels of features on latent fingermarks 
developed on glass slides under low power optical microscope (donor 3) using chitosan 
microparticles at 2:1 in buffer AB-12. Magnification: (a) 8x, (b and c) 35x. 
 
 
Additionally, Figure 4.25 from donor 4, showed a bifurcation, a short ridge and an 
enclosure (level 2) Figure 4.25b; incipient ridges (level 3) Figure 4.25c were also 
observed. 
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Figure 4.25: Representative examples of the three levels of features on latent fingermarks 
developed on glass slides under low power optical microscope (donor 4) using chitosan 
microparticles at 2:1 in buffer AB-12. Magnification: (a) 8x, (b and c) 35x. 
 
 
 
Finally, Figure 4.26 from donor 5, shows a bifurcation and an ending (level 2) Figure 
4.26b; pores (level 3) Figure 4.26c were also observed. 
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Figure 4.26:  Representative examples of the three levels of features on latent fingermarks 
developed on glass slides under low power optical microscope (donor 5) using chitosan 
microparticles at 2:1 in buffer AB-12. Magnification: (a) 8x, (b and c) 35x. 
 
 
 Figure 4.27 shows high power microscope images of at CS: TPP particles at 2:1 
using AB-12, applied to the fingermark in Figure 4.9c (donor 1). Aggregates of 
chitosan microparticles can be clearly seen on residues which form the fingerprint 
ridges and produced a grade 4 print. This may due to lipophilic (van der Waals) 
interactions between alkyl groups of chitosan particles and alkyl chains of the lipid 
residues (Chen et al., 2009). This result is similar to previous studies (used gold 
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nanoparticles) with reported increases in quality of developed fingermarks with 
increases in the length of the alkyl groups, with the longer alkyl group chains 
obtaining clearer fingermarks due to increasing lipophilic interactions (Sametband et 
al., 2007, Choi et al., 2007).  
 
 
 
Figure 4.27: (a-c) High power optical microscope magnified images of latent fingermarks 
(donor 1) on glass microscope slide, (a) before development, magnification 4x, (b) after 
development chitosan microparticles at CS: TPP of 2:1 in buffer AB-12, magnification 4x (c) 
a close up view of ridges, magnification 10x shows particles adsorbed on fingermarks ridges 
(Sametband et al., 2007). 
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In order to confirm these results, more donors donated their fingermarks for 
enhancement on glass slides under a high power optical microscope and similar 
results were obtained and produced grade 4 fingermarks (Figure 4.28- 4.31). 
 
 
 
Figure 4.28: High power optical microscope images of latent fingermarks (donor 2) on glass 
slide; (a) development by chitosan microparticles at CS: TPP of 2:1 in buffer AB-12, 
magnification 4x; (b) a close up view of ridges, magnification 10x shows particles adsorbed 
on fingermarks ridges. 
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Figure 4.29: High power optical microscope images of latent fingermarks (donor 3) on glass 
slide; (a) development by chitosan microparticles at CS: TPP of 2:1 in buffer AB-12, 
magnification 4x; (b) a close up view of ridges, magnification 10x shows particles adsorbed 
on fingermarks ridges. 
 
 
 
Figure 4.30: High power optical microscope images of latent fingermarks (donor 4) on glass 
slide; (a) development by chitosan microparticles at CS: TPP of 2:1 in buffer AB-12, 
magnification 4x; (b) a close up view of ridges, magnification 10x shows particles adsorbed 
on fingermarks ridges. 
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Figure 4.31: High power optical microscope images of latent fingermarks (donor 5) on glass 
slide; (a) development by chitosan microparticles at CS: TPP of 2:1 in buffer AB-12, 
magnification 4x; (b) a close up view of ridges, magnification 10x shows particles adsorbed 
on fingermarks ridges. 
 
 
 
On the other hand, fingermarks treated with chitosan microparticles at CS: TPP (1:1) 
using AB-12 showed weaker development and produced grade 1 fingerprints (Figure 
4.32) in comparison to those treaded with chitosan microparticles at CS: TPP (2:1) 
using AB-12 produced grade 4 fingermark (Figures 4.27, 4.29 and 4.31). 
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Figure 4.32: High power optical microscope images of latent fingermarks to donor 1, 3 and 5 
on glass slides, (a) development by chitosan microparticles at CS: TPP of 1:1 in buffer AB-
12, magnification 4x; (b) a close up view of ridges, magnification 10x. 
 
 
The optical microscope is typically an appropriate technique to observe and obtain 
information on latent fingermark development (Moret et al., 2015). However, 
observations with scanning electron microscope can provide further valuable 
information on detailed morphology and particle attachments.  
 
 
4.5.2 Scanning electron microscopy (SEM) 
To further probe the previous results, scanning electron microscopy was used to 
examine the treated latent fingermarks. A previous study (Moret et al., 2015) reported 
that SEM is not suitable to study untreated fingermarks, due to sample processing 
preparations, including coating with a conductive layer of metal and high vacuum (to 
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produce a good-quality image), will lead to inevitable and uncontrollable 
modifications of components. These  processes, either coating and high vacuum, will 
have destructive effects on the fingermark residue such as evaporation of lipids 
(Bright et al., 2013). SEM images, Figure 4.33 and 4.34, show latent fingerprints 
deposited on the glass microscope slides developed with different chitosan 
microparticles from the donor 1. As can be seen in Figure 4.33a and Figure 4.34a 
comparison of SEM images from the ridge area of samples developed with CS: TPP 
at 2:1 using AB-12, and CS: TPP at 2:1 using AB-13, where it is clear that 
significantly more chitosan microparticles are deposited on fingermark ridges using 
CS: TPP at 2:1 prepared with buffer AB-12 (Figure 4.33a). Moreover, the 
microparticles aggregate on the fingermark ridges creating large clusters, probably 
due to hydrophobic and electrostatic interactions between the CS: TPP microparticles 
and the fatty residues of the latent print (Choi et al., 2008). On the other hand, very 
little chitosan microparticles were deposited between the ridges for CS: TPP at 2:1 
using AB-13 (Figure 4.34a). 
 
 
  195 
 
 
 
Figure 4.33: SEM images (donor 1) of fingermark development on a glass microscope slide 
with chitosan microparticles at 2:1 ratio in buffer AB-12; (a) magnification 22x, general 
overview with digital camera (inset). (b-d) Magnification 50x, 100x and 200x respectively.  
Representative particles adhered on ridges. 
 
 
In addition, Figure 4.33 shows a low magnification SEM image of the developed 
fingermark, indicating chitosan microparticles adsorbed on ridges and gave a good 
detail quality. By increasing the magnification, the development ridges of the 
fingermarks became clearer and evidence for interaction of CS: TPP microparticles is 
observed on the surface ridges (Figure 4.33b, c, d). This result could be attributed to 
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the particles 2:1 in AB-12 which have a relatively high surface charges which can be 
attracted to the lipid residue as discussed earlier. In contrast, samples developed with 
CS: TPP at 2:1 using acetate buffer AB-13, displayed very slight or no associated 
particles on the fingermark ridges (Figure 4.34). Moreover, Figure 4.34a is an SEM 
image at low magnification, showing unclear developed of the fingermark. By 
comparison with developed fingermark shown in Figure 4.33a, limited developed 
fingermark ridges. At the same magnifications, Figure 4.34 b, c, d display developed 
fingermark ridges with no great amounts chitosan particles adsorbed. This result could 
be attributed to the particles of CS: TPP ratio 2:1 in AB-13 having a low surface 
charge (lower electrostatic interactions) which could not interact with lipid residues. 
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Figure 4.34: SEM images (donor 1) of fingermark development on glass slide with chitosan 
microparticles at 2:1 ratio in buffer AB-13; (a) magnification 22x, general overview with 
digital camera (inset). (b-d) Magnification 50x, 100x and 200x respectively. 
 
 
 
Additional samples from other donors demonstrated almost the same results (Figures 
4.35 and 4.36) for donor 2; (Figures 4.37 and 4.38) for donor 3, (Figures 4.39and 
4.40) for donor 4, (Figure 4.41 and 4.42) for donor 5. 
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Figure 4.35: SEM images (donor 2) of fingermark development on glass microscope slide 
with chitosan microparticles at 2:1 ratio in buffer AB-12; (a) magnification 22x, general 
overview with digital camera (inset). (b-d) Magnification 50x, 100x and 200x respectively. 
Representative particles adhered on ridges. 
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Figure 4.36: SEM images (donor 2) of fingermark development on glass microscope slide 
with chitosan microparticles at 2:1 ratio in buffer AB-13; (a) magnification 22x, general 
overview with digital camera (inset). (b-d) Magnification 50x, 100x and 200x respectively. 
 
 
 
 
 
 
 
  200 
 
 
 
Figure 4.37: SEM images (donor 3) of fingermark development on glass microscope slide 
with chitosan microparticles at 2:1 ratio in buffer AB-12; (a) magnification 22x, general 
overview with digital camera (inset). (b-d) Magnification 50x, 100x and 200x respectively. 
Representative particles adhered on ridges. 
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Figure 4.38: SEM images (donor 3) of fingermark development on glass microscope slide 
with chitosan microparticles at 2:1 ratio in buffer AB-13; (a) magnification 22x, general 
overview with digital camera (inset). (b-d) Magnification 50x, 100x and 200x respectively. 
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Figure 4.39: SEM images (donor 4) of fingermark development on glass microscope slide 
with chitosan microparticles at 2:1 ratio in buffer AB-12; (a) magnification 22x, general 
overview with digital camera (inset). (b-d) Magnification 50x, 100x and 200x respectively. 
Representative particles adhered on ridges. 
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Figure 4.40: SEM images (donor 4) of fingermark development on glass microscope slide 
with chitosan microparticles at 2:1 ratio in buffer AB-13; (a) magnification 22x, general 
overview with digital camera (inset). (b-d) Magnification 50x, 100x and 200x respectively. 
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Figure 4.41: SEM images (donor 5) of fingermark development on glass microscope slide 
with chitosan microparticles at 2:1 ratio in buffer AB-12; (a) magnification 22x, general 
overview with digital camera (inset). (b-d) Magnification 50x, 100x and 200x respectively. 
Representative particles adhered on ridges. 
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Figure 4.42: SEM images (donor 5) of fingermark development on glass microscope slide 
with chitosan microparticles at 2:1 ratio in buffer AB-13; (a) magnification 22x, general 
overview with digital camera (inset). (b-d) Magnification 50x, 100x and 200x respectively. 
 
 
 
Furthermore, the morphology which has potential to improve interactions to the latent 
fingermarks can effect on quality of development fingermarks with increasing TPP 
has studied. For comparison purposes with high TPP ratio of CS: TPP particles, SEM 
images of developed latent fingermarks on glass microscope slide using CS: TPP ratio 
at 1:6 and 2:1 using buffer AB-12 are shown in Figure 4.43. 
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Figure 4.43: SEM images (donor 1) latent fingerprint developed of CS:TPP microparticles in 
buffer AB-12 on glass slides (Magnification 22x) at ratio (a) 2:1 and (b) 1:6. 
 
 
It is observed that chitosan microparticles are adhere on fingermark ridges using CS: 
TPP ratio at 2:1 prepared using AB-12 (Figure 4.43a). The microparticles bind on the 
fingermark ridges making large clusters, maybe due to hydrophobic and electrostatic 
interactions between the fatty residues of the latent print and the chitosan particles 
(Wydro et al., 2007). In contrast, fewer chitosan microparticles were adheres on 
fingermark ridges for CS: TPP ratio at 1:6 (Figure 4.43b). This result may be 
attributed to the surfaces of chitosan microparticles. The surface morphologies of 
chitosan microparticles were examined using scanning electron microscopy analysis 
(Figure 4.44a). SEM images allow observations on the morphology of particles and is 
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dependent on CS: TPP ratio. The effectiveness with which the microparticle powder 
attract to the ridges depends on surface morphology of the particles; relatively fine 
smooth microparticles probably adhere more easily to fingermark residues than rough 
lager, coarse ones (Wilshire, 1996). Furthermore, the results indicated that the 
microparticles prepared with AB-12 (pH 4.8 and I.S 0.2 M) at the higher CS: TPP 
ratio 2:1 had highly smoother surface (Figure 4.44a) than those of microparticles 
prepared with the lower CS: TPP ratio 1:6 which had a rougher surface (Figure 
4.44b). This result could be attributed to the particles 1:6 have lower surface charge 
(zeta potential is 4.8 ± 0.1 mV), which lead to decreasing electrostatic interactions. 
 
 
 
Figure 4.44: SEM images of the surface of CS: TPP microparticles using buffer AB-12 at 
CS:TPP ratio  of (a) 2:1 and (b) 1:6. The insert of each SEM images display high magnified 
images (the scale bar was 10 µm). 
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Furthermore, as can be seen in Figure 4.45, the rough particles (1:6 ratio, using AB-
12) are poorly adhered on to the developed fingermark ridges, which is in agreement 
with previous study (Wilshire, 1996). Additionally, Figure 4.45 shows that particles 
were attached on some ridges, due to reduced electrostatic interactions; and at 
increased magnification were found to have rough particles surfaces. 
 
 
Figure 4.45: (a) SEM image low magnification (donor 1) of fingermark development by 
CS:TPP particles in buffer AB-12 at ratio 1:6 on glass slide from Figure 4.43b. (b) Increased 
magnification SEM image from the centre of (a). (c, d) Two more increased in magnification. 
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It has been reported in a previous study that the particle size has a large influence on 
the adhesion efficiency to fingermarks and that fine particles adhere better than larger 
ones. Small flake-like particles (around 1 - 10 µm) have also good adhesion to the 
fingermark ridges (Wilshire, 1996). Furthermore, poor fingermark development was 
observed with powder particles which were ~ 50 µm in diameter (James et al., 
1991b). However, another study reported that particle sizes of 45 - 63 µm obtained 
the best result in fingermark development (Theaker et al., 2008). Previous studies 
(Choi et al., 2008, Dilag et al., 2009, Dilag et al., 2013, Choi et al., 2007, Ma et al., 
2011, Becue et al., 2008, Wang et al., 2009) applied different methods to visualise 
fingerprints using nanoparticles (small particle size) and obtained a good results. On 
the other hand, most of these methods applied luminescent techniques, which require 
specialist technical development, and expensive instruments, therefore they are 
inappropriate for immediate use in a crime scene (Theaker et al., 2008). In a present 
study the relative large particle size could be explained as the reason for aggregation 
of chitosan microparticles which may occurred by two processes. The first reason has 
been described in a previous study that the particles were increasing in size after 
centrifugation due to smaller particles adsorbing on to the surface of larger particles 
through partial physical interactions to form agglomerates (Yien et al., 2012). 
Secondly, it has been postulated by (Dilag et al., 2009) that drying particles using the 
freeze drying process could definitely cause the CdS/chitosan particles to become 
aggregated, thus increasing the particle size. However, based on previous results, it 
can be demonstrated that the surface charge of particles is most effective in latent 
fingermark visualisation than particle size. Pharmaceutical sieves could be used as a 
cheap and simple approach to prepare particles of defined sizes for example in the 
range 40-65 µm. 
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4.5.3  Ageing study of latent fingermarks  
Based on previous results which demonstrated that chitosan particles at CS: TPP ratio 
of 2:1 in buffer AB-12 give the best results (clear fingerprint features) in latent 
fingermark development. A further set of experiments were carried out to investigate 
the ageing of latent fingermarks deposited on glass slides. Split fingermarks, which is 
fingermark was deposited and physically divided in two prints at centre line, were 
used due to estimate the inherent variability in fingermarks composition from the 
same donor (intra variability) and also between donors (inter variability). This lead to 
potential comparison half prints with the same quality of material, pressure at time of 
donation and the same chemical components (Sears et al., 2012). In the series of 
experiments, a set of fifteen split fingermarks depletion (5 donors per 3 their fingers 
involved index, middle and ring) were taken. The left halves of fingermarks were left 
to age for 7 days, while the right halves fingermarks were left to age for 14 days. Both 
halves were then developed with chitosan particles as powder CS: TPP at 2:1 in buffer 
AB-12. As can be seen in Figure 4.46, the comparisons of two aged fingermarks (7 
days and 15 days old prints) using split depletion produced a blurred images and very 
weak development. This method has therefore been shown to produce poor quality 
fingermarks development on fingermarks aged for 7 days and 14 days, this is most 
likely due to loss of lipid component residues of the fingermarks. This result is similar 
to previous studies with reported a reduction in the fatty acid (lipid) with the time 
after deposition (Archer et al., 2005, Bright et al., 2013, Weyermann et al., 2011). 
Therefore, the chitosan microparticles were unsuccessful in developing the aged (7 
and 14 days) fingermarks on glass slides, with inadequate ridge definition.  
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Figure 4.46: Split depletion of dusted fingermarks aged on glass slides for 7 days (left halves) 
and 14 days (right halves) using CS:TPP at 2:1 in buffer AB-12, (a) donor 1, (b) donor 2, (c) 
donor 3, (d) donor 4, (e) donor 5; where index finger (left column), middle finger (medium 
column) and ring finger (right column). 
 
 
 
However, when the same method of CS: TPP particles at 2:1 in buffer AB-12 were 
applied to the fingermarks after aged for 1 day on glass slides (left halves of split 
depletion series), the development technique was effective in fingermark 
development, possibly due to the relatively high amount of lipids present in the 
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fingermark residue resulting in clear development (grade 4). Therefore, it can be 
demonstrated that this method is effective on one day aged fingermarks and details 
can be observed with the naked eye. The results were consistent for all donors as per 
all their three fingers (Figure 4.48a, Figure 4.49a and Figure 4.50a) for donor 5; 
(Figure 4.51a, Figure 4.52a and Figure 4.53a) for donor 4; (Figure 4.54a, Figure 
4.55a and Figure 4.56a) for donor 3; (Figure 4.57a, Figure 4.58a and Figure 4.59a) 
for donor 2; (Figure 4.60a, Figure 4.61a and Figure 4.62a) for donor 1. 
 
A previous study reported that the stability (in terms of particle size) of chitosan 
nanoparticles (CS: TPP) after one year storage at 25 °C the size of nanoparticles 
remained similar to those of the freshly prepared samples (Morris et al., 2011). The 
effective of chitosan particles degradation after the development fingermarks ageing 
were examined. All fingermark development for five donors were collected and stored 
together under the same environmental conditions (Moret et al., 2015) Figure 4.47. 
As can be seen Figure 4.47 shows a comparison between two fingerprints (thumbs), 
one which is 24 hours old after developed, that had clear ridge detail across the whole 
mark (Figure 4.47a), and the other was taken two months after development and still 
retains most of the details and ridges (Figure 4.47b). As a result, this method allowed 
the developed marks to be seen by naked eye for long periods of time. Therefore, one 
further advantage of this technique is that they do not quickly fade. This may be due 
to the strong attractive binding between chitosan particles and lipid residues in latent 
fingermarks which leads to chitosan-lipid interactions. This interactions are consistent 
with the findings reported in previous study (Wydro et al., 2007) and concluded that a 
number of possible processes may be contributed to these interactions including (i) 
lipophilic interactions between lipid residues of the latent fingerprint and ends of long 
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carbon chain of chitosan particles, (ii) chitosan microparticles may bind with fatty 
acids through interactions of their ammonium groups with carboxylic groups of fatty 
acids, and possibly (iii) hydrogen bonds between hydroxyl groups of cholesterol and 
chitosan may be formed.  
 
 
 
Figure 4.47: Latent fingermarks deposited on glass slides and developed using chitosan 
microparticle as a powder at CS: TPP (2:1) in buffer AB-12 for five donors. Those pictures 
have been observed and taken: (a) after the 24 h post-development (upper row) and (b) after 
two months post-development (lower row). 
 
 
 
4.5.4  Method limitation (Split fingermarks depletion series) 
There is variability in fingermarks composition from the same donor (intra variability) 
or between donors (inter variability), therefore, split prints were used to reduce the 
possible effect of this variability on interpretation of the results. In addition, split 
depletion series (second approach, section 4.4.2.3.1) was used to assess the sensitivity 
of the method and they were commonly compared with the influence of a 
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development method on the residue depleted fingermark (Almog et al., 2014). For 
confirmation of the earlier observations (Figures 4.8 and 4.9), the results were further 
analysed according to limitation of the methods. CS: TPP particles of 2:1 in buffer 
AB-12 consistently produce more potentially identifiable fingermarks (grade 4) than 
CS: TPP of 1:1 in buffer AB-12 (grade 1) across all surfaces evaluated, this is shown 
in Figures 4.48a - 4.62a. To determine the sensitivity and capability of the third 
technique (chitosan particles as a powder), five donors were asked to deposit a six 
split depletion series on non-porous glass microscope slides, which consisted of 
multiple successive contacts down the glass slides with a right three fingers (index, 
middle and ring). When a sequence of fingermarks is left on glass slides each 
successive fingermark in the depletion could be predicted to contain less sweat 
residue than the previous one (Fairley et al., 2012). This gives an indication of the 
sensitivity of the method and its limitation to continue to develop fingermarks with 
gradually decreasing the amounts of residue, prior to dusting with the CS: TPP 
powders. Comparisons of the two CS: TPP particles ratios involving 2:1 and 1:1 at 
four different formulations including AB-10, AB-11, AB-12 and AB-13 by split 
depletion series shown in Figures 4.48 - 4.62. According to donor’s metabolism they 
will deposit different levels of secretions which will also have different compositions, 
therefore the development of fingermarks will vary from individual to individual. This 
is not controlled but is reflected by the fact that the detection of fingermarks differs 
depending on persons (Becue et al., 2008). The fingermarks development for ratios 
CS: TPP at 2:1 (left halves) and 1:1 (right halves) show that 2:1 is much clearer as 
compared to 1:1 (Figures 4.48 - 4.62). Significant differences in sensitivity were 
observed between the two halves developed by chitosan particles formulations 
including AB-10, AB-11, and AB-12 (Figures 4.48 a, b, c – 4.62 a, b, c). Whereas, 
  215 
 
no differences in sensitivity were observed between the two halves developed by 
chitosan particles by AB-13 which both produced a fingerprint grade of 1 (Figure 
4.48d - 4.62d). In general, CS: TPP ratios at 1:1 were a very poor quality (grade 1) 
with very few clear visible ridge details (right halves) (AB-10, AB-11, AB-12 and 
AB-13). Additionally, chitosan particles using AB-13 (both ratios at 2:1 and 1:1) does 
not give any useful ridge detail. The series of depletion cannot be traced past the first 
depletion level, and it becomes difficult to visualise the fingermarks developed at 
ratios 2:1 and 1:1, as it displays blurred prints whose ridges details cannot be 
recognized (Figure 4.48d - 4.62d). Furthermore, using CS: TPP (2:1) particles in 
buffer AB-10 (grade 2) was not sensitive enough to developed fingermarks past the 
first depletion (Figure 4.48c - 4.62c). When using CS: TPP (2:1) particles in buffer 
AB-11 (grade 3) fingermarks were developed up to the second depletion. On the other 
hand, strong ridges clear seen in the development using CS: TPP particles at 2:1 in 
buffer AB -12 (grade 4), the developed fingermarks also can be traced down to 
greater levels with the series of depletion considered. At the beginning, the 
fingermark development is clear and adequate ridge details were still obtained even 
with the naked eye until third depletion and are identifiable fingermarks (left halves) 
(Figure 4.48a - 4.62a). Other donors produced similar results (clear ridges visible 
print) using CS: TPP particles at 2:1 in buffer AB-12 and development grades of 4 
were obtained. 
However, the reduction in effectiveness, where the features of the fingermark unclear 
and difficult to define were observed by the fourth depletion, due to the decline in the 
amount of residue present along the fingermarks ridges (de la Hunty et al., 2015) 
(Figure 4.48a - 4.62a). These results were consistent with each repetition of the 
experiments for each donor. Therefore, it can be demonstrated that limitation method 
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(sensitivity) for fingerprint visualization for chitosan microparticles prepared as a 
powder using a buffer AB-12 (pH 4.8, IS 0.2M) at CS: TPP of 2:1 (left halves) is third 
depletion level which can observed with the naked eye.  
 
 
 
Figure 4.48: Depletion series (donor 5 index finger), with split halves developed by chitosan 
microparticle CS:TPP ratio at (a) 2:1 (left) vs 1:1 (right) using AB-12; (b) 2:1 (left) vs 1:1 
(right) using AB-11; (c) 2:1 (left) vs 1:1 (right) using AB-10; and (d) 2:1(left) vs 1:1 (right) 
using AB-13. (n=10). 
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Figure 4.49: Depletion series (donor 5 middle finger), with split halves developed by chitosan 
microparticle CS:TPP ratio at (a) 2:1 (left) vs 1:1 (right) using AB-12; (b) 2:1 (left) vs 1:1 
(right) using AB-11; (c) 2:1 (left) vs 1:1 (right) using AB-10; and (d) 2:1(left) vs 1:1 (right) 
using AB-13. (n=10). 
 
 
 
Figure 4.50: Depletion series (donor 5 ring finger), with split halves developed by chitosan 
microparticle CS:TPP ratio at (a) 2:1 (left) vs 1:1 (right) using AB-12; (b) 2:1 (left) vs 1:1 
(right) using AB-11; (c) 2:1 (left) vs 1:1 (right) using AB-10; and (d) 2:1 (left) vs 1:1 (right) 
using AB-13. (n=10). 
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Figure 4.51: Depletion series (donor 4 index finger), with split halves developed by chitosan 
microparticle CS:TPP ratio at (a) 2:1 (left) vs 1:1 (right) using AB-12; (b) 2:1 (left) vs 1:1 
(right) using AB-11; (c) 2:1 (left) vs 1:1 (right) using AB-10; and (d) 2:1 (left) vs 1:1 (right) 
using AB-13. (n=10). 
 
 
 
Figure 4.52: Depletion series (donor 4 middle finger), with split halves developed by chitosan 
microparticle CS:TPP ratio at (a) 2:1 (left) vs 1:1 (right) using AB-12; (b) 2:1 (left) vs 1:1 
(right) using AB-11; (c) 2:1 (left) vs 1:1 (right) using AB-10; and (d) 2:1 (left) vs 1:1 (right) 
using AB-13. (n=10). 
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Figure 4.53: Depletion series (donor 4 ring finger), with split halves developed by chitosan 
microparticle CS:TPP ratio at (a) 2:1 (left) vs 1:1 (right) using AB-12; (b) 2:1 (left) vs 1:1 
(right) using AB-11; (c) 2:1 (left) vs 1:1 (right) using AB-10; and (d) 2:1 (left) vs 1:1 (right) 
using AB-13. (n=10). 
 
 
 
Figure 4.54: Depletion series (donor 3 index finger), with split halves developed by chitosan 
microparticle CS:TPP ratio at (a) 2:1 (left) vs 1:1 (right) using AB-12; (b) 2:1 (left) vs 1:1 
(right) using AB-11; (c) 2:1 (left) vs 1:1 (right) using AB-10; and (d) 2:1 (left) vs 1:1 (right) 
using AB-13. (n=10). 
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Figure 4.55: Depletion series (donor 3 middle finger), with split halves developed by chitosan 
microparticle CS:TPP ratio at (a) 2:1 (left) vs 1:1 (right) using AB-12; (b) 2:1 (left) vs 1:1 
(right) using AB-11; (c) 2:1 (left) vs 1:1 (right) using AB-10; and (d) 2:1 (left) vs 1:1 (right) 
using AB-13. (n=10). 
 
 
 
Figure 4.56: Depletion series (donor 3 ring finger), with split halves developed by chitosan 
microparticle CS:TPP ratio at (a) 2:1 (left) vs 1:1 (right) using AB-12; (b) 2:1 (left) vs 1:1 
(right) using AB-11; (c) 2:1 (left) vs 1:1 (right) using AB-10; and (d) 2:1 (left) vs 1:1 (right) 
using AB-13. (n=10). 
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Figure 4.57: Depletion series (donor 2 Index finger), with split halves developed by chitosan 
microparticle CS:TPP ratio at (a) 2:1 (left) vs 1:1 (right) using AB-12; (b) 2:1 (left) vs 1:1 
(right) using AB-11; (c) 2:1 (left) vs 1:1 (right) using AB-10; and (d) 2:1(left) vs 1:1 (right) 
using AB-13. (n=10). 
 
 
 
Figure 4.58: Depletion series (donor 2 Middle finger), with split halves developed by 
chitosan microparticle CS:TPP ratio at (a) 2:1 (left) vs 1:1 (right) using AB-12; (b) 2:1 (left) 
vs 1:1 (right) using AB-11; (c) 2:1 (left) vs 1:1 (right) using AB-10; and (d) 2:1 (left) vs 1:1 
(right) using AB-13. (n=10). 
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Figure 4.59: Depletion series (donor 2 ring finger), with split halves developed by chitosan 
microparticle CS:TPP ratio at (a) 2:1 (left) vs 1:1 (right) using AB-12; (b) 2:1 (left) vs 1:1 
(right) using AB-11; (c) 2:1 (left) vs 1:1 (right) using AB-10; and (d) 2:1 (left) vs 1:1 (right) 
using AB-13. (n=10). 
 
 
 
Figure 4.60: Depletion series (donor 1 index finger), with split halves developed by chitosan 
microparticle CS:TPP ratio at (a) 2:1 (left) vs 1:1 (right) using AB-12; (b) 2:1 (left) vs 1:1 
(right) using AB-11; (c) 2:1 (left) vs 1:1 (right) using AB-10; and (d) 2:1(left) vs 1:1 (right) 
using AB-13. (n=10). 
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Figure 4.61: Depletion series (donor 1 middle finger), with split halves developed by chitosan 
microparticle CS:TPP ratio at (a) 2:1 (left) vs 1:1 (right) using AB-12; (b) 2:1 (left) vs 1:1 
(right) using AB-11; (c) 2:1 (left) vs 1:1 (right) using AB-10; and (d) 2:1(left) vs 1:1 (right) 
using AB-13. (n=10). 
 
 
 
Figure 4.62: Depletion series (donor 1 ring finger), with split halves developed by chitosan 
microparticle CS:TPP ratio at (a) 2:1 (left) vs 1:1 (right) using AB-12; (b) 2:1 (left) vs 1:1 
(right) using AB-11; (c) 2:1 (left) vs 1:1 (right) using AB-10; and (d) 2:1 (left) vs 1:1 (right) 
using AB-13. (n=10). 
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4.6 Summary 
In this study chitosan microparticles were successfully obtained from the ionotropic 
gelation method using different processing conditions. This method gives us the 
ability to design tuneable CS: TPP microparticles for specific forensic applications. It 
is proposed the CS: TPP particles deposit onto fingerprints due to the lipophilic and 
electrostatic interaction with the fatty components in fingerprint ridges. Latent 
fingerprints were developed using chitosan microparticles as a powder (third 
technique) on glass microscope slides obtained variable degrees of success depending 
on how the microparticles were prepared. A clear relationship between size and 
charge on the microparticles and the fingerprint quality was found. In the present 
study it was demonstrated that CS: TPP ratio has the strongest effect on quality 
fingerprint. Microparticles were obtained (pH 4.8, CS: TPP of 2:1 and 0.2 M of ionic 
strength using AB-12) with average diameter of 171.3 µm and a zeta potential of 
+14.3 mV which may have good potential for applications in fingerprint development 
on non-porous surfaces (glass slides). The effectiveness of an enhancement method 
was evaluated and limitation to detecting fingerprints (sensitivity) by this method 
which is third depletion level for one day aged. The advantages of using chitosan 
microparticles as a powder technique are that they are non-toxic (Aramwit et al., 
2015) sustainable (Yan and Chen, 2015), underutilised (it is the second most abundant 
polymer on the planet (Matlack, 2010) and therefore poses less potential health and 
environmental hazards, quick, easy to apply and able to produce good quality 
fingerprints under the conditions studied. As well as the developed marks can be 
easily visualised and remain visible for a long period of time (2 months) there is 
therefore no requirement that the fingerprints need to be photographed immediately. 
Furthermore, this method of visualisation is non-destructive and therefore avoiding 
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potential degradation of the physical evidence and unlike some other recent 
developments in fingerprint visualisation this method is not dependent on prior 
knowledge of any materials handled by the subject/suspect. Disadvantage of this 
method is that it is not effective on aged fingermarks. To our knowledge this is the 
first time that particle size, shape, viscosity and zeta potential have been used as a 
way of predicting latent fingerprint quality.  
  226 
 
 
 
 
 
 
Chapter 5 
 
Formulation, characterization and in 
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5 Formulation, characterization and in vitro evaluation of ibuprofen loaded 
chitosan-TPP nanoparticles as a model pharmaceutical application 
 
5.1 Introduction 
 
Chitosan, has been widely investigated in drug delivery systems for pharmaceutical 
applications (Qandil et al., 2009). Furthermore, low molecular weight (LMW) drugs 
can be incorporated into chitosan nanoparticles which can be used to control the 
release of drugs. Nanoparticles are sub-micron particles with size less than 1000 nm, 
and with several morphologies, such as nanocapsules, nanospheres, nanoliposomes, 
and nanodrugs. Nanoparticles have been widely applied in drug delivery systems to 
deliver drugs or biomolecules (Liu et al., 2008b). Among the numerous methods 
developed for preparation of nanoparticles, the ionic gelation method is simple to 
process and can also be used to optimize the required particle sizes such that any 
encapsulated drug can penetrate the epithelial membrane (Nanda et al., 2012). 
Particles sizes for example in the range of 10-500 nm are believed to be acceptable for 
intravenous injection (Koo et al., 2011). This is because these particles can spend 
longer in circulation and can also be retained longer in the body and may deposit in 
tumor tissue through active targeting or by the improved permeation and retention 
effect (Danhier et al., 2010, Jonassen et al., 2012). However, It has been observed that 
the number of microspheres which can cross the epithelium is lesser than the number 
of nanoparticles (McClean et al., 1998) and a range of 10-200 nm is more suitable as 
it is more efficient in penetrating different biological membranes such as the mucosal 
membrane (Krasnici et al., 2003, Mitra et al., 2001, Masarudin et al., 2015). 
Therefore, all things being considered, there are not any major issues associated to the 
presence of nanoparticles in the general circulation. In this study, LMW chitosan was 
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used because of the fact that an increase in molecular weight increases the particle 
size, as the solubility of higher molecular weight chitosan is lower, and consequently, 
an increase in particle diameter or even aggregates may be obtained (Wu et al., 2005). 
In addition, high molecular weight (HMW) chitosan has slow dissociation and release 
of drug. To overcome these problems of HMW chitosan, several studies have been 
conducted by using LMW chitosan (Choi et al., 2016). Furthermore, LMW chitosan 
and its concentration should be within range of 1.0 – 3.0 mg/mL and for 1 mg/mL of 
TPP cross linker to form nanoparticles of the CS: TPP (see Chapter 3, section 3.6) 
(Wu et al., 2005, Xu and Du, 2003). Moreover, LMW chitosan concentration should 
increase drug encapsulation (Li and Huang, 2012). Therefore, a chitosan 
concentration of 3 mg/mL was used in this study. Considering the possible 
pharmaceutical applications of ibuprofen loaded nanoparticles in drug delivery 
systems, small particles, relatively high drug entrapment efficiency of nanoparticles 
and continuous drug release should be taken into consideration. Ibuprofen, (RS)2-
methyl-4-(2-methylpropyl) phenyl propanoic acid, is an effective non-steroidal anti-
inflammatory drug (NSAID) (Ganesh and Lee, 2013) used for relief from headaches, 
dental pain, menstrual cramps, muscle aches, fever, symptoms of rheumatoid arthritis 
and osteoarthritis.. Ibuprofen is usually completely excreted after less than 24 hours 
and its biological half-life is 2 hours (Ganesh and Lee, 2013, Abioye et al., 2016) and 
is a biopharmaceutical classification system (BCS) class II drug (Al-Hamidi et al., 
2015). Moreover, ibuprofen is absorbed at greater than 95 % in the plasma of the 
human body and may be completely bound to plasma proteins (Najafabadi et al., 
2014, Abioye and Kola-Mustapha, 2015). However, ibuprofen has a free carboxylic 
acid group (COOH) in the chemical formula which leads to side effects in the 
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gastrointestinal (GI) tract such mild dyspepsia and gastric bleeding, therefore its use is 
often limited (Depan et al., 2009, Kamari and Ghiaci, 2016) (Figure 5.1).  
 
. 
 
 
Figure 5.1: Ibuprofen dissociation 
 
 
Hydrophobic ibuprofen is a weakly acidic drug; therefore it can be easily dissolved at 
alkaline solution pH > 7.0. Whereas, it is almost insoluble in water (49 μg/mL at 25 
°C) with a pKa of 4.5 and it has a low solubility in acidic solution at pH 1.2 (53 
μg/mL at 25 °C) (Lin et al., 2005, Abioye and Kola-Mustapha, 2015). Ibuprofen is 
generally marketed as tablets such as NurofenTM and as liquid formulations such as 
CalprofenTM with different potencies. The main advantage of a chitosan-TPP 
formulation is that the ibuprofen in the chitosan particles remains unaltered 
chemically and is the same as the native ibuprofen, after being released (Win et al., 
2005). In this study ibuprofen is used as a model drug to prepare drug loaded chitosan 
nanoparticles using two different ionotropic gelation methods (see section 5.2.5.1 and 
5.2.5.2 which differ in the order mixing) to investigate the drug entrapment efficiency 
(DEE) of chitosan nanoparticles. The factors that influence the formulation of 
nanoparticles including CS: TPP ratios and different concentrations of ibuprofen on 
DEE of the chitosan nanoparticles were investigated. The obtained ibuprofen-loaded 
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chitosan-TPP nanoparticles were characterized in terms of particle size determination, 
zeta potential, and ibuprofen loading to determine the optimum ratio to be used in 
drug release. Finally, in vitro drug release profile of drug-loaded chitosan 
nanoparticles were studied during incubation in phosphate buffer saline (PBS).  
 
5.2 Methods and materials 
5.2.1 Chemicals   
Chitosan of low molecular weight (LMW ∼ 50,000 g/mol as determined by viscosity 
using equations 5.1-5.4 (see section 5.2.2.1) was purchased from Sigma–Aldrich 
(Gillingham, UK) and was reported to have an average degree of deacetylation (DD) 
of ∼90 % as determined by FT-IR using the equation 5.5 (see section 5.2.2.2). Glacial 
acetic acid and TPP sodium salt was also obtained from Sigma–Aldrich (Gillingham, 
UK). Ibuprofen powder (Ibuprofen 38) was obtained from BASF (Germany), 
phosphate buffer saline (PBS) pH 7.4 was obtained from Fisher Scientific 
(Loughborough, UK). Dialysis tubing cellulose membrane (molecular weight cut off 
14,000 g/mol) was purchased from Sigma–Aldrich. All materials were used without 
any further purification.     
 
5.2.2 Sample preparation   
5.2.2.1 Viscosity analysis of chitosan 
The relative viscosity (ηrel) of chitosan solution was tested at 37.0 ± 0.1°C by a Bohlin 
Gemini HR Nano Rheometer (Malvern Instruments, Worcestershire, UK) using 1 mm 
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gap and 55 mm parallel plate geometry at a constant shear rate of 500 s−1 under 
precise temperature control, according to the following equation: 
 







0

rel
                                                                                        Eq. (5.1) 
 
where η is the average viscosity of the sample and, ηo is the viscosity for the reference 
solvent i.e. dilute acetic acid. All measurements were performed in triplicate. The 
specific (ηsp), viscosity is defined as follows:  
 
1 relsp                                                                                            Eq. (5.2) 
 
A useful method for measuring the intrinsic viscosity is to calculate the relative and 
specific viscosities at one concentration and utilise the Solomon-Ciutâ approximation 
(Solomon and Ciutǎ, 1962, Harding, 1997). The intrinsic viscosity can then be 
accurately estimated (error generally ~1 %) by a single measurement at low 
concentration approximately ≤ 0.5 %.  
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                                                                   Eq. (5.3) 
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The intrinsic viscosities can then be converted to molar mass using the following 
Mark–Houwink–Kuhn–Sakurada (MHKS) power law relationship (Morris et al., 
2009): 
 
                                                                                 Eq. (5.4) 
 
 
5.2.2.2 Fourier transform infrared (FTIR) 
Spectroscopy FTIR spectra of chitosan, ibuprofen, CS: TPP nanoparticle (blank) and 
CS-IBU-TPP nanoparticle samples were recorded using a Fourier transform infrared 
spectrophotometer (Thermo Nicolet 380 FT-IR spectrometer, Thermo Electron 
Corporation), operating from 4000 to 500 cm-1. FTIR spectra depend on the 
interaction of electromagnetic radiation with sample and it is a surface sensitive 
technique. The ATR (Attenuated total reflectance) crystal was cleaned with isopropyl 
alcohol. A background check was performed prior to obtaining sample spectra. 
Powdered samples were placed on the crystal using micro-spatula and force was 
applied by twisting top of the arm of sample stage. The test sample spectra were 
collected. The degree of deacetylation (DD) was calculated from equation 5.5 
(Czechowska-Biskup et al., 2012). 
 
       Eq. (5.5) 
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where A1655 cm
-1
 and A3450 cm
-1
 are the absorbances of the C=O and OH stretches of 
chitosan respectively. Each sample was run in triplicate. 
 
 
5.2.2.3 Preparation of chitosan and TPP samples 
1 mg/mL solution of TPP was prepared by weighing out 250 mg of TPP and making 
up to 250 mL using deionized water. However, the pH of this solution was controlled 
by adding 0.1 N hydrochloric acid (HCl) until a final pH of 5.0 was obtained. 3.0 
mg/mL solution of chitosan was prepared by weighing out 750 mg of chitosan then 
added to glacial acetic acid solution (0.5 %) and this was left stirring overnight at 
room temperature. The solution was then filtered under Gooch crucible (AG 1 X 3) 
vacuum filtration to discard any undissolved chitosan then pH was adjusted to 5.0 
using 0.1 N sodium hydroxide (NaOH). 
 
5.2.2.4 Preparation of ibuprofen samples 
Five different concentrations of ibuprofen solutions 0.5, 1.0, 1.5, 2.0 and 2.5 mg/mL 
were prepared using phosphate buffer saline PBS pH 7.4 (sodium chloride 137 mM, 
potassium chloride 2.7 mM, disodium hydrogen phosphate 10 mM and potassium 
dihydrogen phosphate 2.0 mM). 
 
5.2.3 Ibuprofen assay 
The amounts of ibuprofen entrapped in the chitosan nanoparticles as well as the 
amounts of ibuprofen released from the chitosan nanoparticles were determined by 
UV-Vis spectrophotometer (Shimadzu UV-160A, Wolverton, UK). 
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5.2.3.1 Wavelength of maximum absorbance 
The UV absorption spectra of ibuprofen (1.5 mg/mL) in phosphate buffered saline 
PBS (pH 7.4) was obtained by scanning a wide range of wavelengths (200 – 300 nm) 
in optically homogeneous quartz cuvettes. The wavelength of maximum absorbance 
(peak value) was recorded for ibuprofen and used in all analytical determinations of 
ibuprofen in this study. 
 
5.2.3.2 Standard curve 
A stock solution of ibuprofen was prepared by weighing 80 mg accurately and 
dissolving it in 100 mL phosphate buffer saline (PBS) pH 7.4 produce a 0.80 mg/mL 
solution. This stock solution was further diluted to produce a series of ibuprofen 
solutions containing 0.5, 0.4, 0.3, 0.2, 0.15, 0.12, 0.09, 0.07, 0.05, 0.02 and 0.01 
mg/mL ibuprofen, respectively. The phosphate buffer saline used as a reference 
solution (or blank). The measured absorbance of each solution was plotted as a 
function of the concentration of each solution to produce a standard curve. Linear 
regression analysis was performed on this curve using Microsoft Excel® 2013 
(Microsoft Corporation, Redmond, USA). 
 
5.2.3.3 Validation of Analytical Method 
UV-Visible spectrophotometric method for dissolution studies was validated. 
Validation of dissolution method was done in terms of curve linearity, precision, 
accuracy, limit of detection and limit of quantification. 
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5.2.3.4 UV light absorbance by chitosan and TPP 
To determine if there is any interference caused by chitosan and TPP molecules 
during the spectroscopic analysis of ibuprofen, the UV absorbance profiles of chitosan 
and TPP used in this study were measured. This was done by scanning solutions of 
the chitosan and TPP over a range of wavelengths ranging from 200 nm to 300 nm. 
 
5.2.4 Preparation of blank chitosan-TPP nanoparticles 
CS: TPP nanoparticles were produced by the drop wise addition of an appropriate 
volumes of chitosan solution to appropriate volumes of TPP solutions under magnetic 
stirring at 600 rpm for 60 min, making CS: TPP ratios be 3:1, 4:1, 5:1, 6:1 and 7:1 
respectively (Appendix B). All operations above were conducted at room temperature 
and were sonicated for 5 min (the cycle and amplitude was adjusted to 0.5 and 80 % 
respectively; Hielscher Ultrasonics GmbH, Teltow, Germany) before being subjected 
to further analysis. 
 
In acidic medium there are two forces between chitosan molecules. First is 
electrostatic repulsion due to the ammonium groups of chitosan; second is inter-chain 
hydrogen bonding interactions between chitosan molecules. The CS: TPP ratio is an 
important parameter in effecting the zeta potential and particle size of chitosan 
nanoparticles. If the amount of TPP is small it is unable to a cross-link of chitosan 
chains. Whereas, when the available quantity of TPP is high, this leads to more 
chitosan chains being cross-linked, as a result, particles aggregate then precipitate 
(Fan et al., 2012). It has reported that to obtain a smaller size and higher zeta potential 
(> ±30 mV) of chitosan nanoparticles, the chitosan to TPP ratio is from 3:1 to 7:1 
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(Chapter 3, section 3.6) (Gan et al., 2005, Hu et al., 2008, Gokce et al., 2014). 
Therefore, these ratios have chosen. 
 
5.2.5 Preparation of drug loading/incorporation into chitosan nanoparticles 
(CS-IBU-TPP) 
The ibuprofen loading in chitosan nanoparticle system can be done by two methods as 
described in the sections 5.2.5.1 and 5.2.5.2 depending on whether the ibuprofen is 
first added to the chitosan or to the TPP. It is proposed that ibuprofen will be 
entrapped into the chitosan matrix during the ionotropic gelation process making 
chitosan to TPP ratios of 3:1, 4:1, 5:1, 6:1 and 7:1. For both methods, ibuprofen 
solution was prepared by dissolving 1.5 mg/mL of ibuprofen in PBS (pH 7.4). 
 
5.2.5.1 Internal entrapment of ibuprofen into chitosan matrix 
(ibuprofen first mixed with chitosan), referred to as 
(IBU+CS)/TPP 
Ibuprofen-chitosan nanoparticles can be formed according to Figure 5.2, by adding 
10.1 mL of ibuprofen to 50 mL of chitosan solution and magnetically stirred for 30 
min. Then a 30 mL aqueous solution of TPP has been added drop-wise to the 
chitosan-ibuprofen mixture while stirring with magnetic stirrer for 60 minutes at 600 
rpm. The cross-linked chitosan nanoparticles were then isolated by ultra-
centrifugation at 40,000 x g (Beckman Coulter Optima L-100K, 50Ti rotor) for 60 
min, followed by freeze drying for 24 hours (Alpha 1- 4 LD2 freeze drier, Germany). 
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Figure 5.2: First method an internal entrapment of ibuprofen into chitosan nanoparticles, 
ibuprofen first mixed with chitosan: (IBU+CS)/TPP. 
 
 
5.2.5.2 Internal entrapment of ibuprofen into chitosan matrix 
(ibuprofen first mixed with TPP), referred to as 
CS/(TPP+IBU) 
For the association of ibuprofen with CS: TPP nanoparticles, 10.1 mL of ibuprofen 
solution (1.5 mg/mL) was premixed with 30 mL of TPP solution before adding drop-
wise into the chitosan solution (50 mL) under magnetically stirred for 60 min at 600 
rpm as shown below in Figure 5.3. The cross-linked chitosan nanoparticles were then 
separated by ultra-centrifugation at 40,000 x g (Beckman Coulter Optima L-100K, 
50Ti rotor) for 60 min, followed by freeze drying for 24 hours (Alpha 1- 4 LD2 freeze 
drier, Germany). 
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Figure 5.3: Second method an internal entrapment of ibuprofen into chitosan nanoparticles, 
ibuprofen first mixed with TPP: CS/(TPP+IBU). 
 
 
5.2.6 Effects of CS: TPP ratio on CS-IBU-TPP nanoparticles 
A 10.1 mL of ibuprofen (1.5 mg/mL) were mixed with 30 mL of TPP and stirred for 
30 min. Then CS-IBU-TPP nanoparticles were formed by the drop-wise addition of a 
suitable volume of chitosan solution at selected chitosan to TPP ratios of 3:1, 4:1, 5:1, 
6:1 and 7:1 respectively. The nanoparticle suspensions were gently stirred for 60 min 
at room temperature and were then sonicated for 5 min before being subjected to 
further analysis and applications (Appendix C). The CS-IBU-TPP nanoparticles 
collected by ultra-centrifugation at 40,000 x g (Beckman Coulter Optima L-100K, 
50Ti rotor) for 60 min, followed by freeze drying for 24 hours (Alpha 1- 4 LD2 freeze 
drier, Germany). 
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5.2.7 Effects of ibuprofen concentration on CS-IBU-TPP nanoparticle 
A 30 mL of TPP solution was mixed with different concentrations of ibuprofen 
solutions including 0.5, 1.0, 1.5, 2.0, and 2.5 mg/mL and stirred for 30 min. Then CS-
IBU-TPP nanoparticles with the CS: TPP ratio 5:1 were produced by the drop-wise 
addition of 50 mL chitosan solution under constant stirring (600 rpm for 60 min) and 
were then sonicated for 5 min. The CS-IBU-TPP nanoparticles collected by ultra-
centrifugation at 40,000 x g (Beckman Coulter Optima L-100K, 50Ti rotor) for 60 
min, followed by freeze drying for 24 hours (Alpha 1- 4 LD2 freeze drier, Germany). 
 
5.2.8 Characterization of chitosan nanoparticles 
Measurement of the mean particle diameter (z-average), polydispersity (size 
distribution) and zeta potential of CS: TPP and CS-IBU-TPP nanoparticles in the 
suspension were performed using Malvern Zetasizer NANO-Z (Malvern Instruments 
Limited, Malvern, UK) on the basis of DLS techniques. The dispersion medium 
(water) and refractive index of particles was set at 1.330 and 1.6 respectively. An 
angle scattering of 173° was utilized. To determine particle size a glass cuvette was 
used. Approximately 1.0 mL of sample was pipetted into the cuvette and three 
readings were taken. An average of these readings was then recorded. Zeta potential 
of samples was measured using the same instrument used to determine particle size. 
Measurements were performed using a folded capillary zeta cell.  To determine the 
zeta potential approximately 1.0 mL of sample was pipetted into a folded capillary 
cell by using a syringe and measurements were performed at 25 ± 0.1 °C in triplicate 
to obtain data value an average of 3 measurements. 
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5.2.9 Drug entrapment efficiency (DEE) of ibuprofen in CS-IBU-TPP 
nanoparticles 
Drug entrapment efficiency (DEE) indicates the efficiency of the preparation method 
to incorporate the drug into the carrier system as it expresses the amount of the drug 
entrapped within the nanoparticle compared to the initial drug loading. Where 100% 
DEE means that the entire drug quantity added, has been incorporated into the 
nanoparticle (Gomathi et al., 2017). DEE depends on the physicochemical properties 
and the interactions between the drug, carrier and the surrounding medium. After 
nanoparticle formation, as described in section 5.2.5, the DEE can be determined from 
the supernatant. In order to determine DEE of nanoparticles, CS-IBU-TPP 
nanoparticles were isolated from solution ultra-centrifugation at 40,000 x g (Beckman 
Coulter Optima L-100K, 50Ti rotor) for 60 min, at 25 °C. Based on the absorbance of 
the samples determined using the UV spectrophotometer the ibuprofen concentration 
in the supernatant can be determined. A standard curve (concentration vs. UV 
absorbance) was prepared according to section 5.2.3.2. Drug entrapment efficiency 
were calculated according to the following equations (Adebisi and Conway, 2014): 
 
.1) 
 
 
 
 
 
Drug entrapment efficiency describes the quantity of the ibuprofen entrapped within 
the chitosan nanoparticle as it is related to the initial drug loading.  
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5.2.10 In vitro release of ibuprofen from CS-IBU-TPP nanoparticles 
In vitro ibuprofen release profiles from chitosan nanoparticles were implemented over 
time in release media (PBS pH 7.4) (Figure 5.4). After ultra-centrifugation, the 
supernatant was discarded from the ibuprofen-loaded chitosan nanoparticles. The in 
vitro release studies were conducted using dialysis tubing to contain the ibuprofen–
loaded chitosan nanoparticles in order to minimize the effect that nanoparticles and 
other large molecules could have on the spectrophotometric absorbance of the 
samples. Drug release from chitosan nanoparticles formulations was carried out in pH 
7.4 phosphate buffered saline PBS. The dialysis tubing was first soaked for 10 
minutes in deionized water. 500 mg of ibuprofen-loaded nanoparticle formulations 
were placed into the dialysis tubing. Then were immersed in 200 mL media at 37 ± 1 
°C under 20 dips per minute (DPM) using the USP XXII apparatus 3 (BIO-DIS 
Dissolution Test Station, Vankel Industries, Chatham, US). To maintain the original 
volume, 5 ml sample media were withdrawn at predetermined time intervals and 
replaced with fresh, warm dissolution media of equal volume. The quantity of 
ibuprofen in the release media was assessed by absorption using UV-
spectrophotometric examination at λmax 263.9 nm. From the equation fitted to the 
standard curve (section 5.2.3.2) the amount of free ibuprofen in the release media was 
calculated. The in vitro release studies were performed in triplicate for each of the 
samples. 
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Figure 5.4: Method summary for drug release experiment. 
 
 
 
5.2.11 Statistical analysis 
All experiments were expressed as the mean value ± standard deviations (SD) of at 
least three readings. Statistical significance (p value less than 0.05) between test 
groups was performed by one-way analysis of variance (ANOVA) or Tukey post-hoc 
test using Primer of Biostatistics version. 
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5.3 Results and discussion  
5.3.1 Ibuprofen assay 
5.3.1.1 Wavelength of maximum absorbance 
Ibuprofen (1.5 mg/mL) was dissolved in phosphate buffer saline PBS (pH 7.4), above 
its pKa 4.5 to produce a highly soluble carboxylate species. Figures 5.5 shows the 
UV absorption spectra of chitosan and ibuprofen solution. These solutions were 
scanned over a wavelength range of 200 – 300 nm. The absorbance (Abs) was 
expressed as a function of wavelength and this graph was used to determine the 
wavelength of maximum absorbance (peak values). 
 
  
 
Figure 5.5: UV- absorption spectrum of chitosan (red) and ibuprofen (green). 
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As can be seen in Finger 5.5 there is interference between chitosan and ibuprofen 
over a wavelength range from 200 nm to 240 nm. Therefore, the solutions were 
scanned over other a wavelength range of 240 – 300 nm (Figure 5.6). 
 
 
Figure 5.6: UV- absorption spectrum of ibuprofen in PBS (pH 7.4); the maximum absorbance 
wavelength (λmax) of ibuprofen in PBS was found to be value at 263.9 nm. 
 
 
5.3.1.2 UV light absorbance by chitosan and TPP 
This was done to determine if any interference caused by chitosan and TPP molecules 
during the spectroscopic analysis of ibuprofen, the UV absorbance profiles of chitosan 
and TPP used in this study were determined by scanning a solution of each compound 
over a wavelength range from 240 nm to 300 nm.  
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Figure 5.7: UV- absorbance scan for chitosan. 
 
 
The UV scan of 3.0 mg/mL chitosan solution in diluted acetic acid and 1.0 mg/ml 
TPP in deionised water showed no absorbance at wavelengths ranging from 240 nm 
to 300 nm. It is clear from Figures 5.7 and 5.8 that chitosan and TPP would not 
significantly interfere with the absorbance of ibuprofen at a wavelength of 263.9 nm 
which is in agreement with the previous studies (Zhao et al., 2014, Lu et al., 2005, Liu 
et al., 2014, Ji et al., 2011, Ganesh and Lee, 2013).  
 
 
Figure 5.8: UV- absorbance scan for TPP 
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5.3.1.3 Standard curve and validation for ibuprofen 
The method linearity can be determined by evaluation of the calibration curve. The 
linearly for the ibuprofen assay was determined by performing a linear regression 
analysis of the absorbance against ibuprofen concentration plot (standard curve). The 
standard curve was acquired setting the UV wavelength to 263.9 nm. The correlation 
coefficient (R2) with a value of 0.9999 indicates a good regression within the given 
range of 0.01 to 0.8 mg/mL concentrations, which will be analysed in this study 
(Figure 5.9). The data of standard curve is best described by a linear equation:  
 
y = 1.6893 x + 0.0053                                                                                   Eq. (5.3) 
 
Therefore, this equation was used to calculate the concentration of ibuprofen in the 
samples drawn from the dissolution experiments and drug entrapment efficiency 
experiments. 
 
 
Figure 5.9: Mean calibration curve for ibuprofen preparation in PBS (pH 7.4). Values 
represent mean ± SD (n=3). 
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In this study, besides method linearity there are other parameters including precision, 
accuracy, limit of detection and limit of quantification which were carried out for 
analytical method validation. Precision is defined as the closeness of replicate 
measurements on a single sample. Precision may be considered at two levels: 
repeatability and reproducibility. Repeatability consists of multiple replicates of the 
analysis of samples on the same day and with the same instruments by one analyst, on 
the other hand reproducibility is assessed by different conditions, such as different 
days, different instruments, different analyst and a different laboratory. Precision is 
determined by using the process to examine a sample for an adequate number of times 
to gain statistically valid results, and this is done by analysing samples of each 
concentration between 3 and 5 times.  Moreover, to determine the precision, the 
mean, standard deviation and relative standard deviation (RSD) are calculated for 
replicate measurements.  
 
The relative standard deviation is: 
 
(% RSD) = (SD / Mean) x 100%                                                               Eq. (5.4) 
  
The method precision for this study was determined by reproducibility (inter-day). It 
was evaluated by triplicate measurements at three concentration levels (low, medium 
and high) on different three days. The precision was calculated from the percentage of 
relative standard deviation (% RSD). For precision the RSD for all samples were 
within the satisfactory range (RSD < 1 %). Accuracy is defined according to how far 
or close a measured experimental value is to the true value. Accuracy shows the 
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deviation between the mean value found and the true value. Therefore, the accuracy 
of the test results is calculated as a percentage of the analyte recovered by the assay. 
Like precision, for all samples, it was found that the RSD < 1 % which is accepted as 
a satisfactory value for RSD. 
Limit of detection (LOD) and limit of quantification (LOQ) are, also, important 
parameters. LOD is defined as the minimal concentration of sample of interest which 
can be detected from the background noise with a certain degree of confidence. LOQ 
is the lowest concentration of an analyte which can provide a quantitative result 
within specified limits of accuracy and precision. The LOQ and LOD have been 
determined from calibration curve data. The LOD and LOQ were calculated by 
statistical methods using standard error (SE) for intensity and concentration and the 
slope of the calibration curve for caffeine. The LOD value was predicted by using the 
formula [3.3 x SE /Slope]. Meanwhile, the LOQ was predicted by using the formula 
[10 x SE /Slope] (Bushra et al., 2014). The UV method validation for the ibuprofen 
assay presented in Table 5.1.  
 
Table 5.1: UV-Spectrophotometric method validation for ibuprofen assay 
Wavelength λ = 263.9 nm 
Slope 1.6893 
Intercept 0.0053 
Correlation coefficient (R2) 0.9999 
Precision and accuracy RDS < 1 % 
LOD 8 µg/mL 
LOQ 24 µg/mL 
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5.3.1.3.1 Nanoparticle formation observations 
Chitosan was dissolved in glacial acetic acid at pH 5, below its pKa 6.3, to produce a 
reactive positively charged ammonium group (NH3
+) (protonated amine D-
glucosamine monomeric unit). Due the different pKa values 0.9, 1.9, 5.3, 7.7 and 9.5 
(Pati et al., 2011, Bhumkar and Pokharkar, 2006), multiple anions (P3O10
5−, HP3O10
4−, 
H2P3O10
3−, H3P3O10
2− and H4P3O10
−) may be present in solution depending on the pH 
when TPP is dissolved in water, which is undesirable as they can competitively react 
with the protonated ammonium groups (NH3
+) of chitosan solution (pH 5.0). 
Therefore, the pH of TPP was adjusted to 5.0 to make sure that predominantly 
H2P3O10
3− (~67%) ions exist in solution; this is also beneficial in producing less 
polydisperse nanoparticles (Sullivan et al., 2018). Moreover, the solutions pH of TPP 
and chitosan were adjusted to the same value (pH = 5.0) to reduce the alteration of 
resulting nanoparticle suspension pH. The formation of chitosan nanoparticles by 
ionic gelation occurs spontaneously upon the interaction with the TPP anion solution 
(phosphate groups H2P3O10
3−) with the cation chitosan solution (ammonium groups, 
NH3
+). The results appearance of the solution changed from clear to one that is 
opalescent and colloidal upon the contact of chitosan and TPP. This change in 
solution appearance signified a modification of the physical state of the chitosan to 
form nanoparticles. Furthermore, ibuprofen (IBU) molecular carrier one negative 
charge. In the present study we selected ibuprofen as a model drug in the development 
of controlled drug delivery system (Ganesh and Lee, 2013). Ionized ibuprofen species 
adsorb onto poly-chitosan nanoparticles containing ammonium groups, through their 
hydrophilic carboxylic groups leading to, electrostatic interactions or hydrogen 
bonding (Abioye et al., 2015). The addition of ibuprofen to either the chitosan 
solution or TPP solution before the chitosan interaction with TPP resulted in a final 
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solution that was more opalescent, due to the ions of the carboxylate anion (COO-) of 
ibuprofen and H2P3O10
3− of TPP binding to the ammonium group NH3
+ of chitosan 
(Figure 5.10) (Qandil et al., 2009). As a result, the electrostatic interaction of a strong 
polycation chitosan, with the ibuprofen or with a mixture of TPP/ ibuprofen should 
result in a poly cation–multivalent anion complex by ionotropic gelation. 
 
 
 
Figure 5.10: Scheme illustration ibuprofen loading/incorporation into chitosan nanoparticles 
(CS-IBU-TPP). 
 
 
 
5.3.1.4 Fourier transform infrared (FT-IR) studied 
The FTIR spectra characteristics of pure ibuprofen, blank chitosan nanoparticles and 
loaded ibuprofen chitosan nanoparticles (CS-IBU-TPP) are shown in Figure 5.11. 
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Figure 5.11: FT-IR spectra of (a) Pure ibuprofen, (b) blank CS-TPP nanoparticles (c) 
ibuprofen loaded chitosan nanoparticles (CS-IBU-TPP). 
 
 
The spectra were compared to that of pure ibuprofen, unloaded ibuprofen chitosan 
nanoparticles (CS: TPP) and loaded ibuprofen chitosan nanoparticles (CS-IBU-TPP). 
The spectrum of ibuprofen exhibited characteristic peak at 2921 cm-1, which can be 
attributed to O-H group stretching from carboxylic acid (COOH), and an intense 
absorption at 1706 cm-1 absorption bands for the carbonyl (C=O) (Nokhodchi et al., 
2015). Moreover, a strong absorption at 779 cm-1 represents the aromatic C-H 
stretching due to the presence of para (1,4-)disubstituted benzene ring (Liu et al., 
2014). The spectrum of blank CS: TPP nanoparticles shows absorption bands at 1635 
cm−1 and 1535 cm−1, corresponding to the linkage between the ammonium ions 
(NH3
+) and phosphate ions (H2P3O10
3−) (Bhumkar and Pokharkar, 2006). In addition, 
the spectrum of CS-TPP nanoparticles also shows a peak at 1217 cm-1 which may be 
attributed to the P=O stretching from TPP (Qi and Xu, 2004). Compared with the 
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spectrum of ibuprofen (Figure 5.11a), in the spectrum of ibuprofen loaded chitosan 
nanoparticles (CS-IBU-TPP) (Figure 5.11c), the absorption peak of 1706 cm−1 
disappears and a new peak at 1454 cm−1 (salt of carboxyl) appears (Wu et al., 2005). 
However, two peaks at 1635 cm−1 and 1535 cm−1 in CS: TPP nanoparticles (Figure 
5.11b), slightly shifted to a sharp peaks at 1630 cm-1 and 1530 cm-1 in (CS-IBU-TPP) 
nanoparticles (Figure 5.11c), suggesting that the carboxylic group of ibuprofen 
electrostatic interacts with amino groups of chitosan nanoparticles (Abioye et al., 
2016, Dudhani and Kosaraju, 2010). Furthermore, the FT-IR spectrum of ibuprofen 
loaded chitosan nanoparticles (CS-IBU-TPP) show the peak at 779 cm-1, providing 
evidence that ibuprofen presence in the chitosan nanoparticles (Liu et al., 2014). 
 
5.3.2 Ibuprofen entrapment results using two methods UV-spectrophotometry 
Ionotropic gelation is a popular and widely used preparation method, especially when 
chitosan particulate systems are involved in in vitro drug delivery (Mohammadpour 
Dounighi et al., 2012). Such a great extent of usage is due to the method’s simplicity, 
mildness, effectiveness without organic solvents, and mitigation of toxicity, which 
afford ionotropic gelation with a distinct advantage above other chemical crosslinking 
procedures (Mohammadpour Dounighi et al., 2012, Dash et al., 2011). In particular, 
ionotropic gelation is predicated on the occurrence of electrostatic forces between the 
positive charge of a polycation with the negative charge of a polyanion (Dung et al., 
2007, Sailaja et al., 2010). In the case of this experiment, the polycation was chitosan 
and the anion was ibuprofen (IBU), while TPP was introduced as a crosslinking agent. 
TPP in its sodium salt form is commonly used as a crosslinking agent because of its 
nontoxicity, stabilisation of chitosan, as well as its promotion of gel formation (Gan et 
al., 2005, Gan and Wang, 2007, Zhang et al., 2013). However, in practice, it has been 
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shown that crosslinking agents such as TPP can compete with polyanions such as IBU 
for the limited number of binding sites on chitosan, which could adversely affect drug 
entrapment efficiency (Zhang et al., 2013). Additionally, it is possible that chitosan 
and ibuprofen molecules could interact when they are close together, which could 
eventually have a negative impact on crosslinking. Entrapment efficiency of 
ibuprofen reflects the amount of ibuprofen that is adsorbed on the chitosan 
nanoparticles that are prepared by different methods (Manjanna, Shivakumar, 
&Pramod, 2009, Xu et al., 2003). Thus, (Zhang et al., 2013) maintain that material 
addition sequences are among the most important factors that influence the 
preparation of drug-polymer complexes via ionotropic gelation. The significance of 
material addition sequence as mentioned above is seen clearly in the findings of this 
experiment. To illustrate, as seen in Figures 5.12 and 5.13, the method involving the 
ibuprofen was first mixed with chitosan prior to incorporation with TPP solution, 
referred to as (IBU+CS)/TPP and the addition of IBU into TPP prior to these two 
chemicals are added to chitosan, referred to as CS/(TPP+IBU). Upon mixing either 
chitosan or TPP with ibuprofen there is an initial dilution, however when the TPP is 
added to chitosan (IBU+CS)/TPP or chitosan is added to TPP CS/(TPP+IBU) the 
subsequent dilution of the added material results in nanoparticles which are of the 
same final CS: TPP ratios in both Figure 5.12 and Figure 5.13. 
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Figure 5.12: First method an internal entrapment of ibuprofen into chitosan nanoparticles, 
ibuprofen first mixed with chitosan: (IBU+CS)/TPP. The entrapment efficiency of ibuprofen 
generally increased with CS:TPP ratio for the CS+IBU/TPP design. 
 
 
 
Figure 5.13: Second method an internal entrapment of ibuprofen into chitosan nanoparticles, 
ibuprofen first mixed with TPP: CS/(TPP+IBU).The entrapment efficiency of ibuprofen 
differed greatly and appeared to be independent of CS:TPP ratio in the CS/(TPP+IBU) 
design. 
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In Figure 5.12 the result may be explained due to chitosan and ibuprofen prematurely 
interacted in the (IBU+CS)/TPP solutions. Moreover, it is possible that ibuprofen 
could have formed a preferential complex with chitosan due to the close proximity in 
which they were placed. In this way, it is also plausible to infer that the amount of 
free cationic chitosan sites with which the anionic sites of TPP could interact were 
lessened. In turn, this occurrence may have lowered the chances that chitosan and 
TPP had to interact and subsequently form a tightly bound matrix upon addition of the 
latter. The sequence of material addition in the (CS+IBU)/TPP solution resulted in 
decreased amounts of effectively entrapped ibuprofen due to late addition of the 
crosslinking agent TPP, which is reflected by the low DEE% values (Figure 5.12). 
Furthermore, the trends in DEE% may also be explained by the concentration of 
chitosan (Patel and Patel, 2014, Kunjachan and Jose, 2010). When ibuprofen is first 
mixed with chitosan before the addition of TPP, concentration of chitosan solution 
was initially diluted, then the DEE% increases with increasing CS: TPP ratio and 
therefore increasing concentration of chitosan, as seen in Figure 5.12. In addition, in 
Figure 5.12, as the maximum percentage drug entrapment efficiency is with ratio of 
7:1, which is 27.8%. Other CS: TPP ratios 3:1, 4:1, 5:1, and 6:1 show entrapment 
efficiencies of 13.9%, 19.9%, 26.2% and 21.8% respectively. The graph clearly shows 
that if the drug is first mixed with the chitosan, then the results will not exceed above 
28%.  In fact, the CS: TPP ratio of 7:1 produced the highest DEE% for this material 
addition sequence. Such a result may have occurred due to the greater availability of 
free chitosan molecules that have not formed preferential complexes with ibuprofen 
as CS: TPP rises, which are then free to interact with TPP when it is added. Hence, a 
direct relationship between chitosan concentration and DEE% for this material 
addition sequence may be discerned (Kunjachan and Jose, 2010). However, the 5:1 
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ratio exhibits the second highest DEE% value for this material addition sequence. As 
such, it can be said that this ratio of CS to TPP is the one at which the DEE% for this 
drug delivery system can be optimised for the material addition sequence of 
(IBU+CS)/TPP (Kunjachan and Jose, 2010). When ibuprofen is first mixed with TPP 
(Figure 5.13), concentration of chitosan before mixing is 3 mg/mL and graph 
presenting percentage drug entrapment efficiency (%DEE) with relation to CS: TPP, 
maximum percentage obtained is approximately 76.8% with the ratio used of 5:1 of 
CS: TPP, respectively. Other ratios used from 3:1. 4:1, 6:1 and 7:1 showed percentage 
of drug entrapment efficiency 39.6%, 27.1%, 45.9% and 36.4% respectively. It was 
hypothesized that loading ibuprofen into TPP solution prior to incorporation with 
chitosan solution, the anionic of ibuprofen molecules were further negatively charged 
carboxylate group (COO-) in the TPP solution as the pH of the solution around 7.4, 
which favours the electrostatic reaction between the ions of carboxylate (COO-) and 
the NH3
+ of chitosan and consequential higher drug entrapment efficiency. Across 
both of the material addition sequences that were implemented, it is evident that the 
CS: TPP ratio of 5:1 in the CS/(TPP+IBU) solutions can provide the greatest 
effectivity of drug entrapment, as reflected by the calculated DEE% value of 76.8 for 
this condition. Moreover, previous studies (Jelvehgari et al., 2011, Patel and Patel, 
2014) conducted further corroborate these findings, as the authors discovered that 
drug: polymer ratio and crosslinking agent concentration have a significant impact on 
% entrapment efficiency. At a CS: TPP ratio of 5:1, it is possible that the amounts of 
drug, polymer, and crosslinking agent that were present may have been optimised. 
However, the DEE% decreases with CS: TPP increasing from 6:1 – 7:1. This result 
may be attributed to the carboxylate group of ibuprofen is present in lower amounts, 
as the pH of the solution reduced, therefore little ibuprofen is able to interact when 
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added to chitosan (Al-Hamidi et al., 2015). There are some factors which may cause 
decrease or increase in percentage drug entrapment efficiency such as entrapment 
conditions. The change in these parameters can affect the entrapment efficiency 
(Garlea et al., 2007). Moreover, the water insoluble drugs, usually have lesser drug 
entrapment efficiency than that of soluble. About 65% to 85% of the efficiency is 
obtained by encapsulation of fat-soluble drug by cross-linking technique of 
immobilization (Sinha et al., 2004). 
 
 
5.3.3 Characterization of chitosan nanoparticles and effects of CS-TPP ratio on         
CS-IBU-TPP nanoparticles 
In this study, the influence of different CS: TPP ratios (3:1, 4:1, 5:1, 6:1 and 7:1) on 
CS-IBU-TPP nanoparticles were investigated by measuring the particle size, zeta 
potential and DEE of CS-IBU-TPP nanoparticles. The Malvern Zetasizer NANO-Z 
was used to measure the particle size and zeta potentials characteristics of both 
ibuprofen-loaded chitosan-TPP (CS-IBU-TPP) nanoparticles and chitosan-TPP (CS: 
TPP) nanoparticles. 
 
5.3.3.1 Dynamic light scattering (DLS) 
Particle size is common analysis, which determined the biocompatibilities and 
bioactive of nanoparticles, as well as small nanoparticles have cross epithelia and 
have the higher intracellular uptake than microparticles (Wu et al., 2005). Therefore, 
to improve intracellular uptake, it was better to reduce particle size as much as 
possible. In addition, the particle size investigation is a very important factor 
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characterization process for nanoparticles since it helps understanding their dispersion 
and aggregation method (Desai et al., 1997). As shown in (Figure 5.14a) five ratios 
(3:1, 4:1, 5:1, 6:1 and 7:1) of CS: TPP were chosen to study its effect on the features 
of chitosan nanoparticles. The other parameters were fixed at chitosan concentration 
is 3 mg/mL and ibuprofen concentration is 1.5 mg/mL. The ability of chitosan to 
interact with TPP depends on the formation of inter- and intramolecular cross-linking 
between ammonium groups (NH3
+) and phosphate groups. When the CS: TPP ratio 
was small, the available quantity of TPP was high, as a result increased cross-linking 
density between chitosan and TPP. The particle size characteristics found to influence 
the biological performance of chitosan nanoparticles (Papadimitriou et al., 2008). For 
this reason, before ibuprofen encapsulation into CS: TPP nanoparticles, the effect of 
CS: TPP ratio on the particle size characteristics was studied in order to find the best 
ratio which results in nanoparticles of relatively low size and narrow size distribution. 
With an increase in CS: TPP ratio, the particle size increases due to decreased cross-
linking density between chitosan and TPP (Liu and Gao, 2009), an increase in 
viscosity can also in increase particle size (Kawadkar and Chauhan, 2012). This result 
is similar to previous study with reported increases in the particle size with increases 
in CS: TPP ratio (Gan et al., 2005).  It appears from (Figure 5.14a) that, drug loading 
affects the size of the chitosan nanoparticles. Ibuprofen (1.5 mg/mL) loading 
decreased particle size in comparison to the “native” nanoparticles. These difference 
are statistically significant (p < 0.05) at all CS: TPP ratios. 
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Figure 5.14: The effect of (CS: TPP) ratio on the (a) particle size and (b) polydispersity index 
(PDI), ibuprofen free nanoparticles (blue columns); ibuprofen loaded nanoparticle (brown 
columns). All data are the mean ± SD for n = 3 replicates. 
 
 
It is interesting to notice that when CS: TPP ratio changes from 3:1 to 6:1 a significant 
increase of particle size is observed (p < 0.05). When CS: TPP ratio increased, the 
presence of ibuprofen starts to play a dominant role. It should be noted that with the 
addition of ibuprofen the particle size was reduced, suggesting that the presence of an 
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additional negatively charged carboxylate groups (COO-) in the mixture. Within the 
tested chitosan to TPP ratio range conditions, ibuprofen (1.5 mg/mL) loading 
increased the particle size following a linear relationship (Figure 5.14a) with increase 
in chitosan to TPP ratio: 195 ± 4, 216 ± 2, 247 ± 1, 283 ± 2, and 293 ± 5 for 3:1, 4:1, 
5:1, 6:1 and 7:1, respectively (Appendix D).  
 
Polydispersity index (PDI) is a parameter used to define the particle size distribution 
of chitosan nanoparticles. In addition, the PDI value of 0.1 to 0.25 refers a narrow size 
distribution, whereas, a PDI of more than 0.5 indicates to a broad size distribution 
(Wu et al., 2011). The PDI measured for each ibuprofen loading as well as the empty 
chitosan nanoparticles was more than 0.2 as exhibited in (Figure 5.14b). The empty 
nanoparticles (native) have polydispersity index of 0.22 ± 0.02 to 0.30 ± 0.01, and the 
ibuprofen loaded nanoparticles have polydispersity index of 0.21 ± 0.04 to 0.35 ± 
0.03, as shown in (Figure 5.14b) indicating a narrow size polydispersity. In addition, 
all the values of PDI were below 0.35, indicating that a homogenous dispersion of 
nanoparticles were obtained (Hu et al., 2008). 
 
Zeta potential is another key parameter providing the density of the surface charge, 
and can inflects the stability of nanoparticle in suspension. High zeta potential (> +30 
mV) indicates high stability of nanoparticles due to the electrostatic repulsion 
amongst nanoparticles (Müller et al., 2001, Hu et al., 2008). As shown in Figure 5.15, 
the chitosan nanoparticles with all ratios demonstrated high zeta potential values, 
suggesting that these nanoparticles can be stable for long-term storage. Increases in 
the zeta potential was observed as the CS: TPP ratio increased. Furthermore, the 
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ibuprofen loaded chitosan nanoparticles did not cause a significant reduction in the 
zeta potential at all ratios compared to the “native” nanoparticles (p > 0.05). 
 
 
Figure 5.15: The effect of (CS:TPP) ratio on zeta potential, ibuprofen free nanoparticles (blue 
columns); ibuprofen loaded nanoparticle (brown columns). All data are the mean ± SD for n = 
3 replicates. 
 
 
5.3.4 Effects of CS: TPP ratio on CS-IBU-TPP nanoparticles 
CS: TPP ratio is an important factor, which affects the characteristics of CS-IBU-TPP 
nanoparticles. Drug entrapment efficiency (DEE) of CS-IBU-TPP nanoparticles is 
defined as a percentage of ibuprofen loading content that can be entrapment into CS: 
TPP nanoparticles. As shown in Table 5.2, DEEs of CS-IBU-TPP nanoparticles 
ranged from 27.1 % to 76.8 % at variable CS-TPP ratios and the highest DEE was 
76.8 % corresponding to the CS: TPP ratio at 5:1. In addition, when CS-IBU-TPP 
nanoparticles were prepared at CS: TPP ratio at 5:1, the zeta potential (+37.4 ± 0.4 
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mV) indicated that the solution of CS-IBU-TPP nanoparticles can maintain a stable 
suspension for a long time, furthermore, the particle size of CS-IBU-TPP 
nanoparticles was 247.3 ± 1.0 nm. However, when the CS: TPP ratio is over (5:1), the 
aggregation of nanoparticles occurs, which indicated the reduction of drug entrapment 
efficiency. 
 
Table 5.2: The particle size, zeta potential, drug content (DC) and DEE of CS-IBU-TPP 
nanoparticles at variable CS: TPP ratios. 
CS-TPP 
ratio 
Particle size 
(nm) 
PDI Zeta potential 
(mV) 
DC (%) DEE (%) 
3:1 195.0 ± 4.2 0.21 ± 0.04 +33.4 ± 0.1 4.4 ± 1.2 39.6 ± 7.4 
4:1 216.0 ± 1.9 0.25 ± 0.02 +35.4 ± 0.3 2.7 ± 0.4 27.1 ± 2.5 
5:1 247.3 ± 1.0 0.27 ± 0.01 +37.4 ± 0.4 7.0 ± 0.2 76.8 ± 1.3 
6:1 282.5 ± 2.1 0.32 ± 0.03 +39.0 ± 0.5 3.9 ± 0.8 45.9 ± 6.4 
7:1 293.0 ± 5.3 0.35 ± 0.03 +40.2 ± 0.6 2.9 ± 0.9 36.4 ± 7.9 
 
 
Moreover, the DEE of CS-IBU-TPP nanoparticles was highest therefore, CS: TPP 
ratio at 5:1 would be used in the subsequent experiments to study the influences of 
ibuprofen concentration on the characteristics of CS-IBU-TPP nanoparticles and in 
vitro release study of ibuprofen from CS-IBU-TPP nanoparticles. 
 
5.3.5 Effects of ibuprofen concentration on CS-IBU-TPP nanoparticles 
In this section, a series of ibuprofen concentrations were set to study its effect on the 
characteristics of CS: TPP nanoparticles. The particle size, zeta potential and drug 
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entrapment efficiency (DEE) of CS-IBU-TPP nanoparticles at different concentrations 
of ibuprofen (0, 0.5, 1.0, 1.5, 2.0 and 2.5 mg/mL) were summarized in Table 5.3. As 
shown, the increased particle size and decreased zeta potential of CS-IBU-TPP 
nanoparticles is a good indication of the entrapment of ibuprofen in the chitosan 
nanoparticles. The particle size of CS-IBU-TPP nanoparticles increased from 284.1 
nm to 348.3 nm with the increase of ibuprofen concentration in the range of 0.5 – 2.5 
mg/mL. The particle size distribution for the CS-IBU-TPP nanoparticles are 
represented in Appendix E. It can be observed that when the concentration of 
ibuprofen was lower than or equal to 1.5 mg/mL, the particle size of CS-IBU-TPP 
nanoparticles was smaller than that of the size of “native” nanoparticles (CS: TPP) 
(unloaded drug). This phenomenon may be attributed to a greater cross-linking 
density of the CS-IBU-TPP nanoparticles, which caused by the interactions between 
chitosan and ibuprofen. On the other hand, when the concentration of ibuprofen was 
higher than or equal to 2.0 mg/mL, the particle size of CS-IBU-TPP nanoparticles was 
larger than that of the “native” CS: TPP nanoparticles (unloaded drug). It is thought 
that at higher ibuprofen loading concentration, ibuprofen adsorbed on the particles, 
leading to rise of particle size. This may be confirmed by the reduced in zeta 
potential. Moreover, the PDI of the CS-IBU-TPP nanoparticles suspension increased 
(more than 0.4) at higher ibuprofen loading concentration, which might be caused by 
the formation of linkages or aggregation of the nanoparticles. 
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Table 5.3: The particle size, zeta potential, drug content (DC) and DEE of CS-IBU-TPP 
nanoparticles at variable concentrations of ibuprofen (IBU). 
IBU 
(mg/mL) 
Particle 
size (nm) 
PDI Zeta potential 
(mV) 
DC (%) DEE (%) 
0 293.6 ± 4.2 0.30 ± 0.04 +39.4 ± 0.1 n/a n/a 
0.5 284.1 ± 4.1 0.36 ± 0.02 +38.6 ± 0.5 3.2 ± 0.4 86.6 ± 9.3 
1.0 256.9 ± 3.4 0.27 ± 0.01 +37.4 ± 1.0 3.8 ± 0.8 60.2 ± 11.7 
1.5 247.3 ± 1.0 0.27 ± 0.04 +36.3 ± 0.4 7.0 ± 0.2 76 .8 ± 1.3 
2.0 378.7 ± 9.2 0.49 ± 0.03 +34.1 ± 1.3 3.3 ± 0.5 27.8 ± 6.9 
2.5 348.3 ± 9.9 0.43 ± 0.02 +33.8 ± 1.3 4.2 ± 0.8 29.0 ± 3.6 
 
 
As shown in Table 5.3, all the zeta potentials of CS-IBU-TPP nanoparticles at 
different concentrations of ibuprofen were greater than +30 mV, due to repulsive 
forces between particles and therefore leads to minimal aggregation, indicating a high 
stability of CS-IBU-TPP nanoparticles (Parida et al., 2013). It appears from Table 5.3 
that, the ibuprofen concentration did affect the zeta potential of the CS-IBU-TPP 
nanoparticles significantly (p < 0.05). Therefore, there is a clear decrease in charge. 
The effect of ibuprofen concentration on drug entrapment efficiency (DEE) was 
studied at the concentrations of (0, 0.5, 1.0, 1.5, 2.0 and 2.5 mg/mL), and summarized 
in Table 5.3. The DEEs of CS-IBU-TPP nanoparticles ranged from 27.8 % to 86.6 % 
and the highest DEE was obtained at ibuprofen concentration of 0.5 mg/mL. It should 
be noted that, at high concentrations of ibuprofen 2.0 mg/mL and 2.5 mg/mL, the 
DEE % was 27.8 % and 29.0 % respectively, which may be attributable to the limited 
availability of loading sites for the higher concentration of ibuprofen (Sogias et al., 
2012, Alshehri et al., 2016). Considering the possible pharmaceutical application of 
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nanoparticles in drug delivery system, smaller particle size, relatively high DEE and 
ibuprofen release are more effective in improving the bioavailability of ibuprofen (Hu 
et al., 2008, Wang et al., 2011). In this study, when the concentrations of ibuprofen 
were 0.5 mg/mL and 1.5 mg/mL, the particle size of CS-IBU-TPP nanoparticles were 
284.1 nm and 247.3 nm, respectively; and the higher DEE were 86.6 % and 76.8 %, 
respectively. Therefore, ibuprofen concentrations of 0.5 mg/mL and 1.5 mg/mL were 
chosen to determine in vitro release profiles of ibuprofen in subsequent experiments. 
High concentration of loaded ibuprofen caused increased in PDI values, indicating 
wider piratical size distribution (Appendix E). 
 
5.3.6 In vitro release of ibuprofen (IBU) from CS-IBU-TPP nanoparticles 
In this study, the ibuprofen was not chemically reacted with chitosan, but the 
interactions were due to electrostatic attractions, also it is entrapped within the 
chitosan nanoparticles. Thereby, the ibuprofen remains in a biologically active form 
and can use its effect upon the body as soon as it is released from the polymer 
matrices (Win et al., 2005). In this section ibuprofen was studied in vitro as a model 
drug in drug release study from chitosan-TPP nanoparticles using pH 7.4 PBS for 9 
hours at 37 °C. In vitro release of ibuprofen from chitosan nanoparticles with respect 
to different concentrations of ibuprofen (0.5 mg/mL and 1.5 mg/mL) were shown in 
Figure 5.16. 500 mg of ibuprofen-loaded nanoparticle formulations were weighed 
and injected in the dialysis membranes, which were placed in basket and immersed in 
200 mL of PBS. The ibuprofen-loaded chitosan nanoparticles provided a sustained 
release of ibuprofen releasing between 35 – 50 % of drug during 9 hour period of 
study. 
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Figure 5.16: In vitro release profiles of ibuprofen from CS-IBU-TPP nanoparticles with 
respect to different concentration of ibuprofen, carried out in phosphate buffer at pH 7.4 
maintained at 37 °C. (Mean ± SD, n=3). 
 
 
The drug release curves resemble those that are obtained when diffusion controlled-
release is involved (Siegel and Rathbone, 2012). This observation is to be expected 
given the use of chitosan nanoparticles, which act as a matrix for the drug. In this 
experiment, the chitosan nanoparticles provide surfaces from which the drug particles 
dissociate, surround themselves with solvent, then diffuse, which prolongs the half-
life of ibuprofen (Irvine et al., 2018, Islam and Ferro, 2016). However, a lag period 
from 100 to 300 minutes exists wherein the % release slowed down after an initial 
burst. The initial burst followed by the lag periods can be attributed to the difference 
in dissolution speeds of surface-associated drug particles as compared to those that are 
located further inside (Siegel and Rathbone, 2012). The mechanism of ibuprofen 
release is therefore explained by the diffusion of ibuprofen localized at the particle 
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surface. The diffusion of ibuprofen was enhanced at PBS (pH 7.4) (Lin et al., 2005) 
due to the deprotonation of chitosan, as a consequence, the interaction between the 
polycation chitosan and the polyanion TPP weakened or disappeared. So, ibuprofen 
was released quickly, and then followed by a slow drug release (Zhao et al., 2014). 
Also ibuprofen is readily soluble above pH 7.2 therefore initial dissolution from the 
surface would be expected. Higher ibuprofen loading causes increased total particle 
surface area available for burst release from particles. The drug release reflected that 
the cumulative release of ibuprofen from CS-IBU-TPP nanoparticles of concentration 
1.5 mg/mL (drug content 2.5%) was higher than their nanoparticle counterparts 0.5 
mg/mL (drug content 3.2%) for different time periods. Such observations were 
consistent with respect to time. The drug release also reflected that the release of 
ibuprofen (1.5 mg/mL) from chitosan nanoparticles was significantly higher at the 
start which was maintained until the termination of release. Such findings 
complement the binding profile of ibuprofen on the chitosan nanoparticles (Luo and 
Wang, 2014). The two ibuprofen formulations exhibited slow release profiles under 
the given test conditions. This is because the official threshold of 85% cumulative 
release (Popa et al., 2014) was not met, even when 555 minutes was reached. 
Nevertheless, within the first 20 minutes of observation, the 1.5 mg/ml ibuprofen 
solution displayed a greater extent of release when compared to the 0.5 mg/ml 
ibuprofen solution, a difference which was emphasised with time. Ibuprofen was not 
chemically bound to chitosan, but remained entrapped within chitosan through 
electrostatic interactions. The results from this release study are similar to those found 
using chitosan as a reservoir for ibuprofen. (Tang et al., 2014) reported that around 70 
% of ibuprofen was released from ibuprofen loaded chitosan films over 460 min. 
Another study conducted using chitosan/IB-MSNs (embedded mesoporous silica 
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nanoparticles), and the results showed that 65 % of ibuprofen released (Zhao et al., 
2014). Several factors can be attributed to the observed drug release characteristics of 
the two test solutions. The low degradability and solubility of chitosan at pH 7.4 may 
be among the causes of the slow and less than 50% release of ibuprofen (Agnihotri et 
al., 2004, Popat et al., 2012). Unfortunately, some studies (Jin-gou et al., 2012, 
Jayakumar et al., 2010) show that although chitosan nanoparticles have advantages 
such as biocompatibility and nontoxicity, several drawbacks persist. One such 
drawback entails the insufficient entrapment of a poorly water-soluble drug such as 
ibuprofen within the chitosan matrix due to the insolubility of chitosan at neutral pH, 
under which the dissolution studies were performed (Jin-gou et al., 2012). However, 
had the dissolution study been undertaken at the isoelectric point of chitosan (pH 6.5) 
rather than pH 7.4, then loading efficiency may have improved (Bowman and Leong, 
2006). Ibuprofen is ionised in alkaline solutions leading to an increase in solubility of 
the ibuprofen at high pH. As the pH increased, the solubility of the ibuprofen 
increased and production a highly soluble carboxylate ions due to increase in the 
ionization of the ibuprofen (Hadgraft and Valenta, 2000) (Figure 5.1). Solubility has 
been reported to be very poor 0.059 mg/mL at low pH (0.1 N HCl) (Al Masum et al., 
2012), however, the solubility of the drug dramatically increased, with increasing pH 
(Abioye and Kola-Mustapha, 2015). Another previous study reported the solubility of 
Ibuprofen in PBS at pH 7.4 to be 6.02 mg/ml (Levis et al., 2003). Previous studies 
have suggested that small size of the chitosan nanoparticles produce greater surface 
area for entrapment of ibuprofen. As a result of greater surface area, the release of 
ibuprofen from the small-sized chitosan nanoparticles is faster than their large-sized 
counterparts (Nokhodchi et al., 2010). Hence, ibuprofen at higher doses small size 
(247.3 ± 1.0 nm) and greater surface area, therefore, got effectively trapped and 
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released from (1.5 mg/mL) ibuprofen loaded chitosan nanoparticle (DC 2.5%). On the 
contrary, the (0.5 mg/mL) of ibuprofen loaded chitosan nanoparticle (DC 3.2%) could 
have presented lesser surface area and higher size (284.1 ± 4.1 nm). Hence, the 
loading dose and release of ibuprofen from such nanoparticles were lower compared 
to their 1.5 mg/mL ibuprofen loaded chitosan nanoparticle counterparts. Due to the 
low solubility of ibuprofen and the large volume of dissolution media, it is most 
certainly in sink conditions, the total amount of drug that was added to the dissolution 
bath were 0.025 mg and 0.034 mg for 0.5 and 1.5 mg/mL of ibuprofen solution 
respectively, and with solubility of ibuprofen 6.02 mg/mL, this demonstrates sink 
conditions were present in the experiment. In particular, saturation solubility of a drug 
in the dissolution medium should be at least three times that of the drug concentration 
in order to maintain sink conditions (Phillips et al., 2012). However, for poorly water-
soluble compounds such as ibuprofen (Faruki et al., 2013, Irvine et al., 2018), 
aqueous media cannot create such conditions. As such, lowered levels of drug release 
and slow release rates are not uncommon (Phillips et al., 2012). Also, poor sorption of 
ibuprofen onto the chitosan nanoparticles could be another cause of the observed drug 
release characteristics (Faruki et al., 2013). It is possible that the presence of 
chemicals such as NaOH, KCl, Na2HPO7, and KH2PO4 resulted in the dissociation of 
ibuprofen to the anionic form and therefore insufficient amounts of ibuprofen 
interacted with the chitosan nanoparticles (Oh et al., 2016). With regards to the 0.5 
mg/ml ibuprofen solution, since the drug concentration was lower, it is likely that 
fewer drug molecules interacted with the chitosan nanoparticles, thereby yielding 
slower release rates and % release relative to the 1.5 mg/ml ibuprofen solution. 
Studies further suggest that the release of ibuprofen from the chitosan polymers was 
dependent on pH. Low pH inhibits the release of the ibuprofen from chitosan (Khan et 
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al., 2011). This is because low pH reduces the swelling of chitosan nano-conjugates in 
experimental media or body fluids and ibuprofen is poorly soluble at low pH. For 
example, release of ibuprofen from chitosan is not mediated in the stomach. Hence, 
the chitosan-mediated ibuprofen release incurs a bypass at the stomach, a property 
that reduces the chances of peptic ulcer (Vieira et al., 2013). The overestimation of 
drug content could have been caused by the use of centrifugation to separate the 
chitosan nanoparticles and drug molecules. This is because the application of 
centrifugal forces could have resulted in premature release of the drug as well as a 
greater drug content (Moreno-Bautista and Tam, 2011). In this study ultracentrifuge at 
40,000 g for 60 min was used to separate all ibuprofen loaded chitosan nanoparticles. 
Some studies, however, reported speed at 16,000 rpm for 30 min (Ji et al., 2011), 
10,000 rpm for 5 min (Qiu et al., 2001), 9000 rpm for 20 min (Varga et al., 2014), 
15,000 rpm for 30 min (Thakur et al., 2013), 5000 rpm for 60min (Abioye et al., 
2016), 25,000g for 30 min (Jain and Banerjee, 2008), 13000 g for 10 min (Katas and 
Alpar, 2006), 20,000 g for 30 minutes (Mohammadpour Dounighi et al., 2012) to 
separate  particles. Additionally, the USP apparatus used in the experiment has been 
found to be inappropriate when smaller medium volumes are used for poorly water-
soluble drugs. Larger vessels of capacities up to 1000-mL may reduce the chances of 
errors in future experiments (Pezzini et al., 2015). 
 
5.3.6.1 Comparison of Drug Release Profiles: f2 Analysis 
f2 is logarithmic reciprocal square root transformation of one plus the mean squared 
(the average sum of squares) differences of drug percent dissolved between test 
solution and reference solution (equation 5.5) (Costa and Lobo, 2001). 
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Where, f2 is similarity factor, Tj is average percentage drug dissolved from test 
formulation, Rj is average percentage drug dissolved from reference formulation and 
n is the number of sampling time. The drug release profiles of the two test solutions 
can be further compared using f2 analysis (Costa and Lobo, 2001). f2 evaluation was to 
compare the dissolution between ibuprofen which was loaded on 1.5 mg/mL and 
0.5mg/mL chitosan nanoparticle respectively. In the present experiment, the 
calculated f2 value for the 0.5 mg/ml and 1.5 mg/ml IBU solutions is 52.5. According 
to (Pillay and Fassihi, 1998), an f2 value between 50 and 100 shows that the test and 
reference solutions are equivalent or the same, with a value of 100 representing total 
equivalence or sameness. The obtained f2 value for the test solutions is above 50, 
which suggests that the two test solutions appear to be equivalent for two nanoparticle 
concentrations (Costa and Lobo, 2001, Pillay and Fassihi, 1998, Polli et al., 2004).  
 
 
 
 
 
 
 
Eq. (5.5) 
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5.4 Summary 
It has been previously reported that using ibuprofen as pharmaceutical drug can be 
prepared by the interaction of cationic chitosan with ibuprofen using many different 
methods including chitosan microparticles (Lu et al., 2005, Kulkarni et al., 2007), 
chitosan hydrogels (Liu et al., 2014) chitosan with ibuprofen (Qandil et al., 2009). In 
this chapter, chitosan nanoparticles were successfully prepared using the polyanion 
TPP to create ionic cross-linking with amino groups of chitosan using the ionotropic 
gelation method at different CS: TPP ratios including 3:1, 4:1, 5:1, 6:1 and 7:1. The 
CS and TPP ratio is important and controls the size of the nanoparticles. Moreover, it 
has been demonstrated that chitosan nanoparticles can incorporate appreciable 
quantities of ibuprofen into nanoparticles CS-IBU-TPP using two methods. The 
carboxylate ions (COO-) of ibuprofen and H2P3O10
3− ion of TPP should bind strongly 
to the NH3
+ of chitosan, thereby forming more drug-loaded in chitosan nanoparticles. 
Ibuprofen (1.5 mg/mL) was entrapped during preparation of the nanoparticles system 
at different CS: TPP ratios either by mixed ibuprofen with chitosan then TPP added 
referred to as (CS+IBU)/TPP (first method) or by mixed ibuprofen with TPP then 
chitosan added referred to as CS/(IBU+TPP) (second method). The second method 
has obtained relatively high DEE of ibuprofen and was selected to carry out further 
experiments. The ibuprofen-loaded nanoparticles exhibited relatively narrow particle 
size distribution, as the relatively low polydispersity index (PDI) values. The particle 
size of the drug-loaded nanoparticles was affected by the CS: TPP ratio. It is obvious 
that the incorporation of ibuprofen into CS nanoparticles leads to CS-IBU-TPP a 
decrease of their size compared with the non-loaded or “native” CS: TPP 
nanoparticles. It may be attributed to the increases of ionic interactions between CS 
and TPP during nanoparticle formation because of the presence of the ibuprofen 
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molecules. It was observed that the optimum CS-IBU-TPP ratio among these studied 
here is CS: TPP at 5:1 ratio, which leads to the highest DEE (76.8 %). At this ratio, 
CS-IBU-TPP nanoparticles with sizes 247.3 ± 1.0 nm, with PDI 0.27 ± 0.01 and with 
zeta potential +37.4 ± 1.0 are produced. Thus, this ratio (5:1) was selected for the 
preparation of drug-loaded nanoparticles at various ibuprofen concentrations. During 
the experiment, CS: TPP ratio at 5:1 and ibuprofen concentration of 0.5 and 1.5 
mg/mL, were supposed to be most effective in delivering ibuprofen. Increasing 
concentration of ibuprofen from 0.5 to 1.5 mg/mL caused an increasing CS: TPP 
interaction, leading to decreasing nanoparticle size. In these conditions, the particle 
sizes of CS-IBU-TPP nanoparticles were 284.1 ± 4.1  nm and 247.3 ± 1.0  nm 
respectively; the zeta potentials were +38.6 ± 0.5 mV and +35.3 ± 0.4 mV, indicating 
high stability of CS-IBU-TPP nanoparticles; the DEE of nanoparticles were 86.6 % 
and 76.8 %; the cumulative release of ibuprofen in vitro were 38.5 % and 48.7 %. 
These results suggested that the potential of ibuprofen loaded chitosan nanoparticles 
(CS-IBU-TPP) is expected to have potential as a method in pharmaceuticals 
applications.  
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Chapter 6 
 
Evaluation of mucoadhesive properties 
of chitosan nanoparticles prepared 
using different chitosan to 
tripolyphosphate (CS: TPP) ratios 
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6 Evaluation of mucoadhesive properties of chitosan nanoparticles prepared 
using different chitosan to tripolyphosphate (CS: TPP) ratios 
6.1 Introduction 
 
Chitosan is highly considered in the medicinal world, for use in drug delivery systems 
especially in those which target specific delivery sites as it demonstrates 
mucoadhesive characteristics (Lehr et al., 1992, Lueßen et al., 1997). Chitosan and 
other mucoadhesive polysaccharides are highly sought after as they can be formulated 
into transmucosal drug delivery systems that can achieve and enhance the local and 
prolonged effect of active drugs over for example 12 - 24 h. Mucoadhesion is often 
defined as where two materials, one of which is a mucosal surface, adhere to each 
other. It is generally understood that electrostatic interactions can occur between 
chitosan’s positively charged NH3+ groups and the negatively charged sialic acid 
residue on mucin (Fiebrig et al., 1995). In addition, in an aqueous environment, the 
interaction between porcine stomach mucin and chitosan, when different additives 
were present confirmed that electrostatic interaction was taking place and being aided 
by hydrogen bonding (Harding et al., 1999). Hydrophobic and hydrophilic 
interactions are also very important (Harding et al., 1999). Depending on the 
physiological conditions and physiochemical properties such as pH, the carboxylate 
group of sialic acid residues on mucin can interact with the positive charge on the 
chitosan particles, due to the protonated amino group (NH3
+) to form electrostatic and 
hydrogen bonds (Morris et al., 2010). If such interactions occur, it would be useful to 
test particle size and zeta potential (surface charge) to gain a better understanding of 
the interactions of mucin with the chitosan nanoparticles. Moreover, the 
mucoadhesiveness was evaluated by measuring the mucin binding efficiency. It is 
therefore clear that the surface charge (zeta potential), the size and occupied space 
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(viscosity) of the nanoparticles will have an influence on their interactions with 
mucin. Previous studies in to altering the charge on the nanoparticles have involved 
modification with poly-ethylene glycol for example (Wu et al., 2005) and have clearly 
demonstrated that mucin binding and drug release are influenced by nanoparticle 
charge (Wu et al., 2005, Xu et al., 2015).  
In this study, once the different ratios (CS: TPP) ratios of chitosan nanoparticles were 
formulated their physico-chemical properties (viscosity, zeta potential, particle size 
and particle size distribution) were measured prior to being mixed with mucin. The 
physico-chemical properties were then determined after mixing, in order to examine 
the interaction between the chitosan nanoparticles and mucin. This provided an 
indication into how CS: TPP nanoparticles may act in vivo and which ratios of        
CS: TPP show potential as drug delivery. Moreover, the mucoadhesiveness was then 
evaluated by measuring the mucin binding efficiency. It is therefore our hypothesis 
that by preparing CS: TPP nanoparticles of controlled viscosity, size and charge 
(Hejjaji et al., 2017, de Pinho Neves et al., 2014, Hashad et al., 2016, Silva et al., 
2017) it will be possible to determine whether a minimum CS: TPP ratio or net charge 
is required for mucoadhesion and from this gain a greater understanding of the 
mucoadhesive process. This will provide important information for designing tunable 
mucoadhesive systems for specific applications, where for example, the degree of 
mucin binding can be controlled. 
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6.2 Methods and materials 
6.2.1 Chemicals   
Chitosan of low molecular mass (LMW) of ∼ 50,000 g/mol as determined by 
viscosity (see section 5.2.2.1), was purchased from Sigma–Aldrich (Gillingham, UK) 
and has an average degree of acetylation (DD) of ∼90 % as determined by FT-IR (see 
section 5.2.2.2). Glacial acetic acid and TPP sodium salt were also obtained from 
Sigma–Aldrich (Gillingham, UK). Extensively degraded pig gastric mucin was kindly 
gift from Biofac A/S (Kastrup, Denmark) and has been fully characterized previously 
in our group (Abodinar et al., 2016). All materials were used without any further 
purification.   
   
6.3  Experimental 
6.3.1 Preparation of chitosan-TPP nanoparticles 
Chitosan-TPP nanoparticles were prepared at seven different ratios (CS: TPP) as 
described in sections 5.2.2.3 and 5.2.4. 
 
6.3.2 Mucin sample preparation 
A 3.5 % (w/v) mucin stock solution was formulated using 3.5 g mucin to   100 mL of 
deionised water (pH 4.2). This was magnetically stirred overnight at room 
temperature (~ 20 °C). The solution was then filtered through filter paper (Whatman 
No.1, Sigma–Aldrich Gillingham, UK) to isolate a larger particles of mucin and 
reduce aggregation. 
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6.3.3 Evaluation of the mucoadhesive properties of chitosan-TPP nanoparticles 
6.3.3.1 Adsorption of mucin on to chitosan-TPP nanoparticles (CS: 
TPP) 
Mucin solution (1 mL) was added to each CS: TPP nanoparticle preparation (19 mL), 
with magnetic stirring at 600 rpm and mixtures were incubated at 37 °C for 1 hour 
prior to analysis, this will be referred to as first stage preparation. To further test the 
interactions of these nanoparticles, it was decided to test mix equal volumes of 
different CS: TPP ratios (10 mL) with mucin (10 mL), referred to as second stage 
preparation, and whether these nanoparticles best interact with mucin for suitable 
pharmaceutical applications. Then the mucin-nanoparticle mixtures were centrifuged 
at 40,000 x g (Beckman Coulter Optima L-100K, 50Ti rotor) for 60 min and the 
supernatant was used for the measurement of the free mucin concentration using the 
standard calibration curve (section 6.3.4.1). In addition, the mucoadhesiveness was 
expressed as the mucin binding efficiency of the nanoparticles and was calculated 
from the following equation: 
 
6.1) 
 
Where Co is the initial concentration of mucin used for incubation, and CS is the 
concentration of free mucin in the supernatant (Papadimitriou et al., 2008, Andersen 
et al., 2015). 
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6.3.3.1.1 Viscosity analysis of chitosan nanoparticles-mucin mixtures 
The relative viscosity (ηrel) of all samples (chitosan solution, mucin solution and 
chitosan nanoparticle-mucin mixtures) were tested at 37.0 ± 0.1°C by a Bohlin Gemini 
HR Nano Rheometer (Malvern Instruments, Worcestershire, UK) using 1 mm gap and 
55 mm parallel plate geometry at a constant shear rate of 500 s−1 under precise 
temperature control, according to the following equation: 
 







0

rel
                                                                               Eq. (6.2) 
 
where η is the average viscosity of the samples and, ηo is the viscosity for the 
reference solvent i.e. dilute acetic acid. All measurements were performed in 
triplicate. A change in relative viscosity of nanoparticles indicates the interaction with 
mucin (Menchicchi et al., 2014).  
 
 
6.3.3.1.2 Zeta potential of chitosan nanoparticles-mucin mixtures 
The zeta potential of the chitosan solution (0.3 %), mucin solution (3.5 %) and 
chitosan nanoparticle-mucin mixtures were measured with a Malvern Zetasizer 
NANO-Z (Malvern Instruments Limited, Malvern, UK) using the capillary cell. All 
samples were taken at 37 ± 0.1 °C and the mean values and standard deviations of 
triplicate measurements were calculated. Mucin solutions were measured at pH 4.2 
and CS: TPP nanoparticle-mucin mixtures were at pH 5. To determine the zeta 
potential approximately 1.0 mL of sample was pipetted into a folded capillary cell by 
using a syringe and measurements were performed at 37 ± 0.1 °C in triplicate to 
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obtain data value an average of ten measurements. Laser, the source of light, Doppler 
electrophoresis is a technique of taking zeta potential measurements. The laser is 
divided to give a reference and an incident beam. The latter (incident beam) goes 
through the sample cell centre, then the forward angle is used to spot and observe 
scattered light. Immediately the measurement of zeta potential commences, reference 
beam’s intensity is taken. This technique takes into account the speed with which 
particles can move in liquids after an application of electric field (its velocity). As 
soon as the applied electrical field and the particle`s velocity are known in advance 
and by use of sample constants; dielectric and viscosity constant, zeta potential now 
becomes determinable 
 
6.3.3.1.3 Particle Size analysis of chitosan nanoparticles-mucin mixtures 
The particle diameter of mucin solution (3.5 %) and chitosan nanoparticle-mucin 
mixtures were measured by dynamic light scattering (DLS) using Malvern Zetasizer 
NANO-Z (Malvern Instruments Limited, Malvern, UK). The dispersion medium 
(water) and refractive index of particles was set at 1.330 and 1.6 respectively. A glass 
cuvette was used and an angle scattering of 173° was utilized. Approximately 1.0 mL 
of sample was pipetted into the cuvette. The laser is used to provide a light source to 
illuminate the sample particles. Some of the laser beam scattered by the particles 
within the sample then the detector measures the intensity of the scattered light. The 
samples were measured in triplicate and the results represent the mean particle 
diameter at 37.0 ± 0.1 °C. 
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6.3.4 Mucin adsorption assay 
Mucin adsorption was studied using a periodic acid /Schiff colorimetric method 
described by Mantle and Allen (Mantle and Allen, 1978) to determine the free mucin 
concentration following incubation with chitosan nanoparticles. 
6.3.4.1 Calibration curve of mucin using PAS/Schiff colorimetric 
assay 
Standard calibration curves for mucin were prepared from 2 mL of mucin standard 
solutions of concentrations (0.01 % – 0.08 %). Mucin concentrations were quantified 
by colorimetric method of the glycoprotein based on the periodic acid/Schiff reagent 
(PAS) (Mantle and Allen, 1978). This method was divided by into two parts: firstly, 
coupling of the oxidised mucin (glycoprotein) using periodic acid reagent (periodate 
anion) to aldehyde (Figure 6.1). 
 
 
Figure 6.1: Periodate oxidation of sialic acid to aldehyde (Matsuno and Suzuki, 2008). 
 
 
Periodic acid reagent was prepared by adding 10 μL of 50 % of periodic acid solution 
to 7 mL of 7 % acetic acid solution (Mantle and Allen, 1978). Secondly, the 
preparation of the Schiff reagent was prepared by adding 1 % basic Fuschin aqueous 
solution to 20 mL of 1 M HCl, and twice mixing the resulting solution with 300 mg of 
activated charcoal, then shaking for 5 min and filtering to remove the charcoal. The 
resulting solution was stored in an amber glass bottle at room temperature. Sodium 
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metabisulphite (0.1 g) was added to every 6 mL of Schiff reagent directly before use 
and the resultant solution was incubated at 37 °C until it became colourless or pale 
yellow (about 90 minutes). A standard calibration curve was constructed by adding 
200 µL of freshly periodic acid reagent to 2 mL of mucin standard solutions (0.01 % – 
0.08 %), solutions then were incubated at 37 °C for 2 hours in a water bath to 
complete periodate oxidation. Then 200 µL of the colourless Schiff reagent was added 
at room temperature in order to react with the aldehyde (from first step) to form a pink 
colour solution. Colour development was complete after 30 minutes and the 
absorbance of the standard solutions were recorded at 555 nm using UV-Vis 
spectrophotometer (Shimadzu UV-160A, Wolverton, UK) (da Silva et al., 2007, Rossi 
et al., 1995). Samples were prepared for analysis as per section 6.3.3.1. 
 
6.4 Statistical analysis 
All experiments were expressed as the mean value ± standard deviations (SD) of at 
least three readings. Statistical significance (p <0.05) between test groups was 
performed by one-way analysis of variance (ANOVA) and a Tukey post-hoc test. 
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6.5  Results and discussion 
Five different ratios of (CS: TPP) nanoparticles (3:1, 4:1, 5:1, 6:1 and 7:1) were 
spontaneously obtained upon addition of a TPP (polyanion) solution to the chitosan 
solution (polycation), according to the procedure previously developed by chapter 
five. These formulations resulted in positively charged chitosan nanoparticles, which 
helps to facilitate electrostatic interactions with the negatively charged carboxylic acid 
groups of the mucin. Pig gastric mucin was used as the pig is physiology similar to 
humans. A lot of similarities clearly exist between pigs and humans, thereby making 
swine an experimental model system that is very essential in conducting 
investigations in a range of scientific parameters (Patterson et al., 2008). In addition, 
the physiological resemblance to human intestines and mechanisms of human disease 
are advantages of pig models advantages which these studies highlighted (Gonzalez et 
al., 2015). There are several distinct advantages that pigs possess which make them 
become a useful translational research animal model (Gonzalez et al., 2015).  
Specifically pigs possess important anatomical and physiological structures that are 
similar to human beings (Shu et al., 2001, Labib et al., 2004, Douglas, 1972). The pig 
possesses a genome with extensive homology that is comparative to that of human. 
The sequence homology that the pig genome has is 60% that of human, in contrast to 
rodents with only 40% homology (Thomas et al., 2003, Humphray et al., 2007). 
Furthermore, the pig chromosomal structure, in contrast to mouse, rat, dog, cat or 
horse, is more like that of human’s (Murphy et al., 2005, Meyers et al., 2005). Just 
like humans, pigs, are omnivores in nature and, as such, share identical physiological 
processes with regards to their metabolism and intestine (Meyers et al., 2005, 
Deglaire and Moughan, 2012, Patterson et al., 2008). The small intestine structure is 
very similar in humans and pigs, and this includes macroscopic features like the 
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intestinal length ratio for every kilogram bodyweight (Block et al., 2011). 
Furthermore, pigs, just like humans, are real omnivores, while other potential 
mammalian models like dogs, cats, ruminants, rabbits and rodents have undergone 
evolution in the development of their alternative digestive strategies (Kararli, 1995). 
The rapid growth rate and size of pigs once they become fully matured, as well as 
their differences in gut-associated lymphoid tissue, are other essentials being taken 
into consideration when pigs are being utilised as animal models in the study of 
human development and disease (Heinritz et al., 2013, Sinkora et al., 2011).  
Extensively degraded pig gastric mucin may differ slightly from the native porcine 
mucus gel due to the manufacturing process. However, off-the-shelf mucin 
formulations are often used research as they have similar functionality (Fefelova et 
al., 2007, Takeuchi et al., 2005) and it is expected that batch-to-batch variability 
would be less of an issue compared to freshly prepared material (Fefelova et al., 
2007). In this study, a 3.5 % pig gastric mucin solution was used because this 
concentration is almost equivalent to mucin concentration in gastric mucus (Bansil et 
al., 2013). The preparation of digested gastric mucins and degradation process were 
made in the form of a by-product derived from large scale pharmaceutical quality 
pepsin preparation in the city of Copenhagen, Denmark at Orthana Kemiske Fabrik 
A/S (a division of the Biofac group). Red lining derived porcine stomachs came from 
abattoirs in the US (Farmland) and kept at a frozen temperature of −18 °C until it was 
brought into the production area to be utilised. First, a large meat crusher (screen 18 
mm) was used in crushing approximately 1000 kg of frozen linings. The crushed raw 
material was placed in a stirred tank prior to a 100 kg of RO water added into it. 
Concentrated hydrochloric acid was used in adjusting the pH to 2.0 prior to heating it 
to a temperature of 38 °C. Then concentrated sodium hydroxide was used in adjusting 
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the pH to 2.8 after 4.5 hours. There was transfer of the processed liquid to a 
precipitation tank and cooled down to a temperature of −5 °C. The precipitation of the 
crude mucin was then performed by slowly adding 97% acetone until a concentration 
of 61% w/w was reached. Mild agitation was used in mixing the precipitation liquid, 
held at a temperature of −5 °C, for 30 minutes. The separation of the processed liquid 
into liquid and solid phases was then made on a Flotweg decanter (1500 rpm inner 
speed, 6000 rpm outer speed), where the solid phase consisted of fat and mucins. By 
adding approximately 5 volumes of water, the precipitate became solubilised. 
Evaporation of acetone remnants was undertaken under vacuum. The liquid was then 
left for 3 days to sediment, prior to pumping out of the clear liquid top phase. 
Cellulose and filter aid based filter plates (at first T2600, T1000 and lastly K250, 
every one of them coming from Seitz, Pall Corporation, New York, USA) covered 
with filter aid (Hyflo Super Cel) were used three times in filtering the crude mucin on 
a Seitz Orion plate and frame filter press The mucin concentration was then made to 
5% solid content with 3 volumes of RO water used in washing it prior to adjusting pH 
to 3–4 and then frozen at a temperature of −18 °C and lyophilized (Abodinar et al., 
2016). Studies on native pig gastric mucin have previously shown an isoelectric point 
at ∼pH 2–2.5 (Caicedo and Perilla, 2015) and sialic acid has a pKa of 2.6 (Hurd, 
1970). Therefore there is potential to interact with the positive charged amino groups 
of chitosan nanoparticles (De Campos et al., 2004) when both sialic acid and chitosan 
are oppositely charged at therefore ~ pH 4.5 - 5. However, there are other 
contributions such as hydrogen bonding and hydrophobic effects might have an effect.  
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6.5.1 Mucoadhesion Studies 
The mucoadhesive properties and the influences of different CS-TPP ratio at 3:1, 4:1, 
5:1, 6:1 and 7:1 nanoparticles were evaluated by measuring the relative viscosity, 
particle size and zeta potential on interaction with negatively charge mucin. Different 
volumes mixing (two preparations) were used to assess the stability and interaction of 
nanoparticles prepared using various CS: TPP ratios and mucin which could lay the 
foundations for potential future use as a drug carrier and/or other pharmaceutical 
applications (section 6.3.3.1). Both preparations were based on the measurements of 
the viscosity, zeta potential (surface charge) and particle size of chitosan nanoparticles 
before and after incubation with mucin at 37° C under moderate stirring.  
 
6.5.1.1 First preparation incubation with mucin 
6.5.1.1.1 Assessment of chitosan nanoparticle-mucin interactions by relative 
viscosity  
The interactions between chitosan nanoparticles CS: TPP) and mucin were initially 
studied by relative viscosity (ηrel) (Figure 6.2). Chitosan solution (0.3 %) and mucin 
solution (3.5 %) were prepared in order to produce relative viscosity (ηrel) closes to 
1.8. Relative viscosities of this order of magnitude are required as at higher relative 
viscosities for example > 2 the onset in polymer entanglement is observed. Therefore, 
the relative viscosities were kept below 2 with the aim of minimising these polymer 
entanglement effects which would obscure changes in viscosity due to interactions 
with mucin (Goycoolea et al., 1995).  
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Figure 6.2: Relative viscosity of mucin (red column), chitosan (green column), a native 
chitosan nanoparticles (blue columns) and chitosan nanoparticle-mucin mixtures-mucin 
(white columns) at 37 °C (mean values ± SD, n=3).  
 
 
It can be seen in Figure 6.2, chitosan nanoparticles were mixed with mucin at 
different CS: TPP ratios (3:1, 4:1, 5:1, 6:1 and 7:1), then the relative viscosities of the 
mixed solutions were determined. The formation of chitosan nanoparticles-mucin 
interactions products were determined on the basis of the changes in relative 
viscosities of the nanoparticle-mucin mixtures (Rossi et al., 2001). The relative 
viscosity of chitosan nanoparticles (CS: TPP)-mucin mixtures increased with 
increasing CS: TPP ratios (Figure 6.2). Increasing CS: TPP ratios (no mucin), caused 
an increase in relative viscosity which was expected due to the increased 
concentration of chitosan used (higher charge on chitosan nanoparticles) (Casettari et 
al., 2013, Perinelli et al., 2018). It was observed however, that chitosan nanoparticle-
mucin mixtures decreased the relative viscosities in compared with CS: TPP 
nanoparticles (blank). This could be due to the electrostatic interactions between 
positively charged ammonium group on the chitosan nanoparticles and the negatively 
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charged sialic acid residue on mucin (Fiebrig et al., 1995, Deacon et al., 1999), 
perhaps with a contribution from hydrogen bonds (Fiebrig et al., 1995). The 
difference between the native chitosan nanoparticle and chitosan nanoparticle-mucin 
mixture was not statistically significant (p > 0.05) on relative viscosity at (CS: TPP) 
3:1. This could be attributed to a small amount of chitosan nanoparticles interacting 
with the mucin causing a limited viscosity change.  However, other CS: TPP ratios 
(4:1, 5:1, 6:1 and 7:1) did significantly affect relative viscosity (p < 0.05). This 
suggests an important interaction occurring between chitosan nanoparticles and 
mucin. This is most likely due to a conformational change to a more compact 
structure (i.e. a reduction in the hydrodynamic volume (Mackie et al., 2017)) for one 
or more of the macromolecules due to an interaction (Mackie et al., 2017, Menchicchi 
et al., 2014, Silva et al., 2017). Moreover, this would also be consistent with a 
decrease in net charge/ zeta potential (Abodinar et al., 2014). A decrease in viscosity 
may also be advantageous from a formulation point of view, for example in ocular 
delivery systems where an increase in viscosity would be unacceptable due the blink 
process requiring low shear viscosities in order to avoid unnecessary damage to the 
corneal epithelium (De Campos et al., 2004), low viscosity aids the spray ability of 
liquid nasal formulations (Morris et al., 2010, Mackie et al., 2017). Although not 
explicitly evaluated, changes in viscosity are related to the swelling and stiffness of 
polymeric systems and could therefore be probed further, this would be influenced 
greatly by the CS: TPP ratio and the pH at which nanoparticles were formed 
(Bhumkar and Pokharkar, 2006) where chain stiffness has been shown to influence 
mucin interactions (Mackie et al., 2017, Menchicchi et al., 2014).  
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6.5.1.1.2 Zeta potential of chitosan nanoparticles-mucin mixtures  
In order to further support the interactions between chitosan nanoparticles and mucin, 
zeta potential was investigated. Determination of the zeta potential of chitosan 
nanoparticles in the presence of mucin has been demonstrated to be a good means of 
studying the mucoadhesive interactions of the chitosan nanoparticles–mucin mixtures 
(Fefelova et al., 2007, Takeuchi et al., 2005, Menchicchi et al., 2014). Furthermore, 
zeta potentials of less than +30 mV indicate lower nanoparticle stabilities due to the 
lower electrostatic repulsion (Hunter, 1993), zeta potential of native chitosan 
nanoparticles increased as the CS: TPP ratio increased (Figure 6.3) which is a highly 
attractive property amongst nanoparticles. Furthermore, this would theoretically allow 
the preparation of nanoparticles of controlled zeta potential in the range +34 - +42 
mV by varying the CS: TPP ratio. Nanoparticles outside of this range could be 
prepared under different pH conditions or by using different CS: TPP ratios, for 
example. 
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Figure 6.3: Zeta potential values obtained for mucin (red column), chitosan (green column), 
native chitosan nanoparticles (blue columns) and chitosan nanoparticle-mucin mixtures (white 
columns) at 37 °C. All values represent the mean ± SD (n = 3). 
 
 
Chitosan has a mucoadhesive properties, therefore it would be expected that the 
surface charge of chitosan nanoparticles might be changed by the adhesion of the 
mucin and in this case a decrease in zeta potential was observed upon mixing with 
mucin at all CS:TPP ratios (Figure 6.3). The occurrence of such change was detected 
by measuring the changes in the zeta potential of chitosan nanoparticle-mucin 
mixtures with different of CS: TPP ratios. The zeta potential of mucin and chitosan 
were determined to be -4.0 ± 3.1 and +46.7 ± 0.4 mV, respectively. It is known that 
chitosan has positive charge at pH 5.0 due to presence of ammonium ions (NH3
+) 
(Vllasaliu et al., 2010). The negative charge, however, of mucin is as a result of the 
ionization of sialic acid (COO-). Therefore, chitosan nanoparticles could lead to a 
strong electrostatic interaction with the mucin. An addition of mucin to the different 
ratios of CS: TPP nanoparticles results in a significant (p < 0.05) decrease in zeta 
potential for all CS: TPP ratios (Figure 6.3). The reduction of zeta potentials could be 
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due to the ionic reaction between negatively charged sialic acid in mucin and 
positively charged amino groups in chitosan nanoparticles (Grießinger et al., 2015). 
Moreover, as shown in Figure 6.3, the zeta potential decreased sharply as the CS: 
TPP ratio decreased from mixtures 4:1 to 3:1, which might be caused by decrease 
amount in these nanoparticles which leads to most of NH3
+ groups interacting with 
COO- groups on the of sialic acid. These results were in agreement with lowest 
relative viscosity of 3:1 mixture (Figure 6.2). Furthermore, this may be attributed to 
the fact that native (3:1) ratio nanoparticles had lower zeta potential values (+34.7 ± 
5.6 mV) than other ratios including 4:1, 5:1, 6:1 and 7:1. On the other hand, a small 
increase in zeta potential of chitosan nanoparticles-mucin mixtures were observed as 
the CS: TPP ratio increased from 5:1 to 7:1, which might be due to increase positive 
charge surfaces on the particles. This may also be confirmed by the changes in 
particle size and polydispersity index (PDI) of native CS: TPP nanoparticles.  At all 
CS: TPP ratios greater than 3:1 the zeta potential decreased by ~ 5 mV which is in the 
range of the overall charge on mucin and may be indicative of the majority of the 
mucin being bound to the nanoparticles at these ratios.  
 
6.5.1.1.3 Particle size of chitosan nanoparticle-mucin mixtures  
In all cases there is an increase in particle size upon addition of CS: TPP nanoparticles 
to mucin, clearly indicating an interaction (Figure 6.4), although this increase in 
particle size is generally not as pronounced when the CS: TPP nanoparticles are larger 
i.e. those containing greater amounts of chitosan (Sosnik et al., 2014). In order to 
remove residues of insoluble mucin molecules and reduce mucin aggregation, the 
suspension was filtrated and the particle size was obtained at 41 ± 5 nm. The change 
in zeta potential is related to a change particle size (Morris et al., 2010) and it is clear 
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that as the CS: TPP ratio increases both the zeta potential and particle size also 
increase. This is true both in the presence and absence of mucin which is related to the 
reduction in TPP available to interact with chitosan and therefore a decrease in the 
density internal cross-linking and hence larger particles (Masarudin et al., 2015) 
(Figure 6.4). Nanoparticles at all ratios, other than 3:1, were in the optimal range (200 
– 500 nm) for mucosal interaction (Krogstad et al., 2014). When the mucin solution 
were mixed with different CS: TPP ratios of chitosan nanoparticles from 3:1 to 7:1, 
the particle size increased significantly (Figure 6.4). This is probably due to 
adsorption (binding) of mucin on the chitosan nanoparticles surfaces (Fefelova et al., 
2007). The modification of the particle size was a result of electrostatic interactions 
between the negative charge of mucin and positive charge of chitosan particles. In 
addition, the increase in particle size, together with a decrease in zeta potential 
demonstrates that the mucin is binding to the surface of the chitosan nanoparticles, 
when the CS: TPP ratios varied from 3:1 to 7:1. 
 
 Figure 6.4: Particle size of mucin (red column), a native chitosan nanoparticles (blue 
columns) and chitosan nanoparticle–mucin mixtures (white columns) at 37 °C. All values 
represent the mean ± SD (n = 3). 
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Figure 6.5: PDI of mucin (red column), a native chitosan nanoparticles (blue columns) and 
chitosan nanoparticles–mucin mixtures (white columns) at 37 °C. All values represent the 
mean ± SD (n = 3). 
 
 
This result may be attributed to the overall negative charge of mucin, due to the 
presence of sialic acid, and the overall positive charge of the chitosan nanoparticles. 
The interaction at ratio CS: TPP (4:1) between chitosan nanoparticles and mucin can 
was the strongest as the nanoparticles binding the mucin more strongly and hence 
reducing the particle size. Furthermore, this increase in interaction is important in 
respect to potential applications as increased interaction with mucin is indicative of 
increased mucoadhesion, which depending on the specific application may not always 
be optimum. At the lowest CS: TPP ratio (3:1) mucin in mixture is potentially 
available in greater amounts. Therefore we would expect more mucin to be adsorbed 
on to the chitosan nanoparticle surface, which would increase aggregation due to, for 
example, the formation of mucin bridges between chitosan nanoparticles (Fefelova et 
al., 2007), or the aggregation of nanoparticles due to their instability the latter is 
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consistent with the low zeta potential value of the 3:1 mixture (+22.6 ± 4.9 mV). The 
PDI value was used as a reflection for uniformity and stability of particles (Masarudin 
et al., 2015). Moreover, Figure 6.5 shows the highest value (0.44 ± 0.02) of PDI at 
CS: TPP ratio 3:1 mixture indicates a wider range of particle size distribution in 
chitosan nanoparticle-mucin mixtures relative to other CS: TPP ratios (Appendix F). 
At a CS: TPP ratio of 4:1 mixture, chitosan nanoparticles with the smallest size and 
lower PDI were formed. Above the CS: TPP ratio 4:1 mixture, a clear increase in 
chitosan nanoparticle-mucin mixture size is obtained, thereby confirming the 
adsorption of negative mucin onto the surfaces chitosan nanoparticles. In addition, as 
can be shown in Figure 6.5, the CS: TPP ratio from 5:1 to 7:1 mixtures have PDI 
values of 0.30 - 0.35, indicating a narrow size range and a homogenous dispersion of 
chitosan nanoparticle-mucin mixture were obtained (Appendix F) (Hu et al., 2008) 
which is important in terms of the movement/ diffusion of nanoparticles through a 
mucosal layer in vivo (Abdulkarim et al., 2015). On the basis of these observations, 
the strongest interaction, which can be related to the smallest particle size was a CS: 
TPP ratio of 4:1. 
 
6.5.1.1.4 Mucin binding test (adsorption) as indicator of mucoadhesiveness 
Mucin colorimetric assay and calibration curve 
Proteins are commonly measured at ultraviolet region at 280 nm (Layne, 1957), 
nevertheless mucins absorb ultraviolet light poorly, since they generally have no or 
negligible aromatic amino acid content (Wang and Granados, 1997, Christlet and 
Veluraja, 2001). A colorimetric assay, however, provides an effective method of 
detection and analysis of mucin glycoproteins. 
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Figure 6.6: Calibration curve of mucin. (n=3; mean ± SD). 
 
 
From the Figure 6.6, it can be concluded that the assay showed a high sensitivity with 
LOD and LOQ being 0.006 ± 0.05 % and 0.019 ± 0.02 %, respectively with a high 
linearity (R2 > 0.99) and reproducibility with RSD < 3.7 %. 
Mucin is predicted to spontaneously adsorb onto the surface of the chitosan 
nanoparticles (Hu et al., 2015). The mucoadheasive behaviour of chitosan 
nanoparticles was assessed by the suspension of different CS: TPP ratios in fixed 
amount of mucin in aqueous solutions at 37 °C. Furthermore, the amount of mucin 
adsorbed was measured from the change in free concentration of mucin in the reaction 
mixtures according to Eq. 6.1, Section 6.3.3.1.  
After confirming the high surface charge (zeta potentials > +30 mV) for all native CS: 
TPP ratios (Figure 6.3), a mucin binding efficiency test was applied to confirm the 
system’s adhesiveness (Figure 6.7). 
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Figure 6.7: Mucin binding efficiency (adsorption) of different chitosan nanoparticles of 
different CS:TPP ratios. All values represent the mean ± SD (n = 3).  
 
 
The mucin binding efficiency (mucin adsorbed onto the chitosan nanoparticle surface) 
increased from 79.5 ± 1.3 % to 88.9 ± 2.4 % (p < 0.05) as CS: TPP ratios increased 
from 3:1 to 4:1 respectively (Figure 6.7). However, it was demonstrated that, there 
was no significant differences (p > 0.05) in the mucin binding efficiency values (~ 95 
%) when increase in CS: TPP ratios from 5:1 to 7:1. This result may be attributed to 
more NH3
+ functional groups being present to interact with the sialic acid residues on 
mucin. This also agrees with the finding from zeta potential which suggests a large 
amount of mucin has been bound to the nanoparticles at CS: TPP ratios greater than 
3:1 and that native CS: TPP nanoparticles of ratios from 5:1 to 7:1 were shown to 
have available surface charges (> +39 mV).  
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It is known that the smaller particles are able to penetrate to the sub-mucosal layers 
whereas the larger particles localised in the epithelial lining (Gan et al., 2005). Based 
on these results an optimal minimum chitosan nanoparticle CS: TPP ratio of 4:1 is 
required to interact with mucin, nanoparticles with lower amounts of chitosan are 
unstable and prone to aggregation. The zeta potential of 4:1 mixture is +31.3 ± 0.06 
mV (Figure 6.3), its particle size is the smallest (Figure 6.4) and has lowest PDI 
value (Figure 6.5). At CS: TPP ratio of 4:1 there are sufficient levels of CS: TPP 
particles for the mucin to interact with. This result may be attributed to a critical point 
of binding sialic acid being saturated at the CS: TPP ratio of 4:1 and all the mucin 
being adsorbed on to the particles.  
 
6.5.1.2 Second preparation incubation with mucin 
6.5.1.2.1 Assessment of chitosan nanoparticles-mucin interactions by relative 
viscosity, zeta potential and particle size 
 
In this stage equal volumes solutions of chitosan nanoparticles and mucin were mixed 
(Section 6.3.1.1). Table 6.1 compares results which obtained from second preparation 
tests. As be seen from the table below, the relative viscosity, zeta potential and 
particle size of different chitosan nanoparticles ratios were determined upon their 
incubation in the present and absent of mucin.  
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Table 6.1: Second stage measurements of relative viscosity, zeta potential and particle size of different CS: TPP nanoparticles before and after incubation 
with mucin. 
(CS:TPP) 
ratio 
         Relative viscosity  
                (ηrel) 
             Zeta potential 
                  (mV) 
              Particle size 
                 (nm) 
Control 
(CS:TPP) 
(CS:TPP + Mucin) Control 
(CS:TPP) 
(CS:TPP + Mucin) Control 
(CS:TPP) 
(CS:TPP + Mucin) 
3:1 1.03 ± 0.05 1.16 ± 0.02 33.4 ± 3.62 -3.0 ± 1.44 195.0 ± 4.2   
4:1 1.13 ± 0.01 1.17 ± 0.03 35.4 ± 1.70 -2.2 ± 0.95 216.0 ± 1.9   
5:1 1.24 ± 0.02 1.17 ± 0.02 37.4 ± 0.88 -1.5 ± 0.60 247.3 ± 1.0   
6:1 1.32 ± 0.04 1.17 ± 0.01 39.0 ± 0.73 -1.0 ± 0.33 282.5 ± 2.1   
7:1 1.36 ± 0.03 1.18 ± 0.02 40.2 ± 0.74 -0.6 ± 0.17 293.0 ± 5.3   
 : Aggregation/ precipitation of particles 
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The physical state of chitosan nanoparticle-mucin mixtures at different CS: TPP ratios 
(3:1, 4:1, 5:1, 6:1 and 7:1) were visual observed. When observing the samples 
visually, it is noted that there was an increase in the presence of milkiest mixtures 
then observed previously (first preparation). This is indication more mucin binding to 
the particles, where the particles were most noticeable; however, this observation did 
affect (p < 0.05) the results of the viscosity, zeta potential and particle size tests. The 
results, as shown in Table 6.1, indicate that by decreasing in CS: TPP mixture from 
7:1 to 5:1, decreased in the specific viscosity. This is caused by the precipitation of 
the chitosan nanoparticles-mucin interaction product. On the other hand, by a further 
decreasing in CS: TPP mixture from 4:1 to 3:1, an increase in the specific viscosity 
was observed. This was due to the excess mucin which has not interacted with the 
chitosan nanoparticles. These results confirmed with surface charge of particles 
(Table 6.1). Moreover, the results exhibited that an excess of mucin was adsorbed 
(interaction) on all different ratios of CS: TPP nanoparticles surfaces and potentially 
caused further aggregation (Figure 6.8). This result may be explained by the fact that 
the hydrogen bonding occurred which formation of bridges between nanoparticles 
(bridging effect) (Fefelova et al., 2007, Sogias et al., 2008).  
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Figure 6.8: Diagrammatic representation of adsorption of mucin on CS:TPP nanoparticles 
and aggregation of nanoparticles in the presence of an excess of mucin (Sogias et al., 2008).  
 
 
In order to confirm the above observation model we have studied the interactions 
between chitosan nanoparticles and mucin using zeta potential measurements. When 
chitosan nanoparticles were mixed with mucin solution, the resultant zeta potential of 
chitosan nanoparticles shifted to a negative values because of the negative charge of 
the mucin Table 6.1. Therefore, the particles in suspension were unstable as zeta 
potential less than ±30 mV, and aggregates were present due to loss repulsive forces. 
This is due to the adsorption (binding) of fully mucin molecules on the chitosan 
nanoparticles were responsible for the aggregation (Figure 6.8), due to mucin bridges 
between nanoparticles (Sogias et al., 2008) or due to nanoparticle instability if the 
zeta potential is in the ranges -30 mV - +30 mV.  As a result, second preparation test 
for all chitosan nanoparticles-mucin mixture are not stable systems and the charges 
are not sufficient to prevent aggregation of the particles. 
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6.6 Summary  
In this study, it has been demonstrated that different CS: TPP nanoparticle ratios, 
prepared by the ionotropic gelation method, were evaluated for their mucoadhesive 
properties for potential use as in pharmaceutical applications. The incubation of 
different ratios of CS: TPP nanoparticles solutions including 3:1, 4:1, 5:1, 6:1 and 7:1 
with mucin did lead to a modification in their physiochemical properties. Positively 
charged chitosan nanoparticles, which  is one of the main factors responsible for its 
mucoadhesive properties, had the ability to adsorb mucin (Andersen et al., 2015). A 
strong interaction between chitosan nanoparticles and mucin in aqueous solution was 
measured using relative viscosity, zeta potentials and particle size. In addition, a 
mucin colorimetric assay was performed to determine the amount of mucin adsorbed 
on chitosan nanoparticles. The results of this study support the idea the alterations in 
physiochemical properties of nanoparticles after incubation with mucin such as 
decreased in zeta potential and increased in particle size. The experiments were 
conducted at 37 °C, as this is closer to physiological conditions. The first stage has 
obtained better mucoadhesion results. For all CS: TPP ratios examined, a minimum 
value of viscosity was reached for a 3:1 CS: TPP ratio, however chitosan 
nanoparticles at this ratio (3:1) was not stable as its zeta potential was +22.6 ± 4.9 
mV). Whereas a CS: TPP ratio of 4:1 mixture displayed the strongest interaction with 
mucin. This result may be attributed to a critical point of binding carboxylate groups 
being saturated at the CS: TPP ratio of 4:1 and a possible of all mucin adsorbed on 
particles. Taken all together we can conclude that a minimum CS: TPP ratio of 4:1 is 
required to produce stable nanoparticles able to form strong interactions with mucin, 
which is consistent with a greater mucin binding efficiency at CS:TPP ratios of 4:1 
and higher.  
  302 
 
 
 
 
 
 
Chapter 7 
 
General Conclusions and Future 
Recommendations 
 
 
 
 
 
 
 
 
 
 
  303 
 
7 General Conclusions and Future Recommendations 
The purpose of this research was to prepare chitosan micro/nanoparticles at different 
CS: TPP ratios then investigation the potential of these particles for forensic and 
pharmaceutical applications. To achieve this purpose, the physicochemical properties 
of chitosan particles must be characterized. Furthermore, the aims of this thesis, as 
stated in Chapter 1 (Section 1.7) were successfully achieved and summarised in the 
following sections. 
 
Chapter 3 discussed their physicochemical properties extensively. Firstly, chitosan 
microparticles in a nine different acetate buffers (AB-1 to AB-9) were successfully 
formed by the ionotropic gelation method at different CS: TPP ratios (6:1, 4:1, 2:1, 
1:1, 1:2, 1:4 and 1:6), pH values (3.3, 4.3 and 5.3) and ionic strength (0.1, 0.3 and 0.5 
M) conditions. Secondly, 63 chitosan microparticles formulation prepared at different 
conditions were studied by determining relative viscosity, zeta potential and particle 
size. Thirdly, for model validation, further formulations of CS: TPP microparticles 
(6:1, 4:1, 2:1, 1:1, 1:2, 1:4 and 1:6), were prepared in a four different acetate buffers 
(AB-10, AB-11, AB-12 and AB-13). The characterisation of particles including 
relative viscosity, zeta potential, particle size, FTIR, XRD and SEM were 
investigated. Finally, using experimental design, the relative viscosity, particle size 
and zeta potential of CS: TPP microparticles under different conditions could be 
predicted using the mathematical models. The mathematical models obtained showed 
good relationships between independent variables (pH, ionic strength and CS: TPP 
ratio) and dependent variables (relative viscosity, zeta potential and particle size) for 
prediction. 
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Chapter 4 focused on forensic application in specific latent fingerprint visualization. 
Seven ratios formulations of CS: TPP microparticles (6:1, 4:1, 2:1, 1:1, 1:2, 1:4 and 
1:6), were prepared in a four different acetate buffers (AB-10, AB-11, AB-12 and 
AB-13). These formulations optimised using a 23 factorial factor design, in order to 
design particles of defined properties for latent fingerprint visualization on nonporous 
surfaces (glass microscope slides). Particles characteristics (such as surface charge 
and size) had effect on the fingerprint quality. One of the more significant finding to 
emerge from this study is that CS: TPP ratio has strong effect on quality fingerprint. 
The optimum conditions of attachment of microparticles to the ridges of latent 
fingermarks/fingerprint on glass are pH 4.8, CS: TPP ratio of 2:1 and 0.2 M of ionic 
strength using AB-12. With these conditions, particles were obtained with average 
diameter of 171.3 µm and the zeta potential of +14.3 mV. The limitation to detecting 
fingerprints (sensitivity) using CS: TPP particles as a powder is the third depletion 
level for one day aged. There is further work that could be done to make small 
changes to the formulation conditions (pH, ionic strength, CS: TPP ratio for example) 
this could potentially enable the fine tuning of nanoparticles in terms of size and 
charge to produce better or even bespoke particles for specific applications rather than 
one size fits all approach, such as visualisation of latent prints on surfaces which have 
thus far proven difficult for example skin. 
 
Chapter 5 highlighted the formation of chitosan nanoparticles (LMW chitosan in 
acetic acid), through ionic cross-linkages with TPP for potential pharmaceutical 
applications. From the analysis of the ibuprofen loaded chitosan nanoparticles by FT-
IR spectrometry, it is evident that chitosan nanoparticles with ibuprofen involves ionic 
interaction between the positive ammonium groups of chitosan nanoparticles and the 
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carboxylate anion of ibuprofen. Firstly, the ibuprofen was entrapped during 
preparation of the nanoparticles system by mixed ibuprofen with chitosan then TPP 
added referred to as (CS+IBU)/TPP (first method) or by mixed ibuprofen with TPP 
then chitosan added referred to as CS/(IBU+TPP) (second method). The findings of 
this results show that the second method obtained relatively high DEE of 
nanoparticles and was selected to carry out further experiments and reinforces the 
importance of the order addition in formulation preparation. Secondly, the effects of 
different CS: TPP ratios (3:1, 4:1, 5:1, 6:1 and 7:1) on ibuprofen loaded chitosan 
nanoparticles was studied. We demonstrated that the optimum CS: TPP ratio amongst 
those studied is CS: TPP at 5:1 ratio, which leads to the highest DEE (76.8 %). At this 
ratio, CS-IBU-TPP nanoparticles with sizes 247.3 nm, with PDI 0.27 and with zeta 
potential +37.4 are produced. Thirdly, effects of ibuprofen concentration (0.5, 1.0, 
1.5, 2.0 and 2.5 mg/mL) on ibuprofen loaded chitosan nanoparticles were 
investigated. During the experiment, CS: TPP ratio at 5:1 and ibuprofen concentration 
of 0.5 and 1.5 mg/mL, were proposed to be most effective in delivering ibuprofen. 
Increasing concentration of ibuprofen from 0.5 to 1.5 mg/mL caused an increasing 
high of CS: TPP interaction, leading to decreasing nanoparticle size. In these 
conditions, the particle sizes of CS-IBU-TPP nanoparticles were 284.1 nm and 247.3 
nm respectively; the zeta potentials were +38.6 mV and +35.3 mV, indicating high 
stability of CS-IBU-TPP nanoparticles; the DEE of nanoparticles were 86.6 % and 
76.8 % respectively. Finally, the cumulative release of ibuprofen in vitro were 38.5 % 
and 48.7 % respectively. There is further work that could be done to further develop 
this formulation that includes optimisation of the particle and studying the effect 
different pH values of formulations and also the effect of the pH of the media on 
ibuprofen release. This study has suggested that the potential of ibuprofen loaded 
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chitosan nanoparticles (CS-IBU-TPP) was expected be a new method using in 
pharmaceuticals applications. 
Chapter 6 focused on evaluating the interaction between different ratios (CS: TPP) 
chitosan nanoparticles including 3:1, 4:1, 5:1, 6:1 and 7:1 and mucin based on relative 
viscosity, zeta potentials and particle size. We demonstrated that interaction between 
chitosan nanoparticle and mucin occurred. CS: TPP nanoparticles were evaluated for 
their mucoadhesive properties for potential use in pharmaceutical applications. The 
experiments were conducted at 37 °C, as this is closer to physiological conditions. The 
changes in relative viscosity, surface charge and particle size of nanoparticles 
indicated an interaction with mucin. The CS: TPP nanoparticles were better at the 
ratio of 4:1 mixture due to the strongest interaction with mucin. This result may be 
attributed to a critical point of binding carboxylate groups being saturated at the ratio 
of 4:1 and a possible of all mucin adsorbed on particles. Mucoadhesion of chitosan 
nanoparticles were obtained with relative viscosity of 1.08 and zeta potential of +31.3 
mV, particle size of 304.6 nm and mucin binding efficiency of 90 %. Further work 
can be done by mixing different mucin concentrations (i.e. 1.0 %, 1.5 %, 2.0 %, 2.5 % 
and 3%) with CS: TPP of 4:1, as well as different pH to determine a change in 
viscosity, surface charge and particle size, as this would indicate the occurrence of 
interaction. 
 
Taking all of the above into account, when a new researcher continues on this work I 
would suggest they investigate trends in fingerprint development which could include 
the encapsulation of for example, florescent dyes inside the particles which may 
improve contrast. If I had time I would like to have done the formulation, 
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characterization and in vitro evaluation of ibuprofen loaded chitosan-TPP 
nanoparticles at ratio 5:1 - 7:1 using different chitosan concentrations with relatively 
high ibuprofen concentrations. 
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9 Appendices 
9.1 Appendix A: 
 
Acetate buffer calculations: 
Molecular weight of glacial acetic acid (CH3COOH) = 60 g/mol 
Molecular weight for sodium acetate trihydrate (CH3COONa.3H2O) = 134.08 g/mol 
CH3COOH + H2O CH3COO- + H3O+ 
CH3COONa + H2O CH3COO- + Na+ 
Equation for weak acid and its salt is:  
pH(buffer) = pKa + log [salt(aq) /acid(aq)] 
The same approach was used for all acetate buffers, summarised as follows:  
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Table A.1: Shows the weights of glacial acetic acid and sodium acetate trihydrate 
used to make 13 acetate buffers 
Acetate 
buffer 
pH Ionic strength Acetic acid (g) 
in 1 L 
Sodium acetate 
trihydrate (g) in 1 L 
AB-1 3.3 0.1  M 5.799 0.466 
AB-2 3.3 0.3  M 17.376 1.397 
AB-3 3.3 0.5  M 28.996 2.331 
AB-4 4.3 0.1  M 4.41 3.55 
AB-5 4.3 0.3  M 13.2 10.7 
AB-6 4.3 0.5  M 22.044 17.746 
AB-7 5.3 0.1  M 1.32 10.616 
AB-8 5.3 0.3  M 3.888 31.54 
AB-9 5.3 0.5  M 6.602 53.08 
AB-10 3.8 0.2 M 10.798 2.746 
AB-11 3.8 0.4 M 21.597 5.491 
AB-12 4.8 0.2 M 5.66 14.39 
AB-13 4.8 0.4 M 11.319 28.781 
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9.2 Appendix B: 
Table B.1: Shows the volumes of chitosan solutions and TPP solutions to make 
five ratios of CS: TPP nanoparticles 
CS:TPP ratios CS (mL) TPP (mL) 
3:1 40 39.5 
4:1 40 30 
5:1 50 30 
6:1 50 24 
7:1 50 21 
 
  
9.3 Appendix C: 
Table C.1: Shows the volumes of chitosan solutions and TPP solutions to effects of 
formation CS: TPP nanoparticles ratios loaded ibuprofen 
CS:TPP 
ratios 
CS (mL) TPP (mL) Ibuprofen (1.5 mg/mL) 
(mL) 
3:1 40 39.5 10.0 
4:1 40 30 8.8 
5:1 50 30 10.1 
6:1 50 24 9.3 
7:1 50 21 8.9 
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9.4 Appendix D:  
Particles size distribution curves of chitosan nanoparticles (CS: TPP) (blank) and 
ibuprofen loaded chitosan nanoparticles (CS-IBU-TPP) 
 
 
Figure D.1: Blank chitosan nanoparticle at CS: TPP (3:1) ratio 
 
 
 
Figure D.2: Blank chitosan nanoparticle at CS-TPP (4:1) ratio 
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Figure D.3: Blank chitosan nanoparticle at CS: TPP (5:1) ratio 
 
 
 
 
Figure D.4: Blank chitosan nanoparticle at CS: TPP (6:1) ratio 
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Figure D.5: Blank chitosan nanoparticle at CS-TPP (7:1) ratio 
 
 
 
Figure D.6: Ibuprofen loaded chitosan nanoparticle (CS-IBU- TPP) at 3:1 ratio 
 
 
 
Figure D.7: Ibuprofen loaded chitosan nanoparticle (CS-IBU- TPP) at 4:1 ratio 
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Figure D.8: Ibuprofen loaded chitosan nanoparticle (CS-IBU- TPP) at 5:1 ratio 
 
 
 
Figure D.9: Ibuprofen loaded chitosan nanoparticle (CS-IBU- TPP) at 6:1 ratio 
 
 
 
Figure D.10: Ibuprofen loaded chitosan nanoparticle (CS-IBU- TPP) at 7:1 ratio 
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9.5 Appendix E:  
Particles size distribution curves of chitosan nanoparticles (CS-IBU-TPP) at 5:1 (CS: 
TPP) fixed ratio and different concentration of ibuprofen 
 
 
Figure E.1: Ibuprofen (0.5 mg/mL) loaded chitosan nanoparticle (CS-IBU- TPP) 
 
 
  
 
Figure E.2: Ibuprofen (1.0 mg/mL) loaded chitosan nanoparticle (CS-IBU- TPP) 
 
 
 
  351 
 
 
Figure E.3: Ibuprofen (1.5 mg/mL) loaded chitosan nanoparticle (CS-IBU- TPP) 
 
 
 
Figure E.4: Ibuprofen (2.0 mg/mL) loaded chitosan nanoparticle (CS-IBU- TPP) 
 
 
 
Figure E.5: Ibuprofen (2.5 mg/mL) loaded chitosan nanoparticle (CS-IBU- TPP) 
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9.6 Appendix F:  
Particles size distribution curves of chitosan nanoparticles-mucin mixture 
 
 
Figure F.1: Chitosan nanoparticles-mucin mixture at 3:1 ratio 
 
 
 
Figure F.2: Chitosan nanoparticles-mucin mixture at 4:1 ratio 
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Figure F.3: Chitosan nanoparticles-mucin mixture at 5:1 ratio 
 
 
 
Figure F.6: Chitosan nanoparticles-mucin mixture at 6:1 ratio 
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Figure F.7: Chitosan nanoparticles-mucin mixture at 7:1 ratio 
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9.7 Appendix G: 
 
THE UNIVERSITY OF HUDDERSFIELD 
School of Applied Sciences 
 
Form 2: Ethical Review Application 
 
SECTION A: TO BE COMPLETED BY THE APPLICANT 
 
Before completing this section please refer to the School Research Ethics web pages which 
can be found at https://www.hud.ac.uk/sas/research/researchgovernanceandethics/ 
Applicants should consult the appropriate ethical guidelines.   
 
Please ensure that the statements in Section C are completed by the applicant (and project 
supervisors for PGR, PGT, and UG students) prior to submission. 
 
Project Title Evaluation of Chitosan: TPP nanoparticles for latent finger print 
visualisation 
Applicant Ezzeddin Hejjaji 
Supervisor (where 
applicable) 
Prof Gordon Morris 
Project start date June 2018 
Project end date July 2018 
Department Applied Sciences/ Chemistry 
 
SECTION B: PROJECT OUTLINE (TO BE COMPLETED IN FULL BY THE 
APPLICANT) 
Issue Please provide sufficient detail to allow 
appropriate consideration of any ethical issues.  
Forms with insufficient detail will need to be 
resubmitted.   
Aims and objectives of the study. Please 
state the aims and objectives of the study.  
To determine whether different formulations of 
chitosan tripolyphosphate (TPP) nanoparticles can 
be used to visualise latent finger prints. Chitosan 
TPP nanoparticles should interact with finger 
marks and this interaction should depend on, for 
example, the nanoparticle charge. In this project 
different nanoparticle formulations are being 
tested. In order to do this we need approximately 4 
or 5 volunteers to leave their finger marks for 
visualisation. NB finger marks are what is made 
by a person, after visualisation they are finger 
prints. 
 
Brief overview of experimental design Adult volunteer participants will be asked to 
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The experimental design only needs to be 
explained in sufficient detail to explain the 
research methods that will be used during the 
study.   
produce finger marks for visualisation using 
chitosan TPP nanoparticles.  
 
Does your study require any permissions 
for study such as NHS Research Ethics 
Committee and R&D approval?  If so, 
please give details of current status of any 
applications made or permissions granted 
 
N/A 
Participants 
Please outline who will participate in your 
research.  Might any of the participants be 
considered ‘vulnerable’ (e.g. children) 
 
Participants will be research students at the 
University of Huddersfield (up to 5 required). 
 
Access to participants 
Please give details about how participants 
will be identified and contacted.   
 
Participants will be contacted through personal 
contacts of the researcher. 
How will your data be recorded and 
stored? 
 
All data will be stored on local university 
computers 
Informed consent.   
Please outline how you will obtain informed 
consent.  
Participants will be shown a summary of how the 
information they provide will be recorded and 
processed. Participants will then be asked to sign a 
statement at the start of the session, demonstrating 
their understanding of how the information will be 
used. Participants will also be told that they can 
withdraw from the study at any point and that if 
they do so they will be allowed to request that the 
information they gave until the point of 
withdrawal be deleted. 
 
Confidentiality 
Please outline the level of confidentiality you 
will offer respondents and how this will be 
respected.  You should also state who will 
have access to the data and how it will be 
stored (this information should be included 
on your information sheet). 
 
Participants will be told that they will not be 
required to provide any of their personal 
information, including their names or other 
identification methods.  
 
Anonymity 
If you offer your participants anonymity, 
please indicate how this will be achieved.   
 
Participants will be referred to as Participant 1, 
Participant 2 etc.   
Harm 
Please outline your assessment of the extent 
to which your research might induce 
psychological stress, anxiety, cause harm or 
negative consequences for the participants 
No element physical or psychological harm should 
be present, and if participants feel uncomfortable 
they will be allowed to leave. 
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(beyond the risks encountered in normal life).  
If more than minimal risk, you should outline 
what support there will be for participants.   
If you believe that that there is minimal likely 
harm, please articulate why you believe this 
to be so.  
Does the project involve the use of any 
human tissue? If so, please provide detail on 
the nature of the samples and any actions you 
are taking to ensure compliance with the 
Human Tissue Act. 
 
N/A 
 
 
 
 
 
Does the project involve the use of 
Genetically Modified Organisms (GMOs)? 
Please provide details explain how you are 
minimising any ethical issues associated with 
researching and producing GMOs (NB this 
committee does not consider H&S matters 
pertaining to the generation and use of 
GMOs). 
 
N/A 
Does the project include any security 
sensitive information? Please explain how 
processing of all security sensitive 
information will be in full compliance with 
the “Oversight of security sensitive research 
material in UK universities: guidance 
(October 2012)” (Universities UK, 
recommended by the Association of Chief 
Police Officers) 
 
Security sensitive materials are confirmed as 
research: 
 
 Commissioned by the military 
 Commissioned under an EU security call 
 Involves the acquisition of security 
clearance 
 Concerns terrorist or extreme groups  
 
N/A 
 
Retrospective applications.  If your application for Ethics approval is retrospective, 
please explain why this has arisen.  
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SECTION C – SUMMARY OF ETHICAL ISSUES (TO BE COMPLETED BY 
THE APPLICANT) 
 
Please give a summary of the ethical issues arising from your research and any action 
that will be taken to address the issue(s).   
 
 
SECTION D – ADDITIONAL DOCUMENTS CHECKLIST (TO BE 
COMPLETED BY THE APPLICANT) 
Please supply copies of all relevant supporting documentation electronically. If 
this is not available electronically, please provide explanation and supply hard 
copy. 
 
I have included the following documents 
Information sheet 
 
Yes     X Not applicable   
Consent form (for 
interviews) 
 
Yes     X Not applicable   
Letters 
 
Yes      Not applicable   
Questionnaire 
 
Yes      Not applicable  X 
Interview schedule 
 
Yes      Not applicable  X 
 
 
SECTION E – STATEMENT BY APPLICANT 
 
I confirm that the information I have given in this form on ethical issues is correct.   
 
Applicant name/signature: Gordon Morris  
   
Date:  25/06/2018  
 
 
Affirmation by Supervisor (where applicable) 
I can confirm that, to the best of my understanding, the information presented by the 
applicant is correct and appropriate to allow an informed judgement on whether 
further ethical approval is required 
 
Supervisor name/signature:  
 
Date:    
 
If you have any queries relating to the completion or consideration of this form, 
please do not hesitate to contact r.m.phillips@hud.ac.uk 
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9.8 Appendix H: 
 
Participant Information sheet 
 
What is the purpose of the study? 
The aim of this study is to find chitosan-tripolyphosphate (CS: TPP) 
nanoparticles can be used in the potential development of latent finger prints.  
Do I have to take part? 
No, participation is completely voluntary. You can opt out at any point during the 
study. 
What are the benefits of taking part? 
You will be participating in ongoing doctoral research project in the 
development of novel finger print development techniques. This will add to the 
body of literature in this area and may in the future be of interest to law 
enforcement agencies. We cannot guarantee the study will help you personally 
but the information we obtain from your contribution to the study will help to 
increase the understanding of how different chitosan nanoparticle formulations 
interact with finger marks. 
What will happen during this study? 
Your finger marks will be taken by making finger marks on glass slides using 3 
different fingers in a depletion series. This is to enable the research team to 
determine whether novel formulations can interact with finger marks with 
different levels of fatty acids for example. In a depletion series the participant 
will make a finger mark on a glass slide and then after an appropriate time 
period on another glass slide and so on. When the participant has made their 
finger marks they are free to leave and the researcher will develop their latent 
finger marks using different chitosan nanoparticle formulations.  
What will happen to the results of this study? 
The results will form part of research project on the potential of chitosan 
nanoparticles as visualisation tools for latent finger marks. Your informational 
will be completely confidential. No identifying factors will be published, and only 
the researcher and their supervisors will have access to the original data. Once 
analysed the results will be written up into a student thesis which will be freely 
available via the University’s repository. It is also expected that some or all of the 
results of the study will be published in the scientific literature at a future date.  
Who is organizing this study? 
The study is organised by the University of Huddersfield. 
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Researcher: Ezzeddin Hejjaji,  
Email: Ezzeddin.Hejjaji@hud.ac.uk 
 
Research Supervisor: Prof. G. Morris 
School of Applied Sciences 
University of Huddersfield 
Email: g.morris@hud.ac.uk 
 
 
 
9.9  Appendix I: 
 
Informed Consent Form 
  Please initial to 
show 
acceptance  
     
1. I have read the participant information sheet. 
 
  ___ 
     
2. I have had the opportunity to ask any questions and to discuss the 
research study. 
 
  
___ 
 
     
3. All my questions (if any) have received satisfactory answers. 
 
 ___ 
     
4. I understand what the purpose of this study is and how I will be involved. 
 
  ___ 
     
5. I do not require any further information but am free to request it at any 
time. 
 
  ___ 
     
6. I have had enough time to decide to join the study. 
 
  ___ 
     
7. I understand that my participation is entirely voluntary, and that I can 
withdraw at any time without giving a reason. 
 
  ___ 
     
8. I agree to take part in this research study. 
 
 
  ___ 
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Further information 
 
If you would like further information or you have any questions, please contact my project 
supervisor  Prof. Gordon Morris  g.morris@hud.ac.uk 
 
  
 
Name (PRINT)  Date Signature 
     
Researcher (PRINT)  Date  Signature 
. 
